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ABSTRACT OF THE DISSERTATION 
Flap Endonuclease 1 Promotes Telomere Replication and Stability 
by Distinct Mechanisms on the Leading and Lagging Strands 
by 
Daniel C. Teasley 
Doctor of Philosophy in Biology and Biomedical Sciences 
Molecular Genetics and Genomics 
Washington University in St. Louis, 2015 
Professor Sheila A. Stewart, Chairperson 
 
High fidelity DNA replication is essential for genomic stability and cell survival; this fact 
is underscored by the redundancy present in DNA replication and repair pathways. The 
complexity of these pathways is most evident at challenging DNA templates, such as 
those with repetitive sequence and transcribed loci. Among these challenging templates 
are telomeres, which are terminal, highly repetitive sequences that maintain genomic 
stability by preventing aberrant end-to-end chromosome fusions. In the absence of 
accurate, complete telomere replication, genomic instability results, ultimately leading to 
cell death or transformation. Here, we describe two unique roles in telomere stability for 
the DNA replication and repair protein flap endonuclease 1 (FEN1). First, we find that 
FEN1 maintains telomere stability by facilitating replication fork reinitiation on the 
lagging strand-replicated telomere. In the absence of FEN1, sister telomere loss (STL) 
occurs at lagging strand-replicated telomeres. Genetic knockdown-rescue experiments 
demonstrated that FEN1’s nuclease activity, interactions with DNA repair proteins via its 
C-terminus, and gap endonuclease activity are essential for preventing STL. Similarly, 
 x 
an analysis of FEN1’s ability to reinitiate stalled replication forks revealed that it is 
dependent on the same activities as its ability to prevent STL, suggesting that FEN1’s 
role in reinitiating stalled replication forks is responsible for its ability to suppress STL on 
the lagging strand. Second, we show that FEN1 maintains telomere stability by limiting 
telomere fragility on the leading strand-replicated telomere. Strikingly, this activity is 
biochemically and genetically distinct from FEN’s role in preventing lagging strand-
specific STL; FEN1’s ability to suppress telomere fragility depends only on its flap 
endonuclease activity, while its C-terminal interactions and gap endonuclease activity 
are dispensable. We show that FEN depletion-induced telomere fragility is increased by 
RNA polymerase II inhibition and rescued by ectopic ribonuclease H1 expression, 
suggesting that FEN1 limits leading strand-specific telomere fragility by processing 
RNA:DNA hybrid/flap structures that arise following co-directional replisome–RNAP 
collisions at the telomere. Notably, this is the first known role for FEN1 in leading strand 
DNA replication, and the first molecular mechanism for telomere fragility at the leading 
strand. Lastly, we demonstrate that while FEN1 interacts directly with the shelterin 
protein TRF1, which is required to prevent telomere fragility, this interaction does not 
contribute to FEN1’s ability to suppress telomere fragility. Together, these data indicate 
that FEN1 has two functionally separate roles in maintaining telomere replication and 
stability: preventing STL on the lagging strand by facilitating replication fork reinitiation, 
and suppressing telomere fragility on the leading strand by processing intermediates 
that result from replisome–RNAP collisions. 
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Chapter 1: 
Introduction to telomere biology 
 
Daniel C. Teasley and Sheila A. Stewart 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is in press in The Encyclopedia of Cell Biology, 2016. © Elsevier
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Introduction 
All eukaryotic genomes are organized into linear chromosomes. As a result, each 
chromosome possesses termini that must be protected from two distinct problems not 
present in organisms with circular genomes. The first of these is the end replication 
problem, a consequence of the mechanism of lagging strand DNA synthesis. During 
lagging strand synthesis, when the last Okazaki fragment on the lagging strand 
template is processed to remove the ribonucleotide primer, an irreparable 5' gap 
remains. This gap on the lagging strand, as well as nucleolytic processing of the 
chromosome ends, results in a progressive shortening of the linear chromosome with 
each cell division (Zakian, 2012). Telomeres are the means by which cells avoid the 
loss of genetic information that would occur as a result of the end replication problem–
instead of a progressive loss of protein-coding sequences, a progressive loss of non-
coding telomere sequence occurs instead. In serving as a stopgap to the end replication 
problem, telomeres also act as a molecular clock that regulates cellular lifespan. In the 
absence of elongation mechanisms, telomeres eventually erode to lengths that are no 
longer sufficient to protect against loss of genetic information. Once telomeres become 
critically short, they trigger cellular senescence to prevent continued division that might 
result in a loss of genetic information and genome instability (Frias et al., 2012). The 
second potential problem resulting from linear chromosome ends arises from the fact 
that all cells possess exquisitely sensitive mechanisms to recognize free DNA ends as 
DNA damage. By coordinating the activities of DNA repair proteins, telomeres protect 
natural chromosome ends from DNA repair events that would result in chromosome 
fusions (de Lange, 2004). Since inappropriate chromosome fusions lead to genome 
instability, telomere integrity is essential for cell proliferation (Frias et al., 2012).  
3 
The molecular events that telomeres are associated with have consequences reaching 
far beyond the proliferation of a given cell. Telomere dysfunction has been linked to a 
number of diseases including dyskeratosis congenita, aplastic anemia, and emphysema 
(Armanios and Blackburn, 2012). Despite the wide range of organismal effects that can 
occur as a result of telomere dysfunction, perhaps no disease is more strongly linked to 
telomere biology than cancer. Telomere attrition is classically considered to be a tumor 
suppressive mechanism due to the fact that shortened telomeres cause checkpoint 
activation and cellular senescence (Xu et al., 2013). Because senescence is a potent 
obstacle to transformation, cells that become neoplastic must stabilize their telomeres. 
Along similar lines, telomere shortening or loss has the potential to cause substantial 
genome instability resulting in apoptosis or mitotic catastrophe (Xu et al., 2013). Despite 
these strong tumor suppressive effects, telomere dysfunction can also act as a tumor 
promoting mechanism. Since genome instability can lead to oncogenic translocations, 
gene amplification, and loss of heterozygosity of tumor suppressor genes, telomere 
dysfunction can also enhance the transformation process (Xu et al., 2013). These 
opposing roles – preventing and promoting cancer – underscore the complexity of the 
molecular activities that maintain telomeres, and the activities that take place in 
response to telomere shortening. 
 
Telomere structure and proteins 
Telomere DNA 
The telomere sequence in eukaryotic organisms is canonically composed of short, G-
rich repeats. Indeed, all identified vertebrate telomeres are composed of the sequence 
5'-(TTAGGG)n-3' oriented toward the chromosome terminus (McEachern et al., 2000). 
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Similar highly repetitive, G-rich sequences exist in other organisms; for instance, 
Tetrahymena thermophila telomeres consist of 5'-(TTGGGG)n-3' repeats (Fulcher et al., 
2014). Telomeres are composed largely of double stranded DNA (dsDNA), with a 
relatively short 3' single strand DNA (ssDNA) overhang of the G-rich strand (Sfeir, 
2012). The length of the overhang can vary – in humans it is typically between 30 and 
500 nucleotides – but its presence is essential, as evidenced by the fact that it is 
actively produced by resection following DNA replication (Novo and Londoño-Vallejo, 
2013; Sfeir, 2012). Telomeres span a wide range of total lengths, from as short as 300 
base pairs in yeasts, to between two and 15 kilobases in humans, and as long as 150 
kilobases in tobacco (Fulcher et al., 2014). 
 
Not all organisms follow the theme of compact, regular repeats; for instance, 
Saccharomyces cerevisiae telomeres are usually designated 5'-(C1-3A/TG1-3)-3' to 
indicate a consensus core telomere sequence (Wellinger and Zakian, 2012). Budding 
yeast telomere repeats in fact range from eight to 26 base pairs in length, and are on 
average less G-rich than typical telomere repeats (McEachern et al., 2000). Even 
human telomeres show slight variability, generally having perfect repeats in the 
centromere-distal majority of the telomere with variant repeats occurring in the 
centromere-proximal end of the telomere (McEachern et al., 2000). Small variations like 
those found in human telomeres are likely the consequence of errors by the DNA 
replication machinery. Since the centromere-proximal end of the telomere is more likely 
exclusively produced by the DNA replication machinery rather than telomerase, 
sequence polymorphisms can manifest and remain (McEachern et al., 2000). 
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Telomere secondary structure 
Because of the repetitive sequence and ssDNA overhang, telomeres can form 
secondary structures more complex than a linear dsDNA stretch with an ssDNA 
terminus. The most documented of these is the telomeric loop, or t-loop. T-loops form 
by a strand invasion event in which the 3' ssDNA overhang invades the dsDNA portion 
of the telomere. This event produces a small (approx. 150 nucleotide) ssDNA 
displacement loop (D-loop) of G-rich sequence at the site of invasion, as well as a large 
dsDNA loop (t-loop) (de Lange, 2004). T-loops were first identified in electron 
micrographs of telomeric DNA, and have since been observed using super-resolution 
fluorescence microscopy (Doksani et al., 2013; de Lange, 2004). At face value, t-loops 
would seem to be an effective means to prevent end-to-end chromosome fusions; by 
sequestering the 3' overhang, t-loops inhibit ATM signaling and non-homologous end 
joining. However, t-loops themselves resemble strand invasion intermediate structures 
produced during homologous recombination; it is unclear if such a structure elicits a 
DNA damage response if persistent, and how telomeres might avoid this response. It is 
likely that telomeric proteins play a role in both the formation and stabilization of t-loops; 
the telomere protein TRF2 in particular is sufficient for t-loop formation in vitro, and is 
necessary for t-loop formation and maintenance in mammalian cells (Doksani et al., 
2013; de Lange, 2004). 
 
In addition to t-loops, telomeres are also capable of forming G-quadruplexes. G-
quadruplexes form by an association of four single strands of DNA or RNA (monomeric, 
dimeric, or tetrameric in origin) in a helical structure, where the strands assemble such 
that four guanines align in a cyclic Hoogsteen hydrogen-bonded tetrad (Paeschke et al., 
6 
2010). G-quadruplexes are characterized by the stacking of multiple tetrad cores that 
are connected by linker “loops”, and can form in multiple orientations (Phan, 2010). Both 
the ssDNA overhang, and ssDNA portions of the G-strand that form during replication or 
repair can presumably form into G-quadruplexes. The ability of the telomere to form G-
quadruplexes is a significant phenomenon, as G-quadruplexes inhibit both semi-
conservative DNA replication and telomerase-mediated telomere lengthening 
(Paeschke et al., 2011). Data from ciliates demonstrating that G-quadruplexes form at 
telomeres in a cell cycle-specific manner, and the observation that treatment of 
mammalian cells with G-quadruplex-stabilizing small molecules triggers telomere 
dysfunction, suggest that G-quadruplexes at the telomere must be actively regulated by 
the cell (Lipps and Rhodes, 2009). Among the strongest candidates for G-quadruplex 
regulation in the cell are helicases—in particular, the Fanconi anemia group helicase 
FANCJ and RecQ helicase BLM are known to unwind G-quadruplexes, and are known 
to contribute to telomere stability (Lipps and Rhodes, 2009). 
 
Proteins associated with the telomere 
In addition to the DNA itself, telomeres are host to a number of proteins important for 
telomere maintenance and function. In mammals, the network of proteins present at the 
telomere are coordinated by six telomere-specific proteins: TRF1 (telomeric repeat-
binding factor 1, also TERF2), TRF2 (telomeric repeat-binding factor 2, also TERF2), 
POT1 (protection of telomeres protein 1), Rap1 (telomeric repeat-binding factor 2-
interacting protein 1, also TERF2IP), TPP1 (adrenocortical dysplasia protein homolog, 
also ACD), and TIN2 (TERF1-interacting factor 2, also TINF2) (de Lange, 2005) (Figure 
1.1). These six proteins together form the shelterin complex, which exclusively binds 
7 
telomeres due to the DNA binding specificities of TRF1 and TRF2 for telomeric dsDNA, 
and POT1 for telomeric ssDNA. 
 
TRF1 and TRF2 share homology in the form of a central TRFH dimerization domain and 
C-terminal Myb DNA binding domain, though TRF1 possesses an acidic N-terminus, 
while TRF2’s N-terminus is basic. TRF1 is also substantially more divergent (65% 
identity between human and mouse) in mammalian evolution than TRF2 (82% identity) 
(Broccoli et al., 1997). While both proteins bind telomeric dsDNA and are abundant at 
telomeres, their functions in telomere maintenance and stability are very different. TRF1 
is required for semi-conservative DNA replication through the telomere, and prevents a 
phenotype known as telomere fragility by recruiting helicases to the telomere to facilitate 
replication fork progression (Sfeir, 2012). TRF1 is also capable of looping, bending, and 
pairing arrays of telomere repeats, which may be involved in positioning or folding of 
telomeres, though TRF1 is dispensable for t-loop formation (Doksani et al., 2013; de 
Lange, 2005). TRF2 suppresses ATM kinase activation at the telomere, thus preventing 
a DNA damage response (H2AX phosphorylation and 53BP1 accumulation) and p53 
activation (Sfeir, 2012). In the absence of TRF2, ligase IV- and Ku-mediated non-
homologous end joining occurs, resulting in aberrant end-to-end chromosome fusions 
and early embryonic lethality in mice. The protective activities of TRF2 likely originate 
from its ability to facilitate t-loop formation, as well as its role (along with TRF1) in 
recruiting TPP1 to the telomere (Doksani et al., 2013; de Lange, 2004, 2005). Putative 
TRF1/2 homologs have been identified in Schizosaccharomyces pombe, trypanosomes, 
and plants (Sfeir, 2012). 
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The other mammalian shelterin protein with telomere sequence binding specificity, 
POT1, binds to the ssDNA overhang. POT1 is responsible for suppression of ATR 
kinase activation at the telomere, which is achieved by exclusion of the ssDNA binding 
protein RPA from the ssDNA overhang (Baumann and Price, 2010). POT1 also restricts 
the length of the ssDNA overhang and regulates the activity of telomerase by competing 
for binding at the overhang, which is the substrate for telomerase elongation (Longhese 
et al., 2012; Sfeir, 2012). POT1 is largely conserved among eukaryotes, with homologs 
in S. pombe, Tetrahymena, nematodes, and plants (Baumann and Price, 2010). In 
mouse and Tetrahymena, there are two POT1 gene homologs, Pot1a and Pot1b, with 
each playing a subset of the roles attributed to the single POT1 gene observed in 
human and yeast. 
 
The three other shelterin proteins (Rap1, TPP1, and TIN2) lack the ability to bind 
telomeric sequence directly in vertebrates, but are telomere-specific by virtue of their 
direct or indirect binding to TRF1 and TRF2. Indeed, simultaneous deletion of TRF1 and 
TRF2 from cells results in telomeres completely devoid of shelterin (Sfeir and de Lange, 
2012). Rap1 is the most conserved of all the shelterin proteins and the only shelterin 
protein with well-defined extra-telomeric functions – it is a transcriptional regulator and 
can modulate nuclear factor kappa B (NF-κB) signaling. At the mammalian telomere, 
Rap1 is a negative regulator of telomere length. It also acts with POT1 to repress 
aberrant homology-directed repair through an unclear mechanism (Sfeir, 2012). In S. 
cerevisiae, which lacks a TRF homolog, Rap1 is highly diverged from its orthologs and 
directly binds telomeric dsDNA; it effectively serves as the shelterin core in this yeast 
(de Lange, 2005). TIN2 is a “bridging” protein that connects TRF1 and TRF2 to one 
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another, and recruits TPP1 to the telomere. TPP1 in turn is required for efficient 
recruitment of POT1 to the telomere, as POT1’s DNA binding affinity is insufficient to 
keep it tethered to the ssDNA overhang (Sfeir, 2012). Both TIN2 and TPP1 are 
exclusive to vertebrate telomeres, and their emergence may coincide with the 
appearance of two TRF genes (de Lange, 2005). 
 
In addition to the telomere-specific shelterin proteins, a growing number of other 
proteins localize to telomeres and are important for telomere function. The majority of 
these proteins are associated with DNA metabolism. The protein complex CST, 
consisting of Cdc13, Stn1, and Ten1 in S. cerevisiae and CTC1, STN1, and TEN1 in 
mammals, associates with the ssDNA telomere overhang and due to structural similarity 
to the heterotrimeric RPA complex, has been proposed to function as a “telomere 
specific RPA” (Longhese et al., 2012). The RecQ helicases WRN and BLM interact with 
shelterin and play roles in lagging strand telomere synthesis and replication fork 
progression (de Lange, 2005). These are but a few of the numerous proteins that 
localize to the telomere and contribute to telomere synthesis and maintenance. 
 
Telomere replication and length maintenance 
Telomeres, like the rest of the genome, must be replicated during S phase to ensure 
genome continuity during cell division. Telomeres can be replicated primarily in two 
ways: first, the semi-conservative DNA replication machinery replicates telomeres along 
with the rest of the genome, and second, the ribonucleoprotein (RNP) enzyme 
telomerase adds telomere repeats to extend telomeres. In addition to these two main 
mechanisms for telomere replication and maintenance, there are two additional 
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identified means of telomere length maintenance: recombination-based telomere 
maintenance and the alternative lengthening of telomeres (ALT) mechanism. 
Additionally, some insects maintain their telomeres by a unique mechanism involving 
retrotransposition, but this will not be discussed here (de Lange, 2004). 
 
Semi-conservative telomere replication 
Telomere replication poses unique challenges for the semi-conservative DNA 
replication machinery. The first of these challenges is the consequence of the 
telomere’s location at chromosome termini. Unlike the rest of the genome, which can be 
replicated by one or more DNA replication origins with replication forks approaching 
from either direction, the most centromere-distal origin is thought to be the sole origin 
responsible for the replication of a given telomere. Additionally, because there are no 
known replication origins within the telomere, the “last” origin to fire must replicate the 
entire length of the telomere; in the event of fork collapse, telomere replication may 
remain incomplete (Gilson and Géli, 2007). This potential problem is exacerbated by the 
second main challenge in telomere replication: the repetitive, G-rich sequence, which 
leads to increased replication fork stalling compared to the rest of the genome (Cesare 
and Karlseder, 2012). The secondary structures that telomeric DNA forms, in particular 
G-quadruplexes and t-loops, must be resolved into linear dsDNA for replication to occur. 
 
The combination of structures that induce replication fork stalling and the lack of a 
replication fork approaching from the opposite direction to rescue a stalled fork 
necessitates robust mechanisms to ensure that telomere replication is completed. 
These mechanisms are coordinated by the shelterin complex, which recruits DNA 
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replication and repair proteins to the telomere. In S. pombe, the TRF1/2 homolog Taz1 
prevents replication fork arrest and telomere loss in a telomerase-negative background 
(Gilson and Géli, 2007). Subsequent work in murine cells has shown that TRF1 is 
required to facilitate replication fork progression through the telomere and prevent 
telomere fragility, and that this activity depends upon the helicases BLM and RTEL1 
(Sfeir et al., 2009). TRF2 also plays critical roles in telomere replication – both by 
recruiting the RecQ helicases BLM and WRN to the telomere, and by acting in a 
pathway with Apollo and topoisomerase 2α to relieve topological stress during 
replication (Ye et al., 2010). The recruitment of two RecQ helicases, BLM and WRN, by 
shelterin is not coincidental; both proteins are able to unwind G-quadruplexes and are 
theorized to have overlapping functions in resolving G-quadruplexes formed on the 
lagging strand during replication. 
 
The cooperation between shelterin and its binding partners described above ensures 
that replication forks can progress through the telomere with as little stalling as possible. 
Nevertheless, replication forks do stall in telomeric sequence, and additional 
mechanisms are in place to ensure successful fork restart. The DNA replication and 
repair protein flap endonuclease 1 (FEN1) localizes to telomeres during and after 
replication, and ensures that replication forks are reinitiated on the lagging strand 
template following stalling (Saharia et al., 2010). The mammalian CST complex rescues 
stalled replication forks that occur as a result of replication stress by facilitating dormant 
origin firing (Stewart et al., 2012a). Stalled replication forks at the telomere appear to 
require ATR, which is recruited to telomeres during S-phase, for restart (Verdun and 
Karlseder, 2006). These are unlikely to be the only contributing mechanisms for 
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replication fork restart at the telomere. The preponderance of DNA replication and repair 
proteins that are recruited to the telomere to facilitate replication fork progression and 
fork restart following stalling illustrates the difficulty of telomere replication by the semi-
conservative DNA replication machinery, as well as the robust series of mechanisms in 
place to ensure that replication is completed in spite of the challenges. 
 
The fact that both leading and lagging strand-replicated telomeres possess similar 3' 
ssDNA overhangs implies that at least the leading strand, which would be expected to 
produce a blunt end, has to be processed to produce an overhang. In fact, leading and 
lagging strand-replicated telomere ends are significantly resected and processed 
following the completion of semi-conservative DNA replication (Gilson and Géli, 2007). 
This process must be highly regulated by the cell, as too little resection would generate 
a short overhang which precludes POT1 binding and t-loop formation, while too much 
resection would accelerate the end replication problem. In S. cerevisiae, resection of the 
leading strand-replicated telomere to produce the G-rich overhang is facilitated by the 
same DNA repair proteins involved in 5' resection at DNA double strand breaks prior to 
homologous recombination, notably Cdk1 and the Mre11-Rad50-Xrs2 (MRX) complex. 
Indeed, yeast strains with deficient Mre11 exhibit shorter 3' ssDNA overhangs (Gilson 
and Géli, 2007). Following recognition of the end by MRX, the nucleases Exo1 and/or 
Dna2 are recruited to the 5' end, and in concert with the helicase Sgs1, cleave the 5’ 
end to produce the 3' ssDNA overhang (Stewart et al., 2012b). In mammalian cells, the 
Apollo nuclease is recruited to telomere ends by its interaction with TRF2. At the leading 
strand-replicated telomere, Apollo initiates resection of the 5' end. At the lagging strand-
replicated telomere, where an overhang already exists following replication, POT1b 
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binds the ssDNA and inhibits the resection activity of Apollo; similarly, after a sufficient 
ssDNA overhang is generated at the leading strand-replicated telomere, POT1b binds 
and inhibits further resection by Apollo (Wu et al., 2012). Exo1 then further and 
transiently resects the 5' ends at both strands to produce long overhangs. Lastly, 
POT1b recruits CST and polymerase α to shorten the extended overhangs, presumably 
by fill-in C-strand synthesis (Wu et al., 2012). 
 
Telomerase 
Semi-conservative replication and telomere end processing cause the end replication 
problem, which manifests as progressive telomere shortening with each cell division 
cycle. The solution to the end replication problem is telomerase, a holoenzyme 
minimally composed of the telomerase reverse transcriptase protein (TERT) and the 
telomerase RNA component (TERC or TR). TERC binds accessory proteins in addition 
to TERT, which contribute to telomerase localization and processing (Martínez and 
Blasco, 2011). Telomerase adds telomeric DNA repeats to the terminal end of an 
existing telomere, thus lengthening telomeres and offsetting the end replication 
problem. 
 
Telomerase is unique among known reverse transcriptase enzymes in being an RNP. 
The TERT protein is the catalytic portion of the holoenzyme, and consists of four 
conserved structural domains. Two of these, the reverse transcriptase and C-terminal 
extension domains, are conserved between TERT and other reverse transcriptases; the 
telomerase essential N-terminal domain and telomerase RNA binding domain are 
unique to TERT (Podlevsky and Chen, 2012). The RNA portion of the telomerase RNP, 
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TERC, is required for telomerase activity not only because it provides the telomere 
repeat sequence template, but also because two conserved regions, the 
template/pseudoknot domain and the CR4/5 domain, contribute to template positioning 
in the active site and provide important protein–nucleic acid contacts (Podlevsky and 
Chen, 2012). In addition to these two regions, which are conserved among all known 
species, vertebrate TERCs contain a conserved H/ACA domain. Each of two stems in 
the H/ACA domain binds a protein complex consisting of dyskerin, NOP10, NHP2, and 
GAR1. These proteins are required for TERC maturation and processing, RNP 
biogenesis, and Cajal body localization of TERC (Podlevsky and Chen, 2012). 
 
TERT protein production occurs via the canonical processes of mRNA transcription and 
cytoplasmic translation, after which TERT is first recruited to nucleoli, and then Cajal 
bodies. TERC is transcribed by RNA polymerase II, after which the ends are processed; 
TERC binds the dyskerin-anchored complex of accessory proteins, which facilitate 
maturation and localization to Cajal bodies. The chaperone proteins HSP90 and p23 
facilitate the assembly of the TERC/accessory protein complex with TERT into the 
active telomerase RNP holoenzyme, after which it localizes to telomeres (Podlevsky 
and Chen, 2012). 
 
At the telomere, the catalytic process of telomere elongation occurs in two steps. In the 
first step, the 3' end of the telomere base pairs with the 5' region of TERC; the TERT 
active site then uses the 3' end of the telomere as a primer to reverse transcribe a 
telomere repeat (in human, the six nucleotides 5'-GGTTAG-3') using TERC as a 
template. In the second step, TERC dissociates from the telomeric DNA, translocates 
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5'-to-3' along the DNA, and re-anneals for a new round of nucleotide addition 
(Podlevsky and Chen, 2012). By repeating the synthesis and translocation steps, 
telomerase can processively add repeats to a single telomere end without ever 
completely dissociating from the DNA. Here, shelterin plays a role in telomere 
synthesis, as the POT1–TPP1 complex has been shown to hold the telomeric DNA 
primer close to telomerase, inhibiting primer release and enhancing processivity 
(Podlevsky and Chen, 2012). Telomerase activity is also restricted in a shelterin-
dependent manner; POT1 bound to the ssDNA overhang is thought to limit the initial 
binding of telomerase to the telomere, and the t-loop structure prevents telomerase 
activity (de Lange, 2005). Once telomerase dissociates from its template, polymerase α 
synthesizes the complementary C-rich strand. It is thought that the CST complex, which 
is known to interact with the polymerase α complex, facilitates this event (Gilson and 
Géli, 2007). In yeast, telomere repeat-containing RNA (TERRA), the noncoding RNA 
product of telomere transcription, may act as a seed to nucleate clusters of telomerase 
prior to telomere recruitment; TERRA transcription is induced by telomere shortening 
(Cusanelli et al., 2013). 
 
Recombination at telomeres and alternative lengthening of telomeres 
In addition to lengthening by telomerase activity, cells have evolved other mechanisms 
to elongate or maintain telomeres. In S. cerevisiae, deletion of the telomerase reverse 
transcriptase EST1 produces colonies of survivor cells. Genetic analysis revealed the 
requirement for recombination in virtually all est1Δ survivor cells, as est1Δ rad52Δ 
strains produce virtually no survivors (Wellinger and Zakian, 2012). In addition to 
RAD52, all survivor cells require the Pol32p replication protein. Survivors are 
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categorized into one of two types (I and II), which appear to have different mechanisms 
but are not mutually exclusive. Type I survivors have telomeres with multiple, repeated 
Y' subtelomere elements and short, terminal telomere repeats; they also possess 
extrachromosomal circular Y' elements thought to serve as recombination substrates. 
These cells grow relatively slowly, easily convert to type II survivors, and require 
RAD51, RAD54, and RAD57 in addition to RAD52 and POL32 (Wellinger and Zakian, 
2012). Type II survivors have telomeres with few subtelomere repeats but extensive 
amplification in telomere repeats. The telomeres in these cells may depend on rolling 
circle amplification as an initiating event to lengthen their telomeres. Type II survivors 
require MRX, RAD59, and SGS1 (Wellinger and Zakian, 2012). Interestingly, the 
recombination-mediated mechanisms of telomere maintenance in yeast appear to be 
promoted by RNA:DNA hybrid formation between telomeric DNA and TERRA (Balk et 
al., 2013). This observation suggests the possibility that TERRA may be required for 
both telomerase-mediated and recombination-mediated telomere elongation pathways. 
 
In mammalian cells lacking telomerase activity, the alternative lengthening of telomeres 
(ALT) mechanism provides a means to maintain telomere length. Found in 10-15% of 
human cancers, ALT appears to be recombination-based and is characterized by 
several striking phenotypes. ALT cells possess an abundance of extrachromosomal 
telomeric DNA, much of which is in the form of double stranded telomeric circles (t-
circles) and C-rich single stranded telomeric circles (C-circles) (Cesare and Reddel, 
2010). ALT cells also exhibit telomere localization to promyelocytic leukemia (PML) 
nuclear bodies, elevated levels of telomere sister chromatid exchange (T-SCE) events, 
and heterogeneous chromosomal telomere lengths. The molecular mechanism(s) 
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responsible for ALT have remained elusive, and two models have emerged to explain it. 
First, the unequal T-SCE model proposes that T-SCE events produce long and short 
telomere lengths in the chromosomes experiencing T-SCE; if the chromosomes with 
longer telomeres were able to segregate into one of the two daughter cells, the 
enhanced proliferative capacity of one daughter over the other could produce selection 
at the population level for theoretically unlimited proliferation (Cesare and Reddel, 
2010). The second model, which is not mutually exclusive from the unequal T-SCE 
model, proposes that ALT is the result of homologous recombination-dependent DNA 
replication. In this model, shorter telomeres extend by recombination-based DNA 
synthesis using an existing telomere sequence substrate in the cell. The telomere 
substrate for the elongating telomere could be a telomere on another chromosome, the 
same telomere via t-loop formation, linear extrachromosomal telomeric DNA, t-circles, 
and/or C-circles (Cesare and Reddel, 2010). Both telomere elongation and length 
maintenance in ALT cells appear to depend on a striking number of DNA replication and 
repair proteins, which suggests that ALT results from deregulation of normal DNA 
metabolic processes. Indeed, the shelterin proteins TRF2 and POT1 have been 
suggested as suppressors of ALT due to both proteins’ ability to inhibit recombination at 
the telomere; ALT cells’ vast expansion of telomeric DNA content may dilute shelterin 
saturation at telomeres and contribute to the phenotype (Cesare and Reddel, 2010). 
Like in recombination-mediated telomere elongation in yeast, TERRA may play a role in 
ALT. Recent data suggests that RNA:DNA hybrid levels between TERRA and the 
telomere are “fine-tuned” by RNase H1 expression in ALT cells (Arora et al., 2014). 
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Telomere Physiology 
Senescence and telomere crisis 
One of the most significant consequences of telomere erosion at the cell biological level 
is the induction of cellular senescence. Indeed, the fact that telomere length is the 
primary determinant of cellular lifespan is well-established (Deng et al., 2008). Telomere 
shortening beyond a critical length causes deprotection of the telomere via a loss of 
TRF2. Deprotection induced by replicative shortening or other telomere dysfunction 
induces a DNA damage response (DDR). The DDR induced by telomere dysfunction 
causes phosphorylation of H2AX and recruitment of 53BP1 and other DNA repair 
proteins to the telomere. Like the classical DDR, the DDR induced by telomere attrition 
activates both the ATM and ATR checkpoints, which in turn activate p53 via the CHK1 
and CHK2 kinases (Deng et al., 2008). p53 activation by telomere shortening induces 
one of two physiological consequences: either entry into cellular senescence by p21 
and RB signaling, or apoptosis (Frias et al., 2012) (Figure 1.2). Both senescence and 
apoptosis serve as potent anti-proliferative mechanisms in cells with eroded telomeres. 
 
Absence of a functional p53 and Rb checkpoint, as often occurs in cancer cells, 
abrogates both senescence and apoptosis as responses to telomere dysfunction and 
attrition. Because this causes checkpoint bypass and continued proliferation, telomeres 
in p53-deficient cells will continue to shorten, ultimately reaching a condition called crisis 
(Figure 1.2). Crisis inherently acts as a second checkpoint to continued proliferation; 
critically short telomeres induce aberrant end-to-end fusions between chromosomes 
followed by chromosome breakage and additional fusion events in what is referred to as 
the breakage–fusion–bridge cycle (Deng et al., 2008). The breakage–fusion–bridge 
19 
cycle causes massive genomic instability and aneuploidy, both of which lead to rapid 
cell death in a majority of cells. However, a small fraction of cells are able to escape 
crisis by activating either telomerase or the ALT pathway (Figure 1.2); in these cells, the 
chromosome fusions resulting from crisis can produce oncogene amplification, tumor 
suppressor loss of function, and gene fusions that contribute to rapid proliferation and 
tumorigenesis (Deng et al., 2008). 
 
Telomeres in cancer cells 
Telomere biology contributes to cancer phenotypes via two distinct but related 
mechanisms. First, telomere shortening induces senescence and/or apoptosis, acting 
as a significant anti-proliferative barrier to the incipient tumor cell; these cells must 
activate either telomerase or ALT to continue proliferating. Second, telomere 
dysfunction, whether induced by DNA damage, genetic mutation, or avoidance of 
replicative senescence, causes genomic instability that can drive tumorigenesis 
 
The observation that telomerase is aberrantly activated in as many as 85-90% human 
cancers, with ALT mechanisms active in the remainder, demonstrates the absolute 
barrier that telomere shortening imposes on incipient tumor cells’ ability to survive 
(Gomez et al., 2012). Despite the universal requirement for a telomere maintenance 
mechanism for unlimited proliferation, the significance of a tumor cell’s use of 
telomerase vs. ALT remains unclear. Several studies have identified an ability of cells to 
switch between the two mechanisms; of particular note is the ability of telomerase-
positive cancer cells to become ALT-positive upon genetic or pharmacologic inactivation 
of telomerase (Hu et al., 2012; Queisser et al., 2013). In tumors that are telomerase-
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positive, studies conflict on the relevance of telomerase expression levels or activity as 
a prognostic marker. In some late-stage non-small cell lung cancers, colorectal cancers, 
and soft tissue sarcomas, telomerase expression correlates with poor prognosis, but 
many of these studies remain controversial (Chen and Chen, 2011). Tumors that are 
ALT-positive (commonly, glioblastoma multiforme and sarcomas) frequently have poor 
prognosis (Cesare and Reddel, 2010). 
 
While aberrant telomere elongation by telomerase or ALT contributes directly to the 
proliferative capacity of cancer cells, telomere-related genomic instability is perhaps just 
as significant a contributor to tumorigenesis. As described above, the breakage–fusion–
bridge cycle can arise from critically short or lost telomeres. In cancer cells, critically 
short telomeres are likely to induce the breakage–fusion–bridge cycle, resulting in 
genomic instability and generating tumor-promoting conditions. Indeed, mice with a 
TERC deletion and p53 deletion experience a wide range of carcinomas consistent with 
human cancers; when examined for cytogenetic abnormalities, the tumor cells in these 
mice show chromosome rearrangements with inverted repeats that are consistent with 
the breakage–fusion–bridge model (Murnane, 2010). Human cancer cells frequently 
contain amplified regions in the genome with inverted repeats (Murnane, 2012). 
Analysis of tumor samples by chromosome painting indicates that the breakage–fusion–
bridge cycle frequently involves a single chromosome involved in multiple sister 
chromatid fusions, continuing over multiple generations until telomere stability can be 
achieved; this allows the cell to survive, and facilitates substantial amplification of loci 
on the involved chromosome(s) (Murnane, 2012). In addition to amplification events 
generated by the breakage–fusion–bridge cycle, telomere loss can trigger end-to-end 
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chromosome fusions that ultimately produce gross chromosomal rearrangements. 
These rearrangements are capable of producing fusion genes that encode oncogenic 
proteins in specific human cancers (Jones et al., 2012). 
 
Non-cancer telomere-related diseases 
Diseases with telomeric origin or contribution can largely be grouped into two 
categories: those that are caused by mutation to specific genes with telomeric functions, 
and those that are associated with changes in telomere length. The first category, often 
referred to as telomeropathies or telomere syndromes, constitutes a diverse group of 
diseases that are monogenic in origin, with mutations typically occurring in one of 
several telomere-associated genes. The most well known telomeropathy is dyskeratosis 
congenita (DC), a disease initially presenting with nail dystrophy, leukoplakia, and 
abnormal skin pigmentation; DC patients frequently progress to experience aplastic 
anemia and increased cancer incidence (Savage and Bertuch, 2010). Among the most 
frequently mutated genes in DC are TERC and TERT; DC is also associated with 
mutations in DKC1 (common), TINF2 (common), NHP2 (rare), and NOP10 (rare) 
(Holohan et al., 2014). In addition, three other disorders presenting with overlapping 
symptoms–Hoyeraal-Hreidarsson, Revesz, and Coats plus syndromes–are associated 
with mutations in the same group of genes, and may constitute a group of diseases 
including DC with common origins that exhibit distinct phenotypes due to different 
mutations or penetrance (Armanios and Blackburn, 2012). Most of the mutations 
identified in DC and the DC-related syndromes cause decreased telomerase function; in 
affected cells, telomere length is frequently below the first percentile in the population 
for the age of the patient (Savage and Bertuch, 2010). Mutations in TERC and TERT 
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have also been identified in studies as either contributors to aplastic anemia, idiopathic 
pulmonary fibrosis, and unexplained severe liver disease (Savage and Bertuch, 2010). 
The symptoms of these conditions are all observed in DC patients as either 
complications or comorbidities, suggesting that abrogation of telomerase function by 
mutation of TERC, TERT, or another protein can produce a wide spectrum of disease 
presentations that are all caused by similar molecular mechanisms. Two mutated genes 
identified in diseases of the DC spectrum, TINF2 (common) and CTC1 (rare), produce 
proteins not known to directly affect telomerase function. TIN2, a shelterin complex 
member, could indirectly affect telomerase recruitment by modulating the binding of 
other shelterin proteins to the telomere, but any mechanism remains unclear. CTC1, 
associated only with Coats plus syndrome, is a member of the mammalian CST 
complex and thus facilitates telomere replication, but there is little evidence about how it 
might contribute to the disease (Armanios and Blackburn, 2012). 
 
In addition to the monogenic telomeropathies described above, several age-related 
human diseases show association with telomere length. A wide number of risk factors 
for atherosclerosis (smoking, hypertension, and obesity), as well as atherosclerosis 
itself, have been studied with regard to telomere length. Reports indicate that tobacco 
use, hypertension with sclerotic plaques, and weight gain correlate with shorter 
telomere lengths; multiple studies have demonstrated that shorter telomeres or 
increased telomere attrition are present in atherosclerotic patients (Khan et al., 2012). 
Some of these studies, particularly those examining atherosclerosis risk factors as 
opposed to the disease itself, have weaknesses: several studies were unable to control 
all the confounding factors, while others showed statistically significant effects only in 
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certain subgroups (i.e., males or females). Nonetheless, the overall picture of data 
certainly indicates that shorter telomere length is associated with atherosclerosis (Khan 
et al., 2012). Age-related musculoskeletal diseases have also been associated with 
telomere length. Chondrocytes from patients with osteoarthritis exhibit shorter telomere 
lengths than control patients; given that chondrocyte senescence causes changes 
known to accelerate osteoarthritis, it is possible that accelerated telomere loss might 
contribute to osteoarthritis (Li et al., 2012). Some studies have indicated that shorter 
telomeres are associated with lower bone mineral density, a characteristic of 
osteoporosis (Li et al., 2012). Other studies, however, have found no such association, 
and so associations between telomere length and age-related musculoskeletal diseases 
are challenging to identify and interpret. In mouse models, a number of other diseases 
appear to be telomere-dependent. Mice with short telomeres display a wide variety of 
phenotypes–these include: immune problems (opportunistic infections, impaired vaccine 
responses, altered T-cell ratios), gastrointestinal problems (enterocolitis, villous 
blunting), defects in fibrosis following injury, and altered β-cell function leading to insulin 
resistance (Armanios and Blackburn, 2012). Many of the phenotypes observed in mice 
appear to be related to telomere-induced senescence. While most of the non-cancer 
diseases with known telomere dependence in humans fall into the DC spectrum of 
disorders and phenotypes, the evidence in mice suggests that telomere-dependent 
senescence contributes to age-related diseases. 
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Figure 1.1. A diagrammatic representation of telomere structure and telomere-
binding proteins. 
TRF1 (green) and TRF2 (red) form homodimers and directly bind telomere dsDNA. 
TIN2 (blue) acts as a bridge between the homodimers and interacts with TPP1 (yellow). 
TPP1 also interacts with POT1 (orange), which binds telomere ssDNA at the 3' 
overhang. RAP1 (purple) interacts with TRF2. The telomere likely exists in a dynamic 
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equilibrium as a linear structure with a free 3' overhang and the t-loop structure, where 
the G-rich 3' end loops and hybridizes with the C-rich strand, forming a displacement 
loop. 
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Figure 1.2. A depiction of telomere length over the course of cell divisions. 
Germline cells and embryonic stem cells (green) possess high telomerase activity and 
maintain long telomeres. Adult stem cells and multipotent progenitor cells (purple) 
possess detectable telomerase activity, but do not express telomerase sufficiently to 
entirely prevent telomere shortening; the telomeres in these cells shorten gradually over 
time. Somatic cells have no detectable telomerase activity, and the telomeres in these 
cells shorten with each cell division. When telomeres shorten to a particular length (M1), 
most cells enter senescence and cease dividing. In cells without functional p53/Rb 
checkpoints, senescence is bypassed; cell division and telomere shortening continue 
until telomere length becomes short enough to trigger crisis (M2). The majority of cells 
that reach crisis die; however, a very small subset of incipient cancer cells that reach 
crisis activate either telomerase or the ALT pathway to stabilize their short telomeres, 
thus becoming immortal. 
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Introduction 
High-fidelity DNA replication is critical for genome stability and continued cellular 
proliferation. Given the importance of high-fidelity DNA replication to genomic stability, it 
is not surprising that numerous redundant mechanisms of DNA replication exist. 
Inherited syndromes in which DNA replication/repair proteins are mutated or lost but 
overall DNA replication continues relatively unabated (Sidorova, 2008; Singh et al., 
2009; Wu and Hickson, 2002) best illustrate the compensatory nature of these 
mechanisms. However, in some cases, this compensation is incomplete, and thus 
patients with these mutations manifest replication defects and genomic instability 
(Sidorova, 2008). 
 
Deficiencies in various DNA replication/repair mechanisms become particularly 
detrimental in highly repetitive DNA sequences that present unique challenges to the 
DNA replication machinery (Gilson and Geli, 2007; Verdun and Karlseder, 2007). For 
example, triplet repeats can lead to replication fork slippage, resulting in deleterious 
expansions and deletions (Kovtun and McMurray, 2008). Similarly, replication fork 
pausing and stalling occur within telomeric repeats (Khadaroo et al., 2009; Makovets et 
al., 2004; Ohki and Ishikawa, 2004; Verdun and Karlseder, 2006), and telomeres were 
recently identified as fragile sites (Martinez et al., 2009; Sfeir et al., 2009). Because 
fragile sites are thought to arise in response to replication stress, these data support the 
hypothesis that telomeric DNA presents a challenging template for the DNA replication 
machinery that requires the actions of specialized replication complexes, including a 
replication fork re-initiation complex (Gilson and Geli, 2007; Maizels, 2006; Parkinson et 
35 
al., 2002). Recent work has shown that telomeres are highly sensitive to the loss of 
DNA replication/repair proteins shown to localize to stalled replication forks, including 
the Werner helicase (WRN) and flap endonuclease 1 (FEN1) proteins (Sharma et al., 
2004). Indeed, cells from WRN patients display overt telomere dysfunction while only 
minor defects in genomic replication are observed (Crabbe et al., 2007; Crabbe et al., 
2004; Sidorova, 2008), suggesting that other proteins compensate for WRN throughout 
the genome but are insufficient at the telomere. 
 
DNA replication mechanisms at the telomere are coordinated by the six-protein 
Shelterin complex (including: TRF1, TRF2, TIN2, POT1, RAP1, and TPP1) (de Lange, 
2005; Gilson and Geli, 2007; Verdun and Karlseder, 2007). For example, TRF2 
interacts with and modulates the activities of numerous DNA replication and repair 
proteins (de Lange, 2005). These interactions include TRF2 binding to the WRN and 
Bloom syndrome (BLM) helicases, which stimulates their activity in vitro, suggesting that 
TRF2 recruits them to replicate or repair telomeric DNA (Opresko et al., 2002). In 
Schizosaccharomyces pombe, the TRF1/2 homolog Taz1 is essential for DNA 
replication through the telomeres (Miller et al., 2006). Upon Taz1 deletion, replication 
forks stall within telomeric repeats and telomeres are rapidly lost (Miller et al., 2006). 
TRF1 plays a similar role in mammalian cells (Martinez et al., 2009; Sfeir et al., 2009). 
After deletion of TRF1, stalled replication forks accumulate within the telomeric repeats, 
resulting in a replication stress response characterized by an ATR (ataxia telangiectasia 
mutated (ATM)- and Rad3-related)-dependent DNA damage response and expression 
of fragile sites within telomeric DNA (Martinez et al., 2009; Sfeir et al., 2009). Together, 
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these data underscore the importance of the coordinated actions of the Shelterin 
components and the DNA replication and repair machinery to efficiently complete 
telomere replication. 
 
FEN1 is a structure-specific endonuclease that plays an important role in DNA 
metabolism. FEN1 participates in Okazaki fragment processing during lagging strand 
DNA replication (Li et al., 1995) and is important for several DNA repair processes (Liu 
et al., 2004; Shen et al., 2005). FEN1 co-localizes to stalled replication forks where it 
interacts with the RecQ helicase, WRN, and is postulated to re-initiate stalled DNA 
replication forks (Sharma et al., 2004; Zheng et al., 2005). Recently, we demonstrated 
that FEN1 is vital for telomere stability (Saharia et al., 2008). Indeed, FEN1 depletion in 
telomerase-deficient cells leads to a DNA damage response at telomeres and telomere 
dysfunction characterized by loss of lagging strand-replicated sister telomeres (Saharia 
et al., 2008; Saharia and Stewart, 2009). Furthermore, genetic rescue experiments 
demonstrate that the nuclease activity and the C-terminal WRN-interacting domain of 
FEN1 are important for telomere stability (Saharia et al., 2008). 
 
The above findings prompted us to investigate how FEN1 contributes to telomere 
stability. Here, for the first time, we demonstrate that FEN1 promotes efficient re-
initiation of stalled replication forks. The C-terminal domain of FEN1 and its gap 
endonuclease activity (GEN) are critical for its ability to re-initiate stalled replication 
forks. However, FEN1 depletion does not affect progression through S phase or SV40 
large T antigen-dependent in vitro DNA replication of non-repetitive sequences. Instead, 
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FEN1 depletion leads to replicative stress within telomeric sequences as evidenced by 
expression of fragile sites. Finally, we demonstrate that the PCNA-interacting domain of 
FEN1 is dispensable for its telomere function and that the GEN activity is critical for its 
ability to prevent sister telomere loss (STL). We propose that FEN1 maintains stable 
telomeres through efficient re-initiation of stalled replication forks that occur in the G-rich 
telomere, ensuring high fidelity telomere replication. 
 
Experimental Procedures 
Cell culture 
All cells were grown as reported (Saharia et al., 2008; Saharia and Stewart, 2009; 
Stewart et al., 2003a; Stewart et al., 2002). Briefly, cells were grown at 37 °C in 5% 
carbon dioxide. HeLa and 293T cells were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) containing 10% heat-inactivated fetal calf serum (FCS) and 1% 
penicillin/streptomycin. BJ fibroblasts were cultured in DMEM with 15% Medium 199 
(Sigma, St. Louis, MO), 15% heat-inactivated FCS and 1% penicillin/streptomycin. 
 
Virus production and infection 
Lentiviral production and cell infections were carried out as described (Saharia et al., 
2008; Saharia and Stewart, 2009; Stewart et al., 2003b). Briefly, 293T cells were 
transfected with TransIT-LT1 (Mirius, Madison, WI). Virus was harvested 48 hours post 
transfection, and infections were carried out overnight in the presence of 10 µg/ml of 
protamine sulfate. Following infection, transduced cells were selected with 1 µg/ml 
puromycin. 
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For adenovirus production, FEN1 cDNAs were cloned into the pShuttle vector 
(Stratagene, La Jolla, CA) at the EcoRV site. The hWT, DA and ΔC cDNAs were 
previously described (Saharia et al., 2008); the ΔP cDNA was previously described 
(Stucki et al., 2001a); the ΔPΔC cDNA was constructed using a forward primer 
complementary to the FLAG epitope 5'-GGT ACC ATG GAC TAC AAA GAC CAT GAC 
GG-3' and the following reverse primer, 5'-CTC GAG TTA TTA GGT GCT GCC TTG 
GCG GCT CTT AC-3', and was cloned into the pShuttle plasmid; the mWT and mED 
cDNAs were previously described (Zheng et al., 2005). Following subcloning, the FEN1 
cDNAs were recombined into the pAdEasy-1 plasmid (Stratagene, La Jolla, CA) and the 
resultant DNA was transfected into HEK293 cells to produce infectious adenovirus. 
Adenovirus production and concentration were carried out according to the 
manufacturer’s protocol using the AdEasy XL Adenoviral Vector System (Stratagene, La 
Jolla, CA). Adenovirus was titered prior to use with the AdEasy Viral Titer kit 
(Strategene, La Jolla, CA) according to the manufacturer’s protocol. 
 
Western blot analyses 
All western blots were conducted as described (Saharia et al., 2008). Antibodies used: 
rabbit polyclonal anti-FEN1 (#586, Bethyl Labs, Montgomery, TX), mouse monoclonal 
anti-Actin (ABCAM, Cambridge, MA), rabbit polyclonal anti-TRF2 (H-300; Santa Cruz 
Biotech, Santa Cruz, CA), mouse monoclonal anti-FLAG M2 (Sigma St. Louis, MO), 
rabbit polyclonal anti-Cyclophilin A (Cell Signaling Technology, Danvers, MA). 
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S phase progression assay 
HeLa cells were cultured for 1 hour in the presence of 50 µM 5-bromo-2-deoxyuridine 
(BrdU) in the dark. The cells were then washed in phosphate buffered saline (PBS), 
replaced in culture medium and harvested at the indicated times. The harvested cells 
were washed with PBS and fixed in 4% paraformaldehyde and 0.1% Triton X-100 in 
PBS for 20 minutes at room temperature. Cells were further permeabilized with 0.1% 
Triton X-100 for 10 minutes on ice and fixed for an additional 5 minutes in 4% 
paraformaldehyde and 0.1% Triton X-100 in PBS. The DNA was denatured with 30 µg 
of DNase I (Sigma, St. Louis, MO) at 37 °C for one hour. BrdU was detected with an 
Alexa Fluor 488-conjugated anti-BrdU antibody (A21303, Invitrogen, Carlsbad, CA) and 
the DNA content of the cells was determined by 7-amino-actinomycin D (7-AAD; BD 
Biosciences, San Jose, CA) staining. The stained cells were analyzed on a 
FACSCalibur machine (BD Biosciences, San Jose, CA). 
 
SV-40 Large-T antigen-dependent in vitro DNA replication assay 
The crude cell extracts for this assay were prepared using HeLa cells as described 
(Brush et al., 1995). Briefly, HeLa cells were harvested, washed in cold isotonic buffer 
[20 mM HEPES, pH 7.8, 1.5 mM magnesium chloride, 5 mM potassium chloride, 250 
mM sucrose, 1 mM dithiothreitol (DTT), 0.1 mM phenylmethylsulfonyl fluoride (PMSF)] 
and then with cold hypotonic buffer (isotonic buffer without sucrose). The cells were 
then swollen on ice for 15 minutes in hypotonic buffer and lysed with 10 strokes of the 
Dounce homogenizer (pestle B). The cell lysate suspension was incubated on ice for 
another 60 minutes. Following this incubation, the lysate was centrifuged at 1700 g at 4 
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°C for 10 minutes to remove the nuclei and then centrifuged again at 12,000 g for 10 
minutes at 4 °C to clarify the lysate. The resulting lysate was flash frozen in liquid 
nitrogen and stored at −80 °C. Linear plasmid DNA (pSVO.11-2K; (Ohki and Ishikawa, 
2004)) used in the replication reactions was prepared by equilibrium centrifugation in 
cesium chloride–ethidium bromide gradients and then digested with BbsI (New England 
Biolabs, Ipswich, MA). The in vitro replication reactions were carried out as described 
(Brush et al., 1995). Briefly, each 25 µL reaction contained 30 mM HEPES/hydrochloric 
acid pH 7.8, 7 mM magnesium chloride, 4 mM ATP, 200 µM each of CTP, UTP, GTP, 
100 µM each of dATP, dGTP, dTTP, 0.5 mM DTT, 40 mM creatine phosphate, 0.625 
units creatine phosphokinase, 50 µM (2.5 µCi) [α-32P]dCTP (Perkin-Elmer, Waltham, 
MA), 50 ng linearized plasmid DNA, 1 µg large T antigen (Chimerx, Madison, WI) and 
100 µg cytoplasmic extract. The reaction was incubated for 10 minutes on ice and then 
at 37 °C for the indicated time. To stop the reaction, an equal volume of stop solution 
(2% SDS, 50 mM EDTA, 1 mg/ml Proteinase K) was added and the reaction was 
incubated for an additional 30 minutes at 37 °C. The reactions were subject to a 
phenol/chloroform/isoamyl alcohol extraction and the DNA was precipitated with 
isopropanol, followed by a 70% ethanol wash. To verify that the products were 
generated by semi-conservative replication, additional samples were digested following 
precipitation with 10 units of DpnI (New England Biolabs, Ipswich, MA) for 5 minutes at 
37 °C, which completely degraded the methylated plasmid template. The isolated DNA 
was separated on an agarose electrophoresis gel to determine replication products that 
were quantified using a Phosphor Imager (Amersham, Piscataway, NJ). 
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Replication re-initiation assay 
The protocol was adapted from (Kennedy et al., 2000; Sengupta et al., 2003). Briefly, 
cells were cultured with 1.5 mM hydroxyurea (HU) for 16 hours. The cells were then 
released from HU inhibition into medium containing 150 µM BrdU for 10 minutes in the 
dark. The cells were fixed immediately, permeabilized with 0.5% Triton X-100, and 
treated with 10 units of DNase I at 37°C for 1 hour to denature the DNA. The antibodies 
used for staining were mouse anti-BrdU (BD Biosciences, San Jose, CA); rabbit anti-
FLAG M2 (Sigma, St. Louis, MO); Alexa Fluor 488 goat anti-mouse and Alexa Fluor 546 
goat anti-rabbit (Invitrogen, Carlsbad, CA).  
 
Chromatin immunoprecipitation (ChIP) 
ChIP was conducted as described (Saharia et al., 2008). 
 
Metaphase preparation, FISH, and chromosome orientation FISH (CO-FISH) 
Metaphase preparation, FISH and CO-FISH were conducted as described (Saharia et 
al., 2008). Aphidicolin treatments were conducted as described (Sfeir et al., 2009). 
 
Statistical Analysis 
The Student’s T-test (two-tailed distribution with equal variance) was used for BrdU foci, 
CO-FISH, and fragile telomere analyses. 
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Results 
FEN1 depletion does not impact S phase progression 
Previously, we demonstrated that FEN1 depletion in telomerase-negative cells resulted 
in telomere dysfunction (Saharia et al., 2008). However, in telomerase-positive cells 
neither telomere dysfunction nor cytogenetic abnormalities were observed upon FEN1 
depletion (Saharia et al., 2008). Although this observation suggested that FEN1 is 
dispensable for genomic replication at large, we wished to more directly assess the 
impact of FEN1 depletion on genomic replication by measuring S phase progression. 
Because telomere dysfunction might impact S phase progression and this defect is 
rescued in telomerase-positive cells (Saharia and Stewart, 2009), telomerase-positive 
HeLa cells were transduced with a lentiviral construct encoding a short hairpin RNA 
(shRNA) targeting the FEN1 3'-UTR (shFEN3) or a control hairpin (shSCR). Expression 
of shFEN3 led to a significant reduction in FEN1 protein compared with control cells 
expressing shSCR. To follow cells through the cell cycle, cells were pulsed with 5-
bromo-2-deoxyuridine (BrdU) for one hour to label the S phase population, and cells 
were followed as they continued through the cell cycle. As expected from our previous 
work, in the absence of telomere dysfunction, there was no difference in S phase 
progression when cells were transduced with shFEN3 or shSCR. As shown in Figure 
2.1A, regardless of the status of FEN1, approximately 35% of the cells were in S phase 
after a one-hour BrdU pulse. Both control and FEN1-depleted cells exited S phase and 
progressed through the cell cycle with similar kinetics (Figure 2.1B). These data 
indicates that FEN1 depletion does not significantly impact cell cycle progression and 
suggests that it is not essential for DNA replication in vivo. 
43 
FEN1 depletion does not impact DNA replication kinetics in vitro 
Above, we showed that FEN1 depletion does not impact S phase progression, 
suggesting that other nucleases compensate for FEN1 loss during Okazaki fragment 
processing. However, because minor effects on DNA replication might be missed by the 
S phase progression assay, we next examined the impact of FEN1 depletion on DNA 
replication kinetics through non-telomeric DNA sequences. To measure replication 
kinetics in the presence or absence of FEN1, we conducted an SV40 Large-T antigen-
dependent in vitro DNA replication assay (Brush et al., 1995) using cell lysates isolated 
from control or FEN1-depleted HeLa cells (Figure 2.1C). The DNA replication reaction 
was reconstituted with lysates from control or FEN1-depleted cells and carried out for 0, 
15, 30, 60, and 120 minutes using a linearized plasmid containing an SV40 origin of 
replication. We compared the kinetics of replication by measuring the formation of newly 
synthesized full length linear DNA. As shown in Figures 2.1D and 2.1E, there was no 
difference in DNA replication efficiency when lysates from control versus FEN1-depleted 
cells were used. In addition, we found that the product was insensitive to DpnI treatment 
(data not shown), indicating that DNA replication was semi-conservative and proceeded 
with the same efficiency in control and FEN1-depleted cells. Previous work (Brush et al., 
1995) utilizing a defined, reconstituted system indicated that FEN1 is required for SV40-
dependent DNA replication. However, our data clearly show that replication continues 
unabated upon FEN1 depletion. These results are in agreement with our S phase 
progression data and suggest that other nucleases (e.g. Dna2 and/or ExoI) present in 
the cell lysate compensate for FEN1 function during DNA replication in non-telomeric 
sequences. 
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FEN1 depletion leads to inefficient replication fork restart 
Recently, we demonstrated that in human cells, FEN1 depletion results in telomere 
dysfunction while having little impact on total genome stability (Saharia et al., 2008). 
Above, we showed that FEN1 depletion has no impact on S phase progression or DNA 
replication kinetics in vitro. These results were intriguing as they suggested that other 
proteins compensate for FEN1 depletion during genomic replication and/or repair, but 
these same proteins are ineffective within telomeric sequences. Interestingly, the 
FEN1ΔC mutant that does not interact with WRN is unable to rescue telomere 
dysfunction upon depletion of endogenous FEN1 (Saharia et al., 2008; Sharma et al., 
2005). Given the data implicating FEN1 and WRN in replication fork re-initiation 
(Sharma et al., 2004; Zheng et al., 2005) and the perceived need for this complex for 
efficient telomere replication, we hypothesized that FEN1 is required for the re-initiation 
of stalled replication forks in telomeric sequences. Therefore, we first addressed how 
FEN1 depletion impacts DNA replication fork re-initiation after hydroxyurea treatment. 
 
We have hypothesized that failure to rescue stalled replication forks results in STLs. 
Therefore, we created an experimental paradigm that allowed us to examine the impact 
of FEN1 depletion on the efficiency of re-initiation of stalled replication forks. Because 
telomerase rescues the STL phenotype (Saharia et al., 2008) and we wished to first 
examine the impact of FEN1 loss on re-initiation of stalled replication forks in the 
absence of telomere dysfunction, we carried out our analysis in telomerase-positive 
HeLa cells. 
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Hydroxyurea treatment causes nucleotide depletion, resulting in DNA replication fork 
stalling. Upon removal of hydroxyurea, nucleotide pools recover and stalled DNA 
replication forks re-initiate, allowing S phase to proceed. To investigate whether FEN1 
contributes to DNA replication fork re-initiation, we induced stalled DNA replication forks 
in HeLa cells by treating them with hydroxyurea for 16 hours and then releasing them in 
the presence of BrdU for ten minutes. Because BrdU is only incorporated where DNA 
replication forks re-initiate, the efficiency of fork re-initiation can be determined by 
quantifying BrdU foci (Figure 2.2A) (Kennedy et al., 2000). We hypothesized that if 
FEN1 participates in the stabilization or restart of stalled DNA replication forks, its 
depletion would result in fewer re-initiation events, and thus, fewer BrdU foci would be 
observed. 
 
HeLa cells were transduced with a lentiviral construct encoding shFEN3 or shSCR. 
Expression of shFEN3 led to a significant reduction in FEN1 protein compared to cells 
expressing a control hairpin (shSCR) (Figure 2.2B). Control cells and FEN1-depleted 
cells were cultured for 16 hours in the presence of hydroxyurea and then released from 
hydroxyurea inhibition in the presence of BrdU for 10 minutes (Figure 2.2A). BrdU foci 
were observed by immunofluorescence. As expected, FEN1 depletion resulted in a 
striking decrease in the number of BrdU foci, indicating that FEN1 is important for 
efficient re-initiation of stalled DNA replication forks in vivo (Figure 2.2C). In cells 
expressing the control hairpin, there was an average of 15 BrdU foci per cell. In 
contrast, FEN1 depletion led to an average of 6.5 BrdU foci per cell, a greater than 50% 
decrease (p < 0.0001; Figure 2.2D). Importantly, upon FEN1 depletion, cells retained 
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the ability to re-initiate stalled DNA replication forks, albeit less efficiently. Together 
these results demonstrate that FEN1 is important for efficient restart and/or stabilization 
of stalled DNA replication forks. 
 
To date, the biochemical properties of FEN1 critical to the restart of stalled DNA 
replication forks have not been determined. Therefore, we carried out the re-initiation 
assay described above in cells depleted of endogenous FEN1 and expressing various 
FEN1 mutants as outlined in Figure 2.3A. The different FEN1 alleles used in this study 
included 1) human wild-type (hWT), which is competent for both replication and repair 
functions, 2) D181A (DA), which lacks nuclease activity (Shen et al., 1996), thus 
representing a loss-of-function allele, 3) delta C (ΔC; 20 amino acid deletion of the C-
terminus), which retains near wild-type ability to process flap structures together with 
the replication clamp (Stucki et al., 2001a; Stucki et al., 2001b), PCNA, and is, 
therefore, competent for Okazaki fragment processing but is unable to bind the BLM 
and WRN helicases and participate in FEN1’s DNA repair functions (Sharma et al., 
2005; Stucki et al., 2001a), 4) delta P (ΔP; an eight-amino acid deletion), which retains 
the ability to interact with the RecQ helicases, BLM and WRN, but is unable to interact 
with PCNA (Stucki et al., 2001a; Stucki et al., 2001b), thus rendering it replication-
incompetent yet repair-competent, and 5) delta P–delta C (ΔPΔC; 44-amino acid 
deletion of the C-terminus), which deletes FEN1’s nuclear localization signal and 
abrogates its ability to interact with PCNA, BLM, and WRN, thus creating a second loss-
of-function allele that retains the nuclease domain. Finally, we expressed a mouse 
E160D (mED) mutant FEN1, which retains near wild-type levels of FEN activity and the 
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ability to participate in DNA replication but is devoid of a GEN activity (Zheng et al., 
2007). The GEN activity has been shown to process DNA bubble structures reminiscent 
of stalled replication forks and is hypothesized to participate in re-initiation of stalled 
replication forks (Liu et al., 2006; Zheng et al., 2005). 
 
To facilitate our analysis, we depleted cells of endogenous FEN1. After depletion of 
FEN1, cells were infected with adenoviral constructs expressing a wild-type or mutant 
FEN1 allele. Transduced cells were allowed to grow for 4 days and then treated with 
hydroxyurea for 16 hours followed by a 10-minute BrdU pulse to label re-initiated DNA 
replication forks (Figure 2.3B). To facilitate identification of successfully transduced 
cells, each of the FEN1 constructs was tagged with a FLAG epitope. Therefore, after 
the BrdU pulse, cells were fixed and stained with anti-BrdU and anti-FLAG antibodies, 
and BrdU foci were only quantified in FLAG-positive cells that expressed the transduced 
cDNAs. As expected, expression of hWT FEN1 recovered the number of BrdU foci lost 
in FEN1-depleted cells to numbers slightly higher than that observed in control cells. 
Indeed, expression of wild-type FEN1 led to an average of 18 BrdU foci per nucleus 
compared to 6.5 foci in FEN1-depleted cells, demonstrating that the phenotype 
observed was specific to FEN1 loss (Figures 2.3C and 2.3D). The significance of this 
slight increase in re-initiated replication forks is unclear but may be related to the level 
of FEN1 expression. In contrast, expression of the nuclease-deficient FEN1 mutant 
(also devoid of GEN activity), DA, did not rescue FEN1 depletion and resulted in an 
average of 5.5 foci per nucleus, indicating that the nuclease activity of FEN1 is critical 
for its function in the re-initiation of stalled DNA replication forks (Figures 2.3C and 
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2.3D). Similarly, expression of the ΔPΔC mutant, a functionally null allele, was unable to 
rescue the reduction in BrdU foci observed upon FEN1 depletion (Figures 2.3C and 
2.3D). Expression of FEN1ΔC also failed to rescue the decreased number of BrdU foci 
observed in FEN1-depleted cells. Because this mutant is able to interact with PCNA and 
is competent for Okazaki fragment processing, this result suggests that the interactions 
between FEN1 and the RecQ helicases, BLM and WRN, are important for FEN1’s role 
in the re-initiation of stalled DNA replication forks (Figures 2.3C and 2.3D). Finally, we 
found that expression of the ΔP mutant resulted in an average of 15.6 BrdU foci 
(Figures 2.3C and 2.3D), demonstrating that the FEN1 interaction with PCNA is not 
critical for its role in the re-initiation of stalled DNA replication forks. 
 
Analysis of our FEN1 mutants indicates that FEN1 activity distinct from its ability to 
participate in Okazaki fragment processing is critical for the restart of stalled DNA 
replication forks. This result and the existence of the FEN1 GEN activity, which is 
stimulated by WRN (Liu et al., 2006) to cleave DNA bubble structures that resemble 
stalled replication forks, suggests that this activity is functionally important at stalled 
replication forks. To establish whether the GEN function is important for the restart of 
stalled replication forks, we next tested the impact of expression of a GEN-deficient 
FEN1 mED allele. Expression of the mED mutant failed to rescue the phenotype 
observed in FEN1-depleted cells, which displayed an average of 5.1 BrdU foci per 
nucleus (Figures 2.3C and 2.3D). As expected, the mouse wild-type protein, mWT, 
completely recovered the number of BrdU foci observed upon FEN1 depletion with an 
average of 17 foci per nucleus (Figures 2.3C and 2.3D). Because the mED mutant 
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processes Okazaki fragments near wild-type levels, these data indicate that FEN1 GEN 
activity is required to restart stalled DNA replication forks. 
 
FEN1 localizes to the telomere 
Our previous work supports the hypothesis that FEN1 activity at the telomere is critical 
for high fidelity DNA replication and that other nucleases compensate for FEN1 loss 
across the genome but fail to do so at the telomere (Saharia et al., 2008). Given these 
results, we next wished to characterize the impact of the FEN1 mutants described 
above at the telomere. Because recent work demonstrates that FEN1 localizes to the 
mammalian telomere (Muftuoglu et al., 2006; Saharia et al., 2008; Verdun and 
Karlseder, 2006), we first examined the ability of the FEN1 mutants to localize to the 
telomere. 
 
To determine whether the various FEN1 mutants retain the ability to localize to the 
telomere, we carried out chromatin immunoprecipitation (ChIP) experiments. As 
expected, the hWT FEN1 and FEN1ΔP mutant localized to the telomere (Figures 2.4A 
and 2.4B). In contrast, the FEN1ΔPΔC mutant was unable to precipitate telomeric DNA 
(Figures 2.4A and 2.4B). The latter result was expected because the ΔPΔC mutant 
lacks the nuclear localization domain and is unable to localize to the nucleus (Figure 
2.3A). Finally, both the mWT and mED proteins localized to the telomere. These data 
indicate that FEN1 mutants that retain the ability to participate in replication fork re-
initiation also localize to the telomere. 
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FEN1 depletion leads to the induction of fragile telomeres 
Telomeres are chromosome fragile sites as evidenced by the appearance of multiple 
telomeric signals after aphidicolin treatment (Martinez et al., 2009; Sfeir et al., 2009). 
Interestingly, the presence of these multiple telomere signals also arises upon depletion 
of Apollo, ATM, ATR, BLM, and TRF1, suggesting that several protein components 
repress telomere fragility (Martinez et al., 2009; Sfeir et al., 2009; Undarmaa et al., 
2004; van Overbeek and de Lange, 2006). Because fragile sites are thought to result 
from replication stress and an inability to resolve stalled replication forks (Durkin and 
Glover, 2007), this observation raised the possibility that the STL observed upon FEN1 
depletion (Saharia et al., 2008) is the result of unresolved stalled replication forks and 
expression of fragile sites within telomeric sequences. Given our results above 
demonstrating that FEN1 facilitates re-initiation of stalled replication forks, we 
postulated that FEN1 depletion would lead to fragile telomere expression. Analysis of 
metaphase spreads prepared from aphidicolin-treated or FEN1-depleted BJ fibroblasts 
revealed an increase in fragile telomeres (data not shown and Figure 2.5A). Indeed, 
16% of the chromosomes from BJ fibroblasts depleted of FEN1 demonstrated the 
fragile telomere phenotype, significantly up from the control cells (8.2%; p < 0.0001). 
Surprisingly, this increase in fragile telomere expression was also observed upon FEN1 
depletion in BJ fibroblasts expressing SV40 Large T antigen and telomerase (BJLT). 
FEN1 depletion in BJLT cells resulted in 15.1% of chromosomes exhibiting multiple 
telomere signals, significantly higher than the 9.3% observed in the control samples 
(Figure 2.5B). These results indicate that FEN1 plays a role in the repression of fragile 
site expression at mammalian telomeres. Furthermore, because telomerase expression 
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rescues the STL phenotype (Saharia et al., 2008) but not expression of telomeric fragile 
sites, these results suggest that fragile telomere expression is either upstream of STLs 
or represents a second form of telomere dysfunction independent of STLs. 
 
FEN1’s DNA replication fork re-initiation activity is critical to telomere stability 
The telomere consists of G-rich repetitive DNA that has the propensity to form 
secondary structures, including G-quadruplexes that can impede the movement of the 
DNA replication fork (Gilson and Geli, 2007; Maizels, 2006; Miller et al., 2006; Ohki and 
Ishikawa, 2004; Verdun and Karlseder, 2006). Indeed, it has been hypothesized that 
stalled DNA replication forks frequently occur at the telomere (Gilson and Geli, 2007; 
Verdun and Karlseder, 2006). Failure to resolve a stalled DNA replication fork within the 
telomere would lead to fork collapse, formation of a double strand DNA break, and 
telomere loss (Branzei and Foiani, 2005). In support of this, recent studies suggest that 
collapsed replication forks at telomeres lead to the formation of very short telomeres 
(Crabbe et al., 2004; Khadaroo et al., 2009; Xu and Blackburn, 2007), and, as 
discussed above, the expression of fragile telomeres (Martinez et al., 2009; Sfeir et al., 
2009). We recently demonstrated that FEN1 depletion results in telomere dysfunction 
characterized by STLs (Saharia et al., 2008), indicating that FEN1 functions in telomere 
maintenance through DNA replication or repair. Given our observation that FEN1 
contributes to efficient re-initiation of stalled DNA replication forks, we next wished to 
determine whether it was the role of FEN1 in Okazaki fragment processing or the restart 
of stalled DNA replication forks that contributes to telomere stability. Because 
telomerase expression compensates for FEN1 loss at the telomere, thus masking the 
STL phenotype (Saharia et al., 2008; Saharia and Stewart, 2009), we utilized BJ 
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fibroblasts, which express insufficient telomerase to maintain telomere lengths 
(Masutomi et al., 2003) for these studies. 
 
To determine the impact of FEN1 mutant expression on telomere stability, endogenous 
FEN1 was depleted from BJ fibroblasts (Figure 2.6A). After shRNA-mediated FEN1 
depletion, cells were infected with an adenovirus expressing a wild-type or mutant FEN1 
allele (Figure 2.6B, greater than 85% of the cells were infected; data not shown). 
Because FEN1 depletion leads to lagging strand-specific STL, we analyzed the strand-
specific loss of telomeres in cells expressing different FEN1 alleles (Saharia et al., 
2008). To carry out this analysis, we utilized a technique referred to as chromosome 
orientation fluorescent in situ hybridization (CO-FISH), which takes advantage of the 
fact that the G- and C-rich strands of the telomere are exclusively replicated by lagging 
and leading strand DNA synthesis, respectively (Figure 2.6C). In agreement with our 
previous results (Saharia et al., 2008), FEN1 depletion led to specific loss of lagging 
strand-replicated telomeres (9.8% in shFEN3 cells compared to 3.1% in the control 
shSCR cells; p < 0.0001) while having no impact on telomeres replicated by the leading 
strand machinery (Figures 2.6D and 2.6E). Expression of wild-type FEN1 rescued the 
lagging strand STL phenotype (3.2% lagging strand STLs were observed, similar to that 
observed in shSCR control cells), indicating that the phenotype was specific to FEN1 
depletion. Similarly, expression of the FEN1ΔP mutant resulted in 3.6% lagging strand 
STLs (p < 0.0001 compared with shFEN3), indicating that the FEN1 interaction with 
PCNA, and, hence, its ability to participate in Okazaki fragment processing is not 
important for its function at the telomere. In contrast, expression of the ΔPΔC null allele 
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led to 8% lagging strand STLs, indicating that it failed to rescue telomere dysfunction 
upon FEN1 depletion. Intriguingly, in contrast to the mWT protein, which rescued the 
lagging strand STL defect upon FEN1 depletion, the mED mutant failed to rescue FEN1 
depletion at the telomere. Indeed, expression of mWT significantly decreased the 
number of lagging strand STLs upon FEN1 depletion to 2.8%, whereas expression of 
the mED mutant resulted in lagging strand STLs (9.7%, p < 0.0001) similar to those 
observed in ΔPΔC-expressing cells (Figure 2.6) and in ΔC-expressing cells (Saharia et 
al., 2008). However, the FEN1ΔC protein demonstrated reduced telomere localization, 
raising the possibility that the STL phenotype observed upon FENΔC expression was 
not because of reduced FEN1 re-initiation function, but, rather, its reduced telomere 
localization. Because the mED mutant retains the ability to participate in Okazaki 
fragment processing and localizes to the telomere at the same efficiency as the wild-
type protein (Figure 2.4), the failure of mED to rescue the STL phenotype indicates that 
the FEN1 gap endonuclease activity is critical for its role at the mammalian telomere. 
Furthermore, these data demonstrate that the FEN1 interaction with PCNA is 
dispensable for its role at the telomere. 
 
Discussion 
Telomeres perform a critical cellular function by distinguishing the chromosome end 
from a bona fide double-stranded DNA break. As such, mechanisms that modify the 
activities of DNA repair and replication proteins, presumably through interaction with the 
Shelterin complex, have evolved to protect the telomere and ensure its faithful 
replication. The need for telomere-specific replication mechanisms is likely due to the 
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nature of the telomeric DNA sequence, which presents a number of challenges to the 
DNA replication machinery (Gilson and Geli, 2007; Verdun and Karlseder, 2007). G-
rich, repetitive, telomeric sequences have a high propensity to form secondary 
structures such as G-quadruplexes (G4) that impede the progressing replication fork, 
leading to the formation of stalled forks (Gilson and Geli, 2007; Maizels, 2006; 
Parkinson et al., 2002). Indeed, telomeres were recently identified as fragile sites (Sfeir 
et al., 2009), and several reports have indicated pausing or stalling of replication forks 
within telomeres (Ivessa et al., 2002; Khadaroo et al., 2009; Makovets et al., 2004; 
Verdun and Karlseder, 2006). Additionally, telomere replication is primarily initiated by 
the most centromere-distal origin of replication and continues unidirectionally toward the 
end of the telomere (Sfeir et al., 2009). If a replication fork stalls within the telomere and 
is not re-initiated, the absence of a converging replication fork would result in telomere 
loss. Therefore, mechanisms that facilitate replication fork movement through the 
telomere are critical to high fidelity telomere replication. 
 
The importance of the Shelterin complex to telomere replication is underscored by 
several studies. For example, Taz1 in S. pombe and TRF1 in mice are required for 
efficient telomere replication. Loss of Taz1 results in replication fork stalling throughout 
telomeric sequences (Miller et al., 2006), whereas loss of TRF1 leads to expression of 
fragile telomeres (Sfeir et al., 2009). The ability of telomere-binding proteins to facilitate 
replication fork progression through the telomere is postulated to require recruitment of 
specialized proteins (Gilson and Geli, 2007; Sfeir et al., 2009). For example, TRF1 and 
TRF2 interact with and stimulate the RecQ helicases, BLM and WRN (Lillard-Wetherell 
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et al., 2004; Opresko et al., 2004; Sfeir et al., 2009), suggesting that they recruit these 
proteins to enhance DNA replication and/or repair at the telomeres. Interestingly, a 
recent study demonstrated that TRF2 increases branch migration of Holliday junction 
intermediates, suggesting that this promotes the formation of chicken foot structures in 
the context of a stalled replication fork at telomeres (Poulet et al., 2009). FEN1 also 
interacts with TRF2 (Muftuoglu et al., 2006; Saharia et al., 2008), and because FEN1 
GEN activity is postulated to process chicken foot structures (Liu et al., 2006; Zheng et 
al., 2005), this raises the possibility that TRF2 engages the RecQ helicase–FEN1 
complex coordinately at the telomere to resolve stalled replication forks and enable their 
efficient restart. 
 
WRN participates in the re-initiation of stalled replication forks in vivo (Dhillon et al., 
2007; Sidorova et al., 2008). Interestingly, FEN1 was shown to localize with WRN, 
raising the possibility that it contributes to replication fork restart (Sharma et al., 2004). 
Furthermore, FEN1 and WRN process branch migrating structures that resemble 
regressed replication forks in vitro (Sharma et al., 2004). The present study 
demonstrates for the first time that FEN1 functionally participates in the re-initiation of 
stalled replication forks in vivo. Together with previous work (Nikolova et al., 2009), this 
indicates that FEN1’s role in S phase is two-fold: first, in Okazaki fragment processing 
during DNA replication and, second, in the re-initiation of stalled replication forks. FEN1 
localizes to mammalian telomeres during S phase (Saharia et al., 2008; Verdun and 
Karlseder, 2006), so it could be involved in one or both of the functions outlined above. 
However, given that the proliferating cell nuclear antigen (PCNA)-interacting domain of 
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FEN1 is dispensable for telomere stability, our data indicate that the role of FEN1 in 
Okazaki fragment processing is non-essential for telomere stability. This result indicates 
that either sufficient FEN1 remains in FEN1-depleted cells to support continued 
replication or that other nucleases such as DNA2 or EXO1, which can also process 
Okazaki fragments (Ayyagari et al., 2003; Bae and Seo, 2000; Kang et al., 2000; Kao et 
al., 2004; Moreau et al., 2001), compensate for FEN1 loss during lagging strand DNA 
replication. However, these same nucleases are insufficient when replication forks stall 
within telomeric sequences. Indeed, we find that in the absence of the ability of FEN1 to 
re-initiate stalled replication forks, sister telomeres are lost despite the presence of other 
nucleases. Interestingly, other proteins involved in the re-initiation of stalled replication 
forks such as PARP1 and PARP2 have also been implicated in telomere maintenance 
(Bryant et al., 2009; Dantzer et al., 2004; Ye and de Lange, 2004), further indicating the 
importance of the re-initiation process for efficient telomere replication. An alternate 
hypothesis is that FEN1 is important for fork stabilization after hydroxyurea treatment. 
The assay we have conducted cannot differentiate between FEN1-dependent fork 
stabilization and fork re-initiation. 
 
Intriguingly, the C-terminal region of FEN1 is essential for its function at the telomere 
and also mediates its interaction with another RecQ helicase, BLM (Sharma et al., 
2005). Similar to WRN, BLM is able to unwind G4 DNA, is critical for the re-initiation of 
stalled replication forks, and has recently been suggested to be important for efficient 
telomere replication (Davies et al., 2007; Sengupta et al., 2003; Sfeir et al., 2009; Sun et 
al., 1998). This suggests that there is complicated interplay between WRN, BLM, and 
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FEN1 at mammalian telomeres. Although the function of BLM at telomeres has not 
been well characterized, recent work suggests that it is important for repression of 
fragile telomeres (Sfeir et al., 2009). Interestingly, FEN1 depletion also leads to an 
increase in fragile telomere expression, raising the possibility that these proteins work 
as a complex to repress telomere fragility. Together, these data are consistent with the 
hypothesis that FEN1 and the RecQ helicases play an important role in the 
maintenance of stable telomeres through re-initiation of stalled replication forks. 
 
Here we demonstrate that FEN1 is important for efficient re-initiation of stalled 
replication forks in vivo. This function of FEN1 is dependent on its C-terminal domain 
and its GEN activity. However, despite the importance of FEN1 in re-initiation of stalled 
replication forks, FEN1 depletion in telomerase-positive cells did not affect S phase 
progression or SV40 Large T antigen-dependent in vitro DNA replication, suggesting 
that other nucleases compensate for FEN1-dependent replication function throughout 
the genome. However, these same proteins fail to compensate for FEN1 at the 
telomere. Indeed, FEN1 depletion leads to increased telomere fragility and lagging 
strand STLs. As with the re-initiation of stalled replication forks, both the FEN1 C-
terminus and GEN activity are essential for its function at telomeres, whereas its ability 
to interact with PCNA is dispensable. Collectively, these data demonstrate that FEN1 is 
necessary for efficient replication of telomeres, and we propose that FEN1 promotes 
replication fork re-initiation within telomeric sequences. 
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Figure 2.1. FEN1 depletion does not affect S phase progression or in vitro DNA 
replication. 
(A) Cell cycle progression of HeLa cells expressing shSCR or shFEN3 is shown. HeLa 
cells were labeled with BrdU for 1 h and analyzed at the indicated times using an anti-
BrdU antibody (FITC-conjugated) and 7-amino-actinomycin D (7-AAD) to label DNA 
content. BrdU-positive cells are displayed on the y axis and represent cells that transit 
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through S phase during BrdU labeling. The x axis displays the DNA content of the cells 
as indicated by incorporation of 7-amino-actinomycin D (G1 and G2/M cells have a 2n 
and 4n content of DNA, respectively). 
(B) Quantification of the percent of BrdU-positive cells in S phase after BrdU pulse 
(representative experiment is shown) is shown. The cells present in the inset boxes in 
(A) are BrdU-positive and consist of cells in G1, S, and G2/M phases of the cell cycle. 
Only the S phase cells (those that are present between G1 and G2 (2n and 4n DNA 
content, respectively) within the BrdU-positive population are plotted on the graph. Error 
bars represent S.E. 
(C) Shown are Western blots of S100 lysates from control and FEN1-depleted HeLa 
cells. Cyclophilin A (CycA, lower panel) is shown as a loading control. 
(D) An SV40 Large T antigen-dependent in vitro DNA replication assay was conducted 
using lysates from control (shSCR) and FEN1-depleted (shFEN3) HeLa cells as 
described under Experimental Procedures. The assay was stopped at the indicated 
times, and the replication products were separated via gel electrophoresis. The 
replication products were detected via autoradiography (Autorad), and the input DNA 
was observed via ethidium bromide (EtBr) staining. 
(E) Shown is quantification of the replication products at the indicated times in (D). Two 
independent experiments were conducted in duplicate, and the average of the four 
experiments is shown. The error bars represent S.E. 
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Figure 2.2. FEN1 depletion decreases re-initiation of stalled replication forks. 
(A) Shown is a schematic of the stalled replication fork re-initiation assay and the 
expected results. HU, hydroxyurea. 
(B) A western blot analysis shows FEN1 depletion. Short hairpins against FEN1 
(shFEN3) or a scrambled sequence (shSCR) were expressed in HeLa cells. FEN1 
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(upper panel) and β-actin (lower panel) protein levels were assessed by western blot 
analysis 
(C) Representative images show that FEN1 depletion decreases BrdU incorporation in 
hydroxyurea-treated cells. Immunofluorescence was conducted using an anti-BrdU 
antibody (green) and 4',6-diamidino-2-phenylindole (DAPI, blue). 
(D) Quantification of the number of BrdU foci per cell in HeLa cells transduced with the 
indicated shRNA is shown. BrdU foci in no fewer than 100 cells were counted for each 
condition, and the experiment was conducted twice (a representative experiment is 
presented). Error bars represent S.E. (*, p < 0.0001). 
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Figure 2.3. The gap endonuclease activity and C terminus of FEN1 are essential to 
re-initiate stalled replication forks. 
(A) The schematic shows the different FEN1 alleles used in the study. Inferences on 
whether the different FEN1 alleles are replication competent or repair competent are 
shown on the right of the schematic with their associated references. These inferences 
were made based on nuclease activity and ability to interact with the WRN and PCNA 
proteins. The mutant proteins are as follows: ΔC (amino acids 360 –380 deleted), ΔP 
(amino acids 337–344 deleted), and ΔPΔC (amino acids 337–380 deleted). 
(B) The timeline of the experimental procedure is given in days. 
(C) Representative images show BrdU incorporation after hydroxyurea treatment in 
FEN1-depleted cells expressing wild-type or FEN1 mutants. Immunofluorescence was 
conducted using an anti-BrdU (green) antibody, anti-FLAG (red) antibody, and DAPI 
(blue). 
(D) Quantification of the number of BrdU foci per cell in FEN1-depleted HeLa cells with 
the indicated ectopic FEN1 expression (wild-type or mutant) is shown. Only cells 
expressing FLAG-tagged FEN1 (marked by red in (C)) was quantified. No fewer than 75 
cells were counted for each condition, and the experiment was conducted twice (a 
representative experiment is presented). The error bars represent S.E. (*, p < 0.0001 
compared with shSCR; Δ, p < 0.0001 compared with hWT; #, p < 0.0001 compared with 
mWT). 
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Figure 2.4. FEN1 mutants localize to the telomere. 
(A) FEN1 alleles localize to the telomere. Representative ChIP analysis of 293T cells 
(Ctrl) or 293T cells transfected with wild-type FEN1 (hWT or mWT) or FEN1 mutants 
(ΔP, ΔPΔC, or mED), subjected to immunoprecipitation with the FLAG (M2) antibody. 
Precipitated DNA was probed for the presence of telomeric sequences as described 
under Experimental Procedures. The inputs indicate 0.1% and 0.2% of total. 
(B) Quantification of the representative ChIP assay is shown. Percent of telomeric DNA 
immunoprecipitated with the FLAG antibody was calculated using input DNA, and the 
control pulldown percentage was set to 1. 
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Figure 2.5. FEN1 depletion results in fragile site expression at telomeres. 
(A) Representative FISH of metaphases obtained from BJ fibroblasts (BJ) or BJ 
fibroblasts expressing SV40 Large T antigen and telomerase (BJLT). Cells expressing a 
control hairpin (shSCR) or depleted of FEN1 (shFEN3) are indicated. Chromosomes 
were hybridized with the PNA telomere probe Cy3-(CCCTAA)3 (red) and stained with 
DAPI (blue). Magnified images show representative fragile telomeres (arrowheads). 
(B) Quantification of telomere fragility, depicted as the number of fragile telomeres 
observed per chromosome. No fewer than 60 metaphases from two independent 
experiments were analyzed for each condition, and an average of the two experiments 
is shown (*, p < 0.0001; Δ, p < 0.001). Error bars represent S.E. 
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Figure 2.6. The gap endonuclease activity of FEN1 is essential for its function at 
the telomere. 
(A) Western blot analysis of FEN1 (upper panel) from BJ fibroblasts expressing a 
control hairpin (shSCR) or depleted of FEN1 (shFEN3) is shown. β-Actin (lower panel) 
is shown as a loading control. 
(B) Shown is a timeline of experimental procedure given in days. 
(C) A CO-FISH schematic is shown. Newly synthesized DNA strands incorporate BrdU 
and BrdC. UV and ExoIII treatment resulted in degradation of newly synthesized DNA 
containing BrdU and BrdC, and the template strands were hybridized with Cy3-
(CCCTAA)3 (red, lagging strand) and fluorescein-(TTAGGG)3 (green, leading strand) 
PNA probes. 
(D) Representative CO-FISH of chromosomes from BJ fibroblasts expressing shSCR or 
shFEN3 and the indicated FEN1 alleles as shown. Ctrl refers to cells that do not 
express exogenous FEN1 protein. Color schemes are as described in (C). DNA was 
stained with DAPI (blue). The arrowheads indicate missing telomeres. 
(E) Shown is quantification of STLs on metaphase chromosomes after depletion of 
endogenous FEN1 and expression of the indicated FEN1 allele, depicted as percentage 
of chromosomes with missing leading (green) and lagging (red) strand telomeres. A 
minimum of 60 metaphases from two independent experiments was analyzed per 
treatment in a blinded fashion, and an average of the two experiments is shown (*, p < 
0.0001). The error bars represent S.E. 
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Introduction 
DNA replication and repair are high-fidelity processes that maintain genome stability. 
Due to the importance of these processes, robust mechanisms have evolved to ensure 
they are completed even when components of the replication and repair pathways are 
compromised or absent due to mutation. In some instances, this compensation is 
inadequate. Indeed, mutations in specific replication or repair proteins give rise to 
genetic disorders such as ataxia telangiectasia, Bloom syndrome, and Fanconi anemia. 
Cells from these patients reveal that while gross DNA metabolism continues largely 
unabated, mild replication defects and sensitivity to DNA damaging agents or ionizing 
radiation contribute to genomic instability and increased cancer incidence (Sidorova, 
2008; Singh et al., 2009). 
 
While the redundancy of replication and repair mechanisms ensures faithful replication 
of the bulk genome, regions with repetitive sequence or an ability to form secondary 
structures are problematic and thus particularly sensitive to mutations in DNA replication 
and repair proteins (Gilson and Géli, 2007). This is best illustrated at common fragile 
sites, where replication stressors lead to replication defects and genomic instability. 
Why particular regions of the genome manifest as fragile sites remains obscure, but 
insufficient replication origins, repetitive sequences, and replication–transcription 
interference have all been implicated (Burrow et al., 2010; Helmrich et al., 2011; 
Letessier et al., 2011). 
 
Recently, telomeres have also been described as fragile sites because treatment with 
aphidicolin, a potent inducer of replication stress, results in reduced replication fork 
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progression and abnormal telomere structures (Martínez et al., 2009; Sfeir et al., 2009). 
In checkpoint-competent backgrounds, aphidicolin treatment increases telomere fragility 
by 1.5 to 4.5-fold (Martínez et al., 2009; McNees et al., 2010; Sfeir et al., 2009), while 
suppression of the ataxia and telangiectasia and Rad3-related (ATR) kinase is sufficient 
to induce a 1.7-fold increase in telomere fragility in murine Seckel cells (McNees et al., 
2010). Telomere fragility is also induced in the absence of telomere-binding proteins 
that participate in telomere replication. Indeed, knockout of the Shelterin complex 
member TRF1, which is required for replication fork progression through the telomere, 
increases the rate of telomere fragility in murine cells by 3.0-to 4.5-fold (Martínez et al., 
2009; Sfeir et al., 2009; Vannier et al., 2012); similarly, depletion of the CST complex 
members CTC1 or STN1, which are important for replication fork restart at the telomere, 
causes between a 2.0- and 3.0-fold increase in telomere fragility in human cells 
(Stewart et al., 2012). 
 
DNA replication and repair proteins are also important in maintaining telomere stability 
by preventing or suppressing telomere fragility. We previously reported that depletion of 
flap endonuclease 1 (FEN1) results in a 2.0-fold increase in telomere fragility (Saharia 
et al., 2010). Loss of the DNA glycosylase Nth1, which participates in the repair of 
oxidative stress-induced lesions, causes a 1.8-fold increase in telomere fragility 
(Vallabhaneni et al., 2013). Helicases and topoisomerases also play roles in reducing 
telomere fragility. Depletion of TopoIIα causes up to an approximately 7-fold increase in 
telomere fragility, and depletion of the RecQ helicase BLM induces a 1.9-fold increase 
in telomere fragility (D’Alcontres et al., 2014; Sfeir et al., 2009). Similarly, RTEL1 
depletion or deletion induces 2.3-fold and 4.0-fold increases in telomere fragility, 
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respectively (Sfeir et al., 2009; Vannier et al., 2012). These studies demonstrate the 
wide range of genetic manipulations that can induce telomere fragility with varying 
levels of severity. 
 
The mechanism(s) by which telomere fragility occurs is not clear, but the large number 
of proteins implicated in the phenotype suggests that multiple mechanisms exist. G-
quadruplexes may play a role, as telomere fragility induced by RTEL1 deletion is 
exacerbated by treatment with the G-quadruplex-stabilizing drug TMPyP4 (Vannier et 
al., 2012). Given these data, if the molecular event inducing telomere fragility occurs 
after the replication fork has passed, RTEL1-induced telomere fragility would be 
expected to exhibit lagging strand specificity; however, few studies have examined 
strand-specific telomere fragility. Sfeir et al. examined TRF1 knockout mouse cells 
using chromosome-orientation fluorescent in situ hybridization (CO-FISH), which is 
capable of distinguishing telomeres replicated by the leading versus lagging strand DNA 
replication machinery; they found that telomere fragility induced by loss of TRF1 did not 
exhibit strand specificity (Sfeir et al., 2009). Similarly, Chawla et al. identified UPF1, an 
ATPase and helicase associated with cytoplasmic RNA quality control, as a telomere 
binding protein; in UPF1-depleted cells, telomere fragility increased at both the leading 
and lagging strands, with a slightly larger increase observed at the leading strand 
(Chawla et al., 2011). Most recently, Arora et al. demonstrated that ectopic expression 
of ribonuclease H1 (RNase H1) reduced fragile telomere formation on the leading 
strand in alternative lengthening of telomeres (ALT)-positive cells (Arora et al., 2014).  
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Among the stressors the replisome encounters, transcription has a significant impact on 
DNA replication. Indeed, head-on collisions between the replisome and RNA 
polymerase (RNAP) are extremely damaging to the replication process (Rudolph et al., 
2007). In contrast to head-on collisions, co-directional replisome–RNAP collisions in 
bacteria are more common and better tolerated by the cell (Liu et al., 1993; Prado and 
Aguilera, 2005). This may be due to a mechanism recently elucidated in viral and 
prokaryotic polymerases: following a co-directional collision with RNAP on the leading 
strand-replicated DNA, DNA polymerase III is removed from the template, moves 
forward to the 3′ end of the nascent transcript, displaces RNAP, and restarts DNA 
synthesis using the transcript as a primer (Pomerantz and O’Donnell, 2008). Despite 
this mechanism, which would seem to permit damage-free replication across a region 
being transcribed, co-directional collisions between the replisome and RNAP can lead 
to unresolved RNA:DNA hybrids. If such collisions occur in mammalian cells, the 
RNA:DNA hybrids left behind would likely lead to DNA double strand breaks, an ataxia 
telangiectasia mutated (ATM)-mediated DNA damage response (DDR), and genomic 
instability (Skourti-Stathaki and Proudfoot, 2014; Sordet et al., 2010). Thus, robust 
mechanisms would need to evolve to remove the RNA:DNA hybrids produced by a 
collision event. 
 
The known role of FEN1 in limiting telomere fragility (Saharia et al., 2010), as well as 
the idea that telomere fragility might be the result of replication stress or interference 
with transcription, led us to explore the mechanism by which FEN1 reduces telomere 
fragility. We show that treatment with α-amanitin, which reduces the rate of RNAP 
elongation and thus may increase the rate of stochastic co-directional replisome–RNAP 
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collisions, exacerbates the telomere fragility induced upon FEN1 depletion. Additionally, 
we find that the telomere fragility phenotype induced by FEN1 depletion and collision 
induction is RNA:DNA hybrid-dependent by rescuing telomere fragility with ectopic 
expression of RNase H1. FEN1’s role in limiting telomere fragility is distinct from its role 
in limiting sister telomere loss, as FEN1 depletion-induced telomere fragility is restricted 
to the leading strand. Neither FEN1’s classical replication role as mediated by its 
interaction with proliferating cell nuclear antigen (PCNA), nor FEN1’s DNA repair 
function mediated by its C-terminal interactions with numerous repair proteins are 
required for its activity in limiting telomere fragility. We find that FEN1’s gap 
endonuclease and exonuclease activities are also dispensable for limiting telomere 
fragility, but that FEN1’s flap endonuclease activity is required. Our data support a 
model in which co-directional replisome–RNAP collisions on the leading strand-
replicated telomere produce RNA:DNA hybrid/flap structures that accumulate in the 
absence of FEN1. We propose that FEN1, a classical lagging strand replication protein, 
acts on the leading strand during telomere replication to resolve RNA:DNA hybrid/flap 
structures resembling Okazaki fragment substrates; in the absence of this activity, the 
subsequent replication stress and DNA damage manifests as telomere fragility. We 
believe this to be the first report placing an Okazaki fragment-processing protein 
explicitly on the leading strand during DNA replication. 
 
Experimental Procedures 
Cell culture 
Cells were cultured at 37 °C in 5% carbon dioxide and atmospheric oxygen, as reported 
previously (Saharia et al., 2008, 2010; Stewart et al., 2003a). 293T cells and HEK 293 
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cells were cultured in high-glucose Dulbecco’s modified Eagle’s medium containing 
10% heat-inactivated fetal bovine serum (ΔFBS) and 1% penicillin/streptomycin (P/S) 
(Sigma-Aldrich, St. Louis, MO). BJ fibroblasts and BJ fibroblasts expressing Large T 
Antigen (BJL) were cultured in high-glucose Dulbecco’s modified Eagle’s medium 
containing 15% Medium 199 (HEPES modification), 15% ΔFBS, and 1% P/S. RPE1 
cells were cultured in Dulbecco’s modified Eagle’s medium (F12 modification) 
containing 7.5% ΔFBS and 1% P/S (Sigma-Aldrich, St. Louis, MO). Treatment with α-
amanitin (Sigma-Aldrich, St. Louis, MO) was performed at 10 µg/mL for 12 hours prior 
to collection. All cell cultures were verified free of Mycoplasma contamination by PCR 
analysis. RPE1 cells were obtained from ATCC; all other cells were obtained from Dr. 
Robert Weinberg (Massachusetts Institute of Technology). 
 
Virus production and infections 
Lentiviral production and transductions were carried out as reported previously (Stewart 
et al., 2003b). Briefly, 293T cells were transfected with an 8:1 ratio of pHR′-CMV-8.2ΔR 
packaging plasmid and pCMV-VSV-G, and a pLKO.1-puro plasmid carrying an shRNA 
using TransIT-LT1 (Mirus Bio, Madison, WI). Supernatant-containing virus was collected 
48 hours post-transfection and 72 hours post-transfection and filtered through a 0.45-
µm PVDF membrane. Target cells were infected for four hours each on two consecutive 
days in the presence of 8 µg/mL protamine sulfate (Sigma-Aldrich, St. Louis, MO). 
Following infection, transduced BJ and BJL cells were selected with 1 µg/mL puromycin 
sulfate (Sigma-Aldrich, St. Louis, MO); transduced RPE1 cells were selected with 15 
µg/mL puromycin sulfate. 
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Production of recombinant adenovirus type 5 was carried out using the AdEasy 
adenoviral vector system (Agilent Technologies, La Jolla, CA) according to the 
manufacturer’s protocol. Following collection of primary adenoviral stock, secondary 
and tertiary viral stocks were prepared by sequential infection of HEK 293 cells and 
purification from a cesium gradient. Briefly, infected cells were lysed in 0.5% Nonidet P-
40 and cell debris was cleared by centrifugation. Viral particles were precipitated from 
the lysate with 6.7% PEG 8000, 0.83 M sodium chloride, collected by centrifugation, 
and washed in PBS. Viral particles were suspended in 1.32 g/mL cesium chloride and 
centrifuged at 33,000 rpm for 18 hours at 4 °C in a swinging-bucket rotor. Intact viral 
particles were collected from the cesium gradient, dialyzed in PBS, suspended in 33% 
glycerol, and frozen. Viral stocks were quantified using the AdEasy viral titer kit (Agilent 
Technologies, La Jolla, CA) according to the manufacturer’s instructions. 
 
Adenoviral transduction was carried out following lentiviral transduction. Cells were 
lifted, combined with concentrated adenovirus, and re-plated in media containing 
puromycin to select for lentiviral integration. Adenovirus was used at a multiplicity of 
infection of 20 on RPE1 cells. Following 48 hours of simultaneous selection and 
adenoviral infection, the media was replaced. 
 
Western blot analysis 
Western blots were conducted as described previously (Honaker and Piwnica-Worms, 
2010). Briefly, cells were washed with PBS and lysed in mammalian cell lysis buffer 
(100 mM sodium chloride, 50 mM tris-HCl pH 8, 5 mM EDTA, 0.5% Nonidet P40) 
supplemented with 2 mM dithiothreitol, 1 mM Microcystin-LR, 2 mM 
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phenylmethylsulfonyl fluoride, 1 mM sodium fluoride, 1 mM sodium orthovanadate, 
protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO), and phosphatase inhibitor 
cocktail set I (EMD Millipore, Billerica, MA). Following centrifugation, clarified lysate was 
quantified using the Bio-Rad Protein Assay (Bio-Rad, Hercules, CA). Lysates were 
resolved by SDS-PAGE and transferred to PVDF membranes for western blotting. The 
following antibodies were used: mouse monoclonal anti-Chk1 (sc8408, Santa Cruz 
Biotechnology, Santa Cruz, CA); rabbit monoclonal anti-Chk1, phospho-S345 (2348, 
Cell Signaling Technology, Danvers, MA); rabbit polyclonal anti-FEN1 (A300-255A, 
Bethyl Laboratories, Montgomery, TX); mouse monoclonal anti-RNase H1 (H00246243-
M01, Novus Biologicals, Littleton, CO); rat monoclonal anti-α-tubulin (ab6160, Abcam, 
Cambridge, UK); mouse monoclonal anti-β-catenin (610154, BD Biosciences, San Jose, 
CA); rabbit polyclonal anti-γH2AX (07-164, Millipore, Billerica, MA). 
 
Metaphase chromosome preparation 
Metaphase chromosome spreads were prepared as described previously (Lansdorp et 
al., 1996). Briefly, BJ and BJL fibroblasts were cultured in the presence of 0.1 µg/mL 
colcemid (Sigma-Aldrich, St. Louis, MO) for five hours; RPE1 cells were cultured in the 
presence of 0.3 µg/mL colcemid for four hours. Following arrest, metaphase cells were 
collected by mitotic shake-off, swollen in 75 mM potassium chloride, and fixed in 3:1 
methanol:acetic acid. Chromosomes were spread by dropping onto glass slides and 
aged for 18 hours at 65 °C. When metaphases were to be analyzed by CO-FISH, 0.3 
µg/mL of 5-bromo-2′-deoxyuridine (Sigma-Aldrich, St. Louis, MO) and 0.1 µg/mL of 5-
bromo-2′-deoxycytidine (MP Biomedicals, Santa Ana, CA) were added to the culture 
media 18 hours prior to collection of the cells. 
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Fluorescent in situ hybridization (FISH) 
FISH was performed as described previously (Lansdorp et al., 1996). Metaphase 
chromosomes were probed with a Cy3-(CCCTAA)3 (telomere) peptide nucleic acid 
(PNA) probe at 0.03 µg/mL and a FAM-CENPB (centromere) PNA probe at 0.03 µg/mL 
(PNA Bio, Thousand Oaks, CA) and mounted using ProLong Gold (Life Technologies, 
Grand Island, NY) with 125 ng/mL DAPI (Sigma-Aldrich, St. Louis, MO). 
 
Chromosome-orientation FISH (CO-FISH) 
CO-FISH was conducted as described previously (Bailey et al., 2001) with 
modifications. Briefly, metaphase chromosomes were rehydrated and treated with 100 
µg/mL RNase for 10 minutes at 37 °C, rinsed, and re-fixed in 4% paraformaldehyde for 
10 minutes at room temperature. Chromosomes were UV sensitized in 0.5 µg/mL 
Hoechst 33258 (Sigma-Aldrich, St. Louis, MO) in 2x SSC for 15 minutes and exposed to 
365 nm UV light for 60 minutes using a UV crosslinker (Vilber-Lourmat, Marne-la-
Vallée, France). Chromosomes were then digested with 3 U/µL exonuclease III 
(Promega, Madison, WI) for 15 minutes at room temperature, denatured in 70% 
formamide in 2x SSC at 72 °C for 90 seconds, and immediately dehydrated in cold 
ethanol before hybridization. Metaphase chromosomes were probed first with a FAM-
(TTAGGG)3 (leading strand telomere) PNA probe at 0.03 µg/mL, then probed with a 
Cy3-(CCCTAA)3 (lagging strand telomere) PNA probe at 0.03 µg/mL (PNA Bio, 
Thousand Oaks, CA) and mounted as described for FISH. 
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Immunofluorescence (IF) and IF–FISH 
IF was carried out as described (Duxin et al., 2009). For IF-FISH, following the 
completion of IF, the cells were probed as described for chromosomes above using a 
Cy3-(CCCTAA)3 (telomere) PNA probe at 0.03 µg/mL (PNA Bio, Thousand Oaks, CA). 
Antibodies used were: rabbit polyclonal anti-γH2AX (07-164, Millipore, Billerica, MA) 
and goat anti-rabbit IgG–Alexa Fluor 488 (Life Technologies, Grand Island, NY). 
 
Fluorescence imaging 
Chromosomes were imaged on a Nikon 90i epifluorescence microscope using a 100x 
1.40 NA Plan Apo VC objective (Nikon Instruments, Melville, NY) with Cargille Type FF 
or Cargille Type LDF immersion oil (Cargille-Sacher Laboratories, Cedar Grove, NJ) at 
room temperature. Cells were imaged using a 40x 1.0 NA Plan Apo objective (Nikon 
Instruments, Melville, NY) under the same conditions as those for chromosomes. Filter 
cube sets used were: DAPI-1160B-000-ZERO, FITC-2024B-000-ZERO, and CY3-
4040C-000-ZERO (Semrock, Inc., Rochester, NY).  Images were captured using a 
CoolSnap HQ2 CCD camera (Photometrics, Tucson, AZ). Individual channel lookup 
tables were auto-adjusted non-destructively and linearly, and images were deconvolved 
with a blind algorithm using NISElements AR (Nikon Instruments, Melville, NY) prior to 
quantification. 
 
RNA preparation and northern hybridization 
RNA was prepared using TRI Reagent (Life Technologies, Grand Island, NY). RNA was 
serially diluted, denatured as previously described (Sambrook et al., 1989), and spotted 
onto a Hybond-XL charged nylon membrane (GE Healthcare, Waukesha, WI) using a 
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Bio-Dot Microfiltration apparatus (Bio-Rad, Hercules, CA) according to the 
manufacturers’ instructions. Samples were also treated with ribonuclease A (Roche 
Applied Science, Penzberg, Germany) and spotted to identify any DNA contamination in 
the RNA preparation. Following UV crosslinking, the membrane was prehybridized in 
northern hybridization buffer (15% formamide, 1% BSA, 100 mM sodium phosphate pH 
7.7, 1 mM EDTA, 7% SDS) for one hour at 65 °C. A purified 1.6 kb fragment consisting 
exclusively of vertebrate telomere repeats was random prime-labeled with [α-32P]dCTP 
(3000 Ci/mmol) using the High Prime DNA Labeling Kit (Roche Applied Science, 
Penzberg, Germany) according to the manufacturer’s instructions to produce a 
telomere-specific DNA probe. Similarly, a purified cDNA of the human 5S ribosomal 
RNA was random prime-labeled to produce a 5S rRNA-specific DNA probe. Probes 
were purified using Illustra ProbeQuant G-50 Micro Columns (GE Healthcare, 
Waukesha, WI) and diluted to 1.2×106 dpm/mL in 10 mL of northern hybridization buffer. 
Probes were hybridized to the membrane overnight at 65 °C, after which the membrane 
was washed and imaged using either autoradiography or a storage phosphor screen 
and imager. Quantitation was performed in Fiji by first background subtracting the 
image and then computing the integrated density for each spot. 
 
Quantitative reverse transcription PCR (qRT-PCR) 
For qRT-PCR, cDNA was synthesized using Superscript III reverse transcriptase (Life 
Technologies, Grand Island, NY) according to the manufacturer’s instructions. qRT-
PCR was conducted using TaqMan Gene Expression Assays (Life Technologies, Grand 
Island, NY) according to the manufacturer protocol. Target genes used for verification of 
α-amanitin efficacy were MYC (Hs00153408_m1) and SIAH1 (Hs02339360_m1). 
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Statistical analysis 
Telomere fragility events were defined as chromatid arms with telomere FISH signal 
observed as either multiple telomere signals or elongated smears as previously 
described (Sfeir et al., 2009). Fragility was counted in metaphase chromosome spreads; 
for each experimental condition, a minimum total of 600 chromosomes was counted. 
The minimum sample size was chosen based on its ability to consistently detect 
aphidicolin-induced and FEN1 depletion-induced telomere fragility. Chromosomes 
completely lacking telomere FISH signal or exhibiting no strand specificity in CO-FISH 
(indicating the technical issue of incomplete brominated strand digestion) were excluded 
and not quantified. Image groups were blinded prior to quantification. Two or more 
independent biological replicates were carried out for each experiment. 
 
Where data are shown as representative, the telomere fragility rate was computed for 
each metaphase chromosome spread (% fragile telomeres), and each experiment was 
statistically analyzed. Where data are shown as combined, telomere fragility rates were 
computed for each metaphase chromosome spread, and a normalized value was 
computed for each metaphase chromosome spread by dividing the raw value by the 
mean of the control values. The mean of the normalized values from each sample in 
two independent experiments was computed and graphed with error bars representing 
the standard error of the mean. For statistical analysis, raw values were centered by 
computing a t-statistic for each data point: the centered value for each chromosome 
spread was calculated by dividing the residual of each raw value relative to the control 
sample’s mean by the median absolute deviation of the control values. Centered values 
from two independent experiments were then combined for statistical analysis. Data are 
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represented either by scatter plots with mean and standard error of the mean marked by 
a line and error bars, or by a bar graph with bars indicating the mean and error bars 
indicating standard error of the mean marked. 
 
For IF, γH2AX foci were counted in each nucleus. A minimum of 30 nuclei was counted 
for each condition in an experiment, and two independent biological replicates were 
combined for data quantification. Data are represented by a box and whiskers plot with 
the box marking 25th and 75th percentiles, line marking the median, whiskers marking 
the 5th and 95th percentiles, and dots marking data points outside the 5–95 percentile 
range. 
 
For all data, p-values were computed using a two-tailed Mann-Whitney U test with a 
95% confidence interval in Prism 5 (GraphPad Software, La Jolla, CA). The Mann-
Whitney U test was chosen because not all samples exhibited normal distributions. All 
figures except the box and whiskers plot include standard error of the mean as an 
indicator of variance, and in all cases the variance within samples was similar. 
 
Results 
FEN1 depletion and transcription inhibition induce replication stress and a DNA 
damage response 
Because telomeres are transcribed to produce telomeric repeat-containing RNA 
(TERRA) (Azzalin et al., 2007; Schoeftner and Blasco, 2008), and because interference 
between replication and transcription is a known cause of genomic instability 
(Azvolinsky et al., 2009; Helmrich et al., 2011; Sabouri et al., 2012), we turned our 
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attention to the impact that putative collisions between the replication and transcription 
machinery would have on telomere stability. Unlike in Schizosaccharomyces pombe, 
where transcription of telomeres and subtelomeres occurs using both strands as 
templates (Bah et al., 2012), mammalian telomeres are transcribed exclusively using 
the C-rich leading strand as a template (Azzalin et al., 2007; Schoeftner and Blasco, 
2008); as such, co-directional collisions are the only type that can occur at the telomere. 
In bacteria, co-directional collisions are resolved by a mechanism that leaves behind an 
RNA:DNA hybrid/flap structure (Pomerantz and O’Donnell, 2008) which would need to 
be resolved in a eukaryotic cell to avoid a DDR and genomic instability (Skourti-Stathaki 
and Proudfoot, 2014; Sordet et al., 2010). FEN1 has been previously shown to reduce 
telomere fragility (Saharia et al., 2010), and the yeast FEN1 homolog Rad27p can 
hydrolyze RNA flaps (Stewart et al., 2006). We hypothesized that co-directional 
collisions are a molecular origin of telomere fragility, and that FEN1 can prevent post-
collision RNA:DNA hybrid/flap structures from accumulating, causing damage, and 
ultimately leading to fragile telomere formation. 
 
To address this hypothesis, we first examined whether increasing the rate of stochastic 
collisions between the replisome and RNAP would increase replication stress and 
trigger a DDR in the context of FEN1 depletion. We treated BJ fibroblasts with the RNA 
polymerase II (Pol II) elongation inhibitor α-amanitin, a cyclic peptide toxin that reduces 
the rate of Pol II transcription approximately 100-fold, allowing chain elongation to 
continue without triggering transcript cleavage (Bushnell et al., 2002; Rudd and Luse, 
1996). We expected α-amanitin treatment to increase the frequency of stochastic 
collisions between the replisome and RNAP and thus increase replication stress and 
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telomere fragility. Following transduction with a validated shRNA targeting the 3′-
untranslated region of the FEN1 mRNA (shFEN1) (Saharia et al., 2008) or a control 
hairpin (shCtrl), we treated BJ fibroblasts with either vehicle or 10 µg/mL α-amanitin for 
12 hours and collected both RNA and protein lysates from the cells. qRT-PCR analysis 
confirmed the efficacy of α-amanitin treatment by quantitation of two short-lived 
transcripts, c-Myc and SIAH1. α-amanitin-treated control cells retained 2% and 6% of 
the c-Myc and SIAH1 mRNAs, respectively, compared to the levels observed in vehicle-
treated control cells. Similarly, in FEN1-depleted cells, α-amanitin treatment resulted in 
4% and 10% of the levels of c-Myc and SIAH1 mRNAs, respectively, compared to 
vehicle-treated cells (Fig. 3.1A). Since transcription inhibition by α-amanitin might 
reduce steady-state TERRA levels and produce telomere phenotypes as a result of 
decreased TERRA, we carried out a northern blot analysis of total RNA to detect 
TERRA. Because TERRA are expressed at low levels in BJ fibroblasts, we utilized a dot 
blot rather than a gel to maximize signal intensity and hybridized the membrane to a 
telomere repeat-specific probe; treatment with ribonuclease A was used to show the 
absence of contaminating DNA, and a 5S rRNA-specific probe was used as a loading 
control. Northern analysis of vehicle- and α-amanitin-treated cells demonstrated that the 
α-amanitin treatment conditions subsequently used for western and metaphase analysis 
did not impact steady state levels of TERRA in our system, demonstrating that the 
phenotypes resulting from the treatment were not due to a loss of TERRA, which are 
known to impact telomere stability (Balk et al., 2013; Deng et al., 2009) (Fig. 3.1B,C). 
 
To determine if Pol II inhibition induces replication stress and a DDR in the context of 
FEN1 depletion, we performed western blot analysis to examine phosphorylation of 
96 
Chk1 at S345 and phosphorylation of histone H2AX at S139 (γH2AX), classical markers 
for the replication stress response and DDR, respectively. BJ fibroblasts transduced 
with the control hairpin and treated with vehicle displayed neither Chk1 phosphorylation 
nor H2AX phosphorylation (Fig. 3.2A). Treatment with α-amanitin induced a small but 
detectable increase in Chk1 phosphorylation, but did not induce γH2AX, indicating that 
α-amanitin treatment can induce limited replication stress, but is not sufficient to induce 
a DDR (Fig. 3.2A). Similarly, BJ fibroblasts depleted of FEN1 and treated with vehicle 
also displayed a small level of Chk1 phosphorylation and no detectable γH2AX (Fig. 
3.2A). Strikingly, upon treatment with α-amanitin, FEN1-depleted cells showed a robust 
phosphorylation of Chk1 and strong induction of γH2AX (Fig. 3.2A). 
 
We also used IF to examine the formation of γH2AX foci in asynchronous BJ fibroblasts, 
and IF-FISH to assess the formation of telomere dysfunction-induced foci. 
Quantification of γH2AX foci demonstrated that while FEN1 depletion induced foci 
formation (2.14-fold in shFEN1+vehicle vs. shCtrl+vehicle, p < 0.0001), there was no 
change in γH2AX foci upon treatment with α-amanitin (Fig. 3.2B,C). Furthermore, we 
did not observe an increase in telomere dysfunction-induced foci in response to FEN1 
depletion or α-amanitin treatment (data not shown). These results indicate first that the 
amount of DNA damage induced in conditions that increase collision events causes a 
response only robust enough to be detected by the more sensitive western analysis. 
Second, they indicate that FEN1 depletion- and Pol II inhibition-induced replication 
stress and DNA damage is not restricted to telomeres; rather, DNA damage likely 
occurs throughout the genome wherever collisions occur. Thus, Pol II inhibition alone 
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induces mild replication stress, and the depletion of FEN1 combined with Pol II inhibition 
results in a DDR that is not observed when FEN1 is depleted alone. 
 
Inhibition of transcription exacerbates the telomere fragility observed upon FEN1 
depletion 
We next examined whether the replication stress and DDR phenotypes observed in 
response to Pol II inhibition and FEN1 depletion manifest as telomere fragility. If failure 
by FEN1 to resolve the structures induced by collision events between the replisome 
and RNAP results in fragility, then we anticipated the rate of telomere fragility in α-
amanitin-treated and FEN1-depleted cells to mirror the replication stress phenotype. As 
before, we transduced BJ fibroblasts with either shCtrl (control) or shFEN1 and treated 
the cells with vehicle or α-amanitin for 12 hours prior to collecting metaphase 
chromosomes. Consistent with our model, cells expressing shCtrl exhibited an 
increased rate of telomere fragility upon α-amanitin treatment (1.55-fold in shCtrl+α-
amanitin vs. shCtrl+vehicle, p = 0.0079) (Fig. 3.2D,E). When examining only the 
vehicle-treated cells, we found that as previously demonstrated, FEN1 depletion causes 
a significant increase in telomere fragility (2.15-fold in shFEN1+vehicle vs. 
shCtrl+vehicle, p < 0.0001) (Fig. 3.2D,E). Strikingly, FEN1-depleted cells treated with α-
amanitin displayed a significant 2.76-fold increase in telomere fragility when compared 
to control, vehicle-treated cells (shFEN1+α-amanitin vs. shCtrl+vehicle, p < 0.0001), 
and a significant 1.28-fold increase compared to FEN1-depleted, vehicle-treated cells 
(shFEN1+ α-amanitin vs. shFEN1+vehicle, p = 0.0017) (Fig. 3.2D,E). These fragility 
data mirror the Chk1 phosphorylation phenotype and support a model in which α-
amanitin treatment increases co-directional replisome–RNAP collision events that result 
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in structures requiring FEN1 for resolution; without FEN1, the collision events generate 
replication stress, a DDR, and fragile telomere formation. These experiments suggest 
that FEN1’s role in limiting telomere fragility is dependent upon its ability to resolve 
structures produced by telomere transcription during DNA replication. 
 
Leading strand-specific telomere fragility is caused by RNA:DNA hybrids 
Our data above suggest a role for telomere transcription in telomere fragility induced by 
FEN1 depletion. Based on findings in prokaryotes, if co-directional collisions occur 
between the replisome and an RNAP, a structure resembling an Okazaki fragment with 
a segment of RNA:DNA hybrid would result (Pomerantz and O’Donnell, 2008); we 
postulate that if not resolved, this structure could give rise to fragile telomeres. Indeed, 
post-collision structures resemble R-loops, which are semi-stable displacement loops in 
which a nascent mRNA remains hybridized to its DNA template, while the coding strand 
DNA remains single-stranded, resulting in replication stress and common fragile site 
expression (Helmrich et al., 2011). At common fragile sites, the enzyme RNase H1 
suppresses replication stress phenotypes induced by R-loop formation by hydrolyzing 
the RNA in RNA:DNA hybrids and thus resolving displacement loops (Helmrich et al., 
2011). We reasoned that since the post-co-directional collision structure resembles an 
R-loop, RNA:DNA hybrids might be responsible for telomere fragility, and thus ectopic 
expression of RNase H1 should resolve the structure and telomere phenotype. 
Additionally, because our model predicts that the causative structure for fragile telomere 
formation occurs after the replication fork has passed the locus in question, we 
wondered if the telomere fragility observed upon FEN1 depletion manifests only on the 
leading strand, where collisions could occur. This question was especially prescient 
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given that FEN1 is canonically a lagging strand replication protein, and has a previously 
established role in limiting sister telomere loss at the lagging strand (Saharia et al., 
2010). 
 
Following lentiviral transduction with a control hairpin (shCtrl) or FEN1-depleting hairpin 
(shFEN1), we transduced RPE1 cells with RNase H1 (Ad-RH1) (Fig. 3.3C) and 
collected cells for protein analysis and metaphase chromosome preparation. To identify 
if telomere fragility exhibited strand specificity, we used CO-FISH, a technique which 
exploits the fact that the C-rich and G-rich strands of the mammalian telomere are 
replicated exclusively by the leading and lagging strand machinery, respectively, 
allowing the use of strand-specific probes to identify which machinery replicated a given 
telomere on a metaphase chromosome (Bailey et al., 2001). Strikingly, FEN1 depletion 
significantly increased leading strand-specific telomere fragility (2.30-fold in shFEN1 vs. 
shCtrl, p = 0.0021) (Fig. 3.3A,B) with no change observed on lagging strand-replicated 
telomeres (1.26-fold in shFEN1 vs. shCtrl) (Fig. 3.3A,B). Additionally, ectopic 
expression of RNase H1 rescued fragility on the leading strand-replicated telomere, 
returning fragility levels to those observed in control cells (1.19-fold in shFEN1+Ad-RH1 
vs. shCtrl) (Fig. 3.3A,B). Given the specificity of RNase H1 for RNA:DNA hybrids, these 
data indicate that RNA:DNA hybrids lead to telomere fragility and suggest that the 
hybrid/flap structures that arise from co-directional collisions on the leading strand are 
responsible for the telomere fragility observed upon FEN1 depletion. Furthermore, given 
that RPE1 cells are telomerase-positive and telomerase expression rescues the sister 
telomere loss observed upon FEN1 depletion, these data indicate that FEN1’s role in 
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limiting telomere fragility at the leading strand is distinct from its known role in limiting 
sister telomere loss at the lagging strand (Saharia et al., 2008, 2010). 
 
α-amanitin is known to slow but not disengage the RNAP from the template strand 
(Bushnell et al., 2002; Rudd and Luse, 1996), and its use would be expected to 
increase replisome–RNAP collisions and RNA:DNA hybrids.  Thus, we next wanted to 
determine if the fragility we observed upon α-amanitin treatment was also RNA:DNA 
hybrid-dependent. To address this question, we transduced RPE1 cells with Ad-RH1 
(Fig. 3.4C) and treated the transduced cells with α-amanitin for 12 hours prior to 
metaphase collection. As before, α-amanitin treatment induced an increase in telomere 
fragility (1.79-fold in α-amanitin vs. vehicle, p = 0.0008) (Fig. 3.4A,B). As in the case of 
telomere fragility following FEN1 depletion, ectopic RNase H1 expression protected α-
amanitin-treated cells from telomere fragility, resulting in levels similar to those 
observed in cells treated with vehicle (1.05-fold in Ad-RH1+α-amanitin vs. vehicle) (Fig. 
3.4A,B). Because α-amanitin treatment exacerbates telomere fragility in the absence of 
FEN1 (Fig. 3.2D,E), the ability of RNase H1 to rescue fragility in both α-amanitin-treated 
(Fig. 3.4A,B) and FEN1-depleted cells (Fig. 3.3A,B) suggests that FEN1’s role in limiting 
telomere fragility is to resolve RNA:DNA hybrid/flap structures that are produced 
following replisome–RNAP collisions. 
 
FEN1 flap endonuclease activity is required for limiting telomere fragility 
Given the unprecedented finding that FEN1 limits leading strand-specific telomere 
fragility, we sought to identify which of FEN1’s known functions were necessary for this 
activity. FEN1 possesses three unique enzymatic activities: an endonuclease activity on 
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unannealed 5′ flaps consisting of either DNA or RNA, a weak exonuclease activity that 
cleaves nicks, gaps, or recessed 5′ ends of double-stranded DNA, and a gap 
endonuclease activity that cleaves double-stranded DNA at the 3′ end of a short single-
stranded gap (Liu et al., 2004; Parrish et al., 2003; Zheng et al., 2005). FEN1 is also 
known to interact with PCNA via a PCNA interacting peptide (PIP) box, directly 
pertaining to its role in DNA replication, and a number of DNA repair proteins via its C-
terminus, pertaining to its role in base excision repair (Guo et al., 2008; Li et al., 1995). 
We utilized a series of previously described FEN1 mutants that impact FEN1’s different 
roles in replication (D181A, ΔP, ΔPΔC) versus repair (ΔC, D181A, ΔPΔC, E160D) in 
genetic knockdown–rescue experiments (Saharia et al., 2008, 2010) (Fig. 3.5A). To test 
whether the reduction in telomere fragility mediated by FEN1 requires its DNA repair 
functions, we used a lentiviral vector to express shCtrl (control) alone, shFEN1 alone, or 
shFEN1 simultaneously with the wild type (WT), ΔC, or D181A allele of FEN1 (Fig. 
3.5A); following transduction we prepared metaphase chromosomes. As before, FEN1 
depletion induced leading strand-specific telomere fragility (2.05-fold in shFEN3 vs. 
shLuc, p < 0.0001) (Fig. 3.5B,D). Expression of the WT allele of FEN1 rescued the 
leading strand-specific induction of telomere fragility upon endogenous FEN1 
knockdown, indicating that the phenotype is specific to FEN1 knockdown (1.18-fold in 
shFEN1+WT vs. shCtrl) (Fig. 3.5B,D). Unexpectedly, expression of the ΔC allele also 
rescued FEN1 depletion-induced telomere fragility on the leading strand (1.02-fold in 
shFEN1+ΔC vs. shCtrl) (Fig. 3.5B,D). In contrast to the WT and ΔC alleles, the D181A 
nuclease-dead allele, which is deficient in all known nuclease activities (Shen et al., 
1996; Tsutakawa et al., 2011), failed to rescue the phenotype, instead resulting in an 
increase in leading strand-specific telomere fragility comparable to the expression of 
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shFEN1 alone (1.83-fold in shFEN1+D181A vs. shCtrl, p < 0.0001) (Fig. 3.5B,D). 
Neither knockdown of FEN1 nor expression of any of the mutant alleles of FEN1 altered 
the level of telomere fragility on the lagging strand, confirming that FEN1 does not play 
a role in the phenotype on lagging strand-replicated telomeres (Fig. 3.5B,D). These data 
indicate that FEN1’s flap endonuclease activity is required to limit leading strand-
specific telomere fragility, but its interactions with several DNA repair proteins including 
WRN and BLM (deficient in the ΔC allele), and thus its DNA repair activities, are 
dispensable for this role. Consequently, FEN1’s ability to limit leading strand-specific 
telomere fragility is distinct from its previously described role in telomere stability, which 
depends upon FEN1’s C-terminally mediated DNA repair activity to suppress sister 
telomere loss on the lagging strand-replicated telomere (Saharia et al., 2008, 2010). 
 
Given that FEN1’s repair activity is dispensable for its ability to limit telomere fragility, 
and telomere fragility is associated with replication stress, we next investigated whether 
FEN1’s interaction with PCNA, and thus its replication activity, might be important in this 
role. To test this possibility, BJ fibroblasts depleted of FEN1 were transduced with the 
WT, ΔP, ΔPΔC, or E160D cDNA of FEN1 (Fig. 3.5A). Analysis of telomere fragility on 
metaphase chromosomes revealed that as before, expression of the WT allele rescued 
the leading strand-specific induction of telomere fragility following FEN1 depletion (1.58-
fold in shFEN1 vs. shCtrl, p < 0.0001; 0.88-fold in shFEN1+WT vs. shCtrl) (Fig. 3.5C,D). 
Surprisingly, expression of both the ΔP and E160D constructs also rescued the fragility 
defect (0.77-fold in shFEN1+ΔP vs. shCtrl; 1.20-fold in BJ shFEN1+E160D vs. shCtrl) 
(Fig. 3.5C,D). Only the ΔPΔC allele, a functionally null allele due to its lack of nuclear 
localization, failed to rescue the leading strand telomere fragility observed upon FEN1 
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depletion, resulting in an increase similar to that observed upon FEN1 depletion alone 
(1.61-fold in shFEN1+ΔPΔC vs. shCtrl, p < 0.0001) (Fig. 3.5C,D). As in the previous 
experiment, none of the FEN1 alleles induced lagging strand-specific telomere fragility 
(Fig. 3.5C,D). These data indicate that FEN1 requires neither its interaction with PCNA 
(deficient in the ΔP allele), nor its gap endonuclease and exonuclease activity (deficient 
in the E160D allele) to limit leading strand-specific fragility. In combination with the data 
from expression of the ΔC and D181A mutants, our experiments identify FEN1 flap 
endonuclease activity as necessary for its role in limiting telomere fragility. These data 
are consistent with FEN1’s known activities, as it has previously been shown to cleave 
flap structures with numerous modifications, including flaps composed of RNA (Bornarth 
et al., 1999; Liu et al., 2004; Stewart et al., 2006). As such, our data and the literature 
support a model in which FEN1’s flap endonuclease activity could cleave the RNA:DNA 
hybrid/flap structures produced following a replisome–RNAP collision event (Fig. 3.6). 
 
Discussion 
The role of FEN1 described here provides new insights into the breadth of its functions 
in maintaining genome stability. In addition to known roles in lagging strand DNA 
replication, base excision repair, and lagging strand telomere stability, we illustrate for 
the first time a role for FEN1 in leading strand replication. Furthermore, we have 
identified transcription as an important contributor to telomere fragility, and we have 
shown that FEN1 may resolve the RNA:DNA hybrid/flap structures resulting from 
collisions between the transcription and replication machinery. The strand specificity of 
telomere fragility observed in the absence of FEN1 shows that it has two independent 
molecular roles for promoting telomere stability: (1) FEN1 limits sister telomere loss at 
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the lagging strand-replicated telomere by facilitating replication fork reinitiation (Saharia 
et al., 2010), and (2) FEN1 limits telomere fragility at the leading strand-replicated 
telomere by resolving RNA:DNA hybrid/flap structures produced by co-directional 
replisome–RNAP collisions (Fig. 3.6). 
 
Though co-directional collisions between the replisome and RNAP are postulated to be 
less deleterious to DNA replication than head-on collisions, they still necessitate 
mechanisms to ensure replication fidelity. In bacteria, the primary replicative helicase, 
DnaB, translocates along the lagging strand template as it unwinds DNA ahead of the 
replication fork; as such, the helicase can move past an RNAP transcribing from the 
leading strand, which would result in an inevitable collision between the two 
polymerases (Pomerantz and O’Donnell, 2008). While accessory helicases such as Rep 
move along the leading strand template, this activity alone cannot prevent co-directional 
collisions (Atkinson et al., 2011; Pomerantz and O’Donnell, 2008). Bacteria thus can 
use a mechanism in which replication restarts on the leading strand template following a 
co-directional collision using the 3ʹ′ end of the nascent mRNA as a primer (Pomerantz 
and O’Donnell, 2008). Collisions between the replisome and RNAP also present a 
problem to the eukaryotic cell, where highly-transcribed Pol II and Pol III genes are 
known to impede replication fork progression (Azvolinsky et al., 2009; Sabouri et al., 
2012). Extremely long genes that require more than a single cell cycle to transcribe are 
also known to induce collision events; these collisions induce common fragile site 
expression (Helmrich et al., 2011). Observations suggest that even though the 
eukaryotic replicative helicase, a complex of Cdc45, Mcm2-7, and GINS (CMG), 
translocates along the leading strand (Fu et al., 2011), its activity is insufficient to 
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prevent collisions from occurring. Indeed, CMG is unable to bypass both biotin-
streptavidin and Qdot (20 nm) roadblocks on the leading strand (Fu et al., 2011). Even 
though the eukaryotic replicative helicase translocates along the leading strand, our 
data suggest that it is unable to bypass an RNAP and/or RNA:DNA hybrid on this 
strand. Together, these observations suggest that eukaryotes require a similar 
mechanism to that used by bacteria for the resolution of co-directional replisome–RNAP 
collisions on the leading strand. 
 
Although FEN1 has no known existing roles in leading strand DNA replication, our 
results provide an explanation consistent with the enzyme’s known substrates and 
activity. The putative RNA:DNA hybrid/flap structure produced following a co-directional 
replisome–RNAP collision is similar to the Okazaki fragment flaps FEN1 cleaves during 
lagging strand replication—differing only in that the flap is composed entirely of 
ribonucleotides. Thus, our model suggests that human FEN1 acts at the leading strand 
because co-directional collisions at the telomere only happen on the leading strand 
template. Because FEN1’s ability to limit telomere fragility does not require its C-
terminal domain, which interacts with the shelterin protein TRF2 to recruit FEN1 to 
telomeres during S and G2 phases of the cell cycle (Muftuoglu et al., 2006; Saharia et 
al., 2008), it is unlikely that FEN1’s ability to process post-collision structures is limited 
to the telomere. However, in other portions of the genome where replication begins from 
origins to either side of a particular locus, transcription could be more coordinated with 
replication to prevent head-on collisions from occurring. Wherever co-directional 
collisions occur, FEN1 is likely able to process the structures produced. 
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Because the replication fork replicates the telomere in the centromere-to-telomere 
direction only, and because mammalian telomeres are only transcribed from the C-rich 
leading-strand template in the same direction (Azzalin et al., 2007; Schoeftner and 
Blasco, 2008), replisome–RNAP collisions at the telomere can only occur co-
directionally. Our work here, as well as the fact that TERRA depletion induces telomere 
fragility (Deng et al., 2009), underscores the role of telomere transcription in fragile 
telomere formation. Indeed, work in yeast has shown that RNA:DNA hybrids produced 
by TERRA transcription promote recombination-mediated telomere elongation (Balk et 
al., 2013). In ALT-positive cells, RNase H1 has recently been shown to regulate the 
levels of RNA:DNA hybrids between TERRA and telomeric DNA (Arora et al., 2014). 
Like in yeast, TERRA RNA:DNA hybrids are hypothesized to promote recombination 
between ALT telomeres. In the absence of RNase H1, hybrids accumulate and promote 
excessive replication stress that causes fragile telomere formation and telomere loss; 
conversely, overexpression of RNase H1 reduces TERRA hybrids such that they cannot 
promote recombination, leading to progressive telomere shortening (Arora et al., 2014). 
Strikingly, the telomere loss that occurs following RNase H1 depletion in ALT cells is 
leading strand-specific (Arora et al., 2014). This work, when combined with ours, 
strongly implicates transcription-associated RNA:DNA hybrid formation at the telomere 
as a contributor to telomere fragility. 
 
Despite the recency of telomere fragility as a defined phenotype, it has been identified 
in reports manipulating the expression of many proteins involved in DNA replication and 
telomere stability. ATR deficiency or depletion, BRCA2 deletion, RAD51 depletion, and 
RECQL1 depletion all induce elevated rates of telomere fragility (Badie et al., 2010; 
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Martínez et al., 2009; McNees et al., 2010; Popuri et al., 2014; Sfeir et al., 2009). In 
addition, CTC1 and STN1, both members of the mammalian CST complex, limit 
telomere fragility (Stewart et al., 2012). Like FEN1, these proteins participate in 
replication fork progression, replication fork reinitiation, and telomere stability. To our 
knowledge, no report has identified any perturbation that induces telomere fragility 
exclusive to the leading or lagging strand, though RNase H1 overexpression has been 
shown to reduce telomere fragility at the leading strand (Arora et al., 2014). Indeed, the 
lack of strand specificity in the telomere fragility produced by TRF1 deletion (Sfeir et al., 
2009), as well as the involvement of G-quadruplexes (which form exclusively on the 
lagging strand) in RTEL1 deletion-induced telomere fragility (Vannier et al., 2012), 
suggests that there are multiple mechanisms leading to fragile telomere formation. Our 
work underscores the complexity of DNA replication, and in placing the canonical 
Okazaki fragment-processing protein FEN1 at the leading strand, reveals the first 
molecular mechanism for fragile telomere formation on the leading strand. 
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Figure 3.1. α-amanitin treatment abrogates expression of mRNAs with short half lives 
but does not alter steady-state TERRA levels. (A) qPCR analysis of c-Myc and SIAH1 
mRNA expression in cells expressing a control hairpin (shCtrl) or FEN1-depleted cells 
(shFEN1), treated with either vehicle or α-amanitin (α-aman). mRNA levels in α-
amanitin-treated cells are shown as a fold change relative to the vehicle-treated cells. 
Fold changes were calculated using the ΔΔCt method; fold changes from two biological 
replicates were averaged to produce the graph. Error bars represent standard error of 
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the mean. (B) Northern dot blot to detect TERRA. RNA was isolated from cells 
expressing a control hairpin (shCtrl) or FEN1-depleted cells (shFEN1) that were treated 
with either vehicle or α-amanitin (α-aman). Serial dilutions of RNA were loaded onto a 
membrane. Samples treated with RNase A to control for genomic DNA contamination 
were also loaded (+RNase A). A telomere repeat DNA probe was hybridized to the 
membrane (telomere probe) to detect TERRA; the membrane was stripped and re-
probed with a 5S rRNA DNA probe (5S) as a loading control. The membrane was 
visualized with autoradiography. (C) Quantification of TERRA in cells treated with α-
amanitin. The northern dot blot in (B) was imaged with a phosphor imager and analyzed 
by densitometry using Fiji; TERRA levels in α-amanitin-treated cells are shown as a fold 
change relative to vehicle-treated cells. Two independent experiments were averaged to 
produce the graph; error bars represent standard error of the mean.  
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Figure 3.2. FEN1 depletion and transcription inhibition induce replication stress, a DNA 
damage response, and telomere fragility. (A) Western analysis of FEN1 expression, 
Chk1 phosphorylation (pS345), and H2AX phosphorylation (γH2AX) in control (shCtrl) 
or FEN1-depleted (shFEN1) cells treated with vehicle or α-amanitin (α-aman). β-catenin 
is shown as a loading control. (B) Quantification of γH2AX foci per cell. Two 
independent biological replicates were combined. The box marks the 25th to 75th 
percentile with the median marked by a horizontal line, whiskers mark the 5th and 95th 
percentiles, and dots represent values outside the 5–95 percentile range. p-values were 
computed using a two-tailed Mann-Whitney U test (***, p < 0.001 relative to shCtrl). (C) 
Representative immunofluorescence images stained with a γH2AX antibody (green) 
and DAPI (blue) from BJ fibroblasts expressing a control hairpin (shCtrl) or depleted of 
FEN1 (shFEN1). Cells were treated with vehicle or α-amanitin (α-aman) as indicated. 
The scale bar (white) represents 25 µm. (D) Representative quantification of the rate of 
telomere fragility. p-values were computed using a two-tailed Mann-Whitney U test (**, p 
< 0.01; ***, p < 0.001). Error bars represent standard error of the mean. (E) 
Representative metaphase chromosomes processed with FISH from BJ fibroblasts 
expressing a control hairpin (shCtrl) or depleted of FEN1 (shFEN1). Cells were treated 
with vehicle or α-amanitin (α-aman) as indicated. Centromeres are green and telomeres 
are red. Arrowheads mark fragile telomeres in the magnified images. 
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Figure 3.3. RNA:DNA hybrids are responsible for FEN1 depletion-induced leading 
strand-specific telomere fragility. (A) Representative metaphase chromosomes 
processed with CO-FISH from RPE1 cells expressing a control hairpin (shCtrl) or 
depleted of FEN1 (shFEN1), with or without ectopically expressed RNase H1 (Ad-RH1). 
Leading strand-replicated telomeres are green and lagging strand-replicated telomeres 
are red. Arrowheads mark fragile telomeres in the magnified images. (B) Representative 
quantification of the rate of strand-specific telomere fragility, with leading strand-specific 
telomere fragility shown in green and lagging strand-specific telomere fragility shown in 
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red. p-values were computed using a two-tailed Mann-Whitney U test (*, p < 0.05; **, p 
< 0.01). Error bars represent standard error of the mean. (C) Western analysis of FEN1 
and RNase H1 expression in control (shCtrl) or FEN1-depleted (shFEN1) cells, with or 
without ectopically expressed RNase H1 (Ad-RH1). Two exposures of the same RNase 
H1 blot are shown. α-tubulin is shown as a loading control. 
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Figure 3.4. RNA:DNA hybrids are responsible for α-amanitin-induced telomere fragility. 
(A) Representative metaphase chromosomes processed with FISH from RPE1 cells 
with or without ectopically expressed RNase H1 (Ad-RH1) and treated with either 
vehicle or α-amanitin (α-aman). Centromeres are green and telomeres are red. 
Arrowheads mark fragile telomeres in the magnified images. (B) Representative 
quantification of the rate of telomere fragility. p-values were computed using a two-tailed 
Mann-Whitney U test (***, p < 0.001). Error bars represent standard error of the mean. 
(C) Western analysis of RNase H1 expression in cells with or without ectopically 
expressed RNase H1 (Ad-RH1) treated with vehicle or α-amanitin (α-aman). Two 
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exposures of the same RNase H1 blot are shown. α-tubulin is shown as a loading 
control. 
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Figure 3.5. FEN1 flap endonuclease activity is required to limit leading strand-specific 
telomere fragility. (A) Schematic showing FEN1 alleles used in this study. Features 
indicated include a PIP box (PIP), nuclear localization signal (NLS), C-terminal region 
(C), and point mutations. The replication competency, repair competency, and ability to 
rescue telomere fragility (this study) of each allele are shown to the right. (B) 
Representative metaphase chromosomes processed with CO-FISH from BJL fibroblasts 
expressing a control hairpin (shCtrl) or depleted of FEN1 (shFEN1). Leading strand-
replicated telomeres are green and lagging strand-replicated telomeres are red. FEN1 
alleles were ectopically expressed where indicated. Arrowheads mark fragile telomeres 
in the magnified images. (C) Representative metaphase chromosomes processed with 
CO-FISH from BJ fibroblasts expressing a control hairpin (shCtrl) or depleted of FEN1 
(shFEN1). Leading strand-replicated telomeres are green and lagging strand-replicated 
telomeres are red. FEN1 alleles were ectopically expressed where indicated. 
Arrowheads mark fragile telomeres in the magnified images. (D) Quantification of 
strand-specific telomere fragility per chromosome, with leading strand-specific telomere 
fragility shown in green and lagging strand-specific telomere fragility shown in red. Two 
independent biological replicates were analyzed, normalized with shCtrl set to 1 for 
each mutant group, and combined. p-values were computed using a two-tailed Mann-
Whitney U test (***, p < 0.001 relative to shCtrl). Error bars represent standard error of 
the mean. 
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Figure 3.6. A model of FEN1’s role following co-directional replisome–RNAP collisions. 
(A) RNA Pol II (RNAP) transcribes TERRA from the C-rich leading strand. The 
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replisome approaches the transcription complex and a co-directional collision occurs. 
Pol II dissociates from the nascent TERRA. (B) The replisome moves to the 3ʹ′ end of 
the TERRA, leaving a 5ʹ′ RNA flap and RNA:DNA hybrid. (C) The replisome resumes 
replication of the leading strand using the 3ʹ′ end of the nascent TERRA as a primer. (D) 
FEN1 cleaves the 5ʹ′ RNA flap left behind by the collision. (E) FEN1’s cleavage leaves 
behind a gap and a stretch of RNA:DNA hybrid that can be repaired. (F) In the absence 
of FEN1, RNA:DNA hybrid/flap structures accumulate and lead to telomere fragility. 
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Introduction 
Faithful DNA replication is a prerequisite for the maintenance of genome stability and 
cellular proliferation. Because of the continual challenges presented to genome stability 
by environmental and endogenous forms of DNA damage, robust mechanisms have 
evolved to ensure that replication is completed even in the absence of some 
components of the DNA replication and repair machinery. However, some regions of the 
genome with repetitive sequences or secondary structures, such as telomeres, are 
sensitive to mutations or deletions of replication and repair proteins (Gilson and Géli, 
2007). Telomere replication and stability are essential for genome stability, and as such, 
unique mechanisms are present to ensure that telomeres can be replicated despite the 
challenges presented by their repetitive sequence and secondary structure. Central to 
these mechanisms are the six telomere-specific proteins making up the shelterin 
complex: TRF1, TRF2, POT1, Rap1, TPP1, and TIN2 (de Lange, 2005). Once thought 
to act as a protective cap that “hides” telomeres from the DNA repair machinery to 
prevent aberrant chromosome end-to-end fusions, an emerging model for shelterin 
function instead proposes that shelterin coordinates the activities of specific replication 
and repair proteins to ensure telomeres are replicated and maintained. Indeed, a host of 
DNA replication and repair proteins can be found at the telomere: the protein complex 
CST (CDC13, STN1, TEN1), RecQ helicases WRN and BLM, and lagging strand 
replication/base excision repair protein flap endonuclease 1 (FEN1) all have known 
roles in facilitating replication fork progression through the telomere and preventing 
telomere loss (de Lange, 2005; Longhese et al., 2012; Saharia et al., 2010).  
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The loss of replication fork progression induces replication stress; if unresolved, stalled 
forks ultimately produce DNA damage and genome instability (Ozeri-Galai et al., 2011). 
Regions of the genome that frequently become unstable following treatment with the 
replication stress-inducing drug aphidicolin (or other forms of replication stress) are 
known as fragile sites. Why particular loci in the genome manifest as fragile sites is 
unclear, and three mechanisms have been proposed to explain what causes a particular 
locus to be fragile: repetitive, AT-rich sequence that causes replication fork stalling; a 
paucity of sufficient replication origins to rescue stalled forks; and transcription of the 
locus that requires longer than a single cell cycle to complete, thus forcing collisions 
between the replisome and transcription machinery (Burrow et al., 2010; Helmrich et al., 
2011; Letessier et al., 2011). These models are not mutually exclusive, and all may 
contribute to fragile site expression under conditions of replication stress. 
 
Recent work has described telomeres as fragile sites because treatment with 
aphidicolin causes a reduction in replication fork progression through the telomere and 
the formation of abnormal telomere structures (Martínez et al., 2009; Sfeir et al., 2009). 
Additionally, deletion of the shelterin protein TRF1 in mouse cells induces telomere 
fragility; TRF1 prevents telomere fragility by facilitating replication fork progression 
through the telomere (Sfeir et al., 2009). Recently, we demonstrated that FEN1 also 
prevents telomere fragility (Saharia et al., 2010); however, FEN1 depletion-induced 
telomere fragility is restricted to the leading strand-replicated telomere, while TRF1 
deletion induces non-strand-specific telomere fragility (Sfeir et al., 2009). This role for 
FEN1 is distinct from the previously described role in preventing sister telomere loss 
(STL), which is restricted to the lagging strand-replicated telomere (Saharia et al., 
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2008). Moreover, the STL phenotype can be rescued by a FEN1 allele deficient in 
Okazaki fragment processing (ΔP), but is not rescued by alleles deficient in DNA repair 
(ΔC, E160D) (Saharia et al., 2008, 2010). Both repair-deficient alleles (ΔC, E160D), as 
well as the Okazaki fragment processing-deficient allele (ΔP), rescue telomere fragility 
induced upon FEN1 depletion, indicating that FEN1’s roles in preventing STL and 
telomere fragility depend upon distinct biochemical activities of FEN1. We previously 
demonstrated that the C-terminally truncated (30 amino acids), repair-deficient allele of 
FEN1 (ΔC) fails to interact with the shelterin protein TRF2, yet still localizes to the 
telomere. Together, these findings suggest that FEN1 is recruited differentially to the 
telomere for its roles in telomere replication and stability: first, FEN1 is recruited to the 
telomere by TRF2 (via the FEN1 C-terminus) to prevent STL on the lagging strand, and 
second, FEN1 is recruited to the telomere independently of its interaction with TRF2 to 
protect against telomere fragility on the leading strand. 
 
Experimental Procedures 
Plasmids and protein expression 
pProFEN1 and pProFEN1ΔC were produced by PCR amplifying the FEN1 cDNA 
(primers: KasI+FEN1-aa2 and 3′-FEN1-HindIII). PCR product was digested with KasI 
and HindIII (New England Biolabs, Ipswich, MA) and ligated into the KasI and HindIII 
restriction sites in pProEX-HTb (Life Technologies, Grand Island, NY). 
 
For protein production, E. coli transformed with pProFEN1 or pProFEN1ΔC were grown 
in 5 mL of TB (12 g/L tryptone, 24 g/L yeast extract, 0.4% v/v glycerol, 17 mM 
monobasic potassium phosphate, 72 mM dibasic potassium phosphate) supplemented 
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with ampicillin (Sigma-Aldrich, St. Louis, MO) overnight at 37 °C. Saturated culture was 
used to inoculate 2 L of TB supplemented with ampicillin to an OD600 of 0.15, and the 
culture was grown at 37 °C to an OD600 of 0.75. Protein expression was then induced 
by addition of isopropyl β-D-1-thiogalactopyranoside to a concentration of 0.4 mM; cells 
were grown for 2 hours at 37 °C and collected by centrifugation. 
 
Cell culture and baculovirus amplification 
Sf9 insect cells (Spodoptera frugiperda) were obtained from Orbigen (San Diego, CA) 
and propagated at 27 °C as adherent cultures in TNM-FH medium (Grace’s insect 
medium, 3.3 g/L lactalbumin hydrolysate, 3.3 g/L yeastolate ultrafiltrate, 2 mM L-
glutamine, 10% heat-inactivated fetal bovine serum, and 50 µg/mL gentamicin). 
Suspension cultures were seeded from adherent culture at 1.0×106 cells/mL and grown 
in TNM-FH supplemented with 0.1% v/v Pluronic F-68. 
 
Autographa californica multicapsid nucleopolyhedrovirus (baculovirus) encoding human 
his-TRF1 was generously provided by Dr. Titia de Lange (Rockefeller University). 
Baculovirus was amplified for protein production by infecting adherent Sf9 cultures at an 
MOI of 0.1 for 5 days; cells were lifted and pelleted, and supernatant (baculovirus) was 
recovered and stored at 4 °C. For protein expression, 1.2×108 cells were collected from 
suspension culture, pelleted, and resuspended in a conical tube in a volume of amplified 
baculovirus stock corresponding to an MOI of 15. The cells were rocked at room 
temperature for 1 hour, transferred to a spinner flask, volume increased to 100 mL with 
TNM-FH with Pluronic F-68, and cultured at 27 °C for 48 hours. 
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Protein purification 
Hexahistidine-tagged proteins were purified using immobilized metal ion affinity 
chromatography (IMAC). Nickel-charged Sepharose beads (Ni Sepharose 6 Fast Flow, 
GE Life Sciences, Waukesha, WI) were prepared by centrifuging 12 mL of slurry for 5 
minutes at 500 × g. The supernatant was removed and replaced with 5 mL of water. 
The beads were washed by gently rocking the beads for 5 minutes at 4 °C. One 
additional wash with water was conducted and two washes with Buffer A20 (20 mM 
imidazole, 0.5 M sodium chloride, 20 mM tris-HCl pH 7.9) were conducted. The beads 
were sedimented by centrifuging for 5 minutes at 500 × g. 5 mL of Buffer A20 was 
added to make a 50% slurry, and the beads were stored at 4 °C. 
 
For purification of recombinant FEN1, 30 mL of sonication buffer (100 mM sorbitol, 50 
mM tris-HCl pH 7.9, 2X bacterial protease inhibitors [100X: 0.5 mM bestatin, 0.4 mM 
leupeptin, 0.2 mM pepstatin A, 0.2 mM E-64]) was added to each pellet of cells and 
incubated at 4 °C for 30 minutes; the cells were subsequently resuspended. The cells 
were sonicated using a Misonix 3000 sonicator and a micro-tip probe (4 pulses: 10 
seconds on, 10 seconds off, power 6). The lysates were transferred to a 30 mL Oak 
Ridge tube centrifuged at 15,000 rpm in an SA-600 rotor for 30 minutes at 4 °C. The 
supernatant was transferred to a new tube, sodium chloride was added to a 
concentration of 0.5 M, imidazole was added a concentration of 20 mM, and 5 mL of 
prepared Ni Sepharose slurry was added. The slurry samples were incubated at 4 °C on 
a rotator for 1.5 hours. The slurries were then poured into a column (Glass econo 
column, 2.5 cm ID x 5 cm, Bio-Rad, Hercules, CA), allowed to settle, and drained of flow 
through. The beads were washed with 40 column volumes (CVs) of Buffer A20, then 
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with 10 CVs of Buffer A40 (40 mM imidazole, 0.5 M sodium chloride, 20 mM tris-HCl pH 
7.9) to elute weakly-bound proteins. A stepwise elution was then carried out by adding 2 
CVs of elution buffers of increasing imidazole concentrations (50 mM, 100 mM, 150 
mM, 200 mM, 300 mM, 500 mM). All remaining protein was removed by adding 3 CVs 
of Buffer A1000 (1 M imidazole, 0.6 M sodium chloride, 20 mM tris-HCl pH 7.9). 
Separate fractions were collected for each elution. Samples from each wash step and 
fractions were denatured, separated on a 10% polyacrylamide-SDS gel, and visualized 
with colloidal Coomassie (LabSafe GEL Blue, G-Biosciences, St. Louis, MO). 
 
To remove imidazole and concentrate the protein, fractions were dialyzed in purified 
protein buffer (30 mM HEPES pH 7.4, 10% v/v glycerol, 137 mM sodium chloride, 1 mM 
EDTA, 0.1 mM phenylmethylsulfonyl fluoride, 0.125x bacterial protease inhibitors, 1 mM 
dithiothreitol, 0.01% NP40). Each fraction was put into a length (approximately 12 cm) 
of dialysis tubing (Fisherbrand nominal MWCO 12k-14k, 25 mm flat width regenerated 
cellulose, Thermo Fisher Scientific, Waltham, MA) and was stirred in purified protein 
buffer at 4 °C for two days with a change of dialysis buffer at the end of the first day. 
The dialysate was recovered from the tubing and stored at −80 °C. 
 
For purification of recombinant TRF1, baculovirus-infected Sf9 cells were washed twice 
with PBS. The cells were resuspended in Buffer A20 and lysed by sonication were using 
a Misonix 3000 sonicator and a micro-tip probe (4 pulses: 30 seconds on, 30 seconds 
off, power 6). The lysate was centrifuged at 16,000 rpm in an SS-34 rotor for 30 minutes 
at 4 °C to pellet cell debris, and the supernatant was collected and filtered through a 
0.45 um PVDF low protein-binding syringe filter. 1 mL of prepared 50% Ni Sepharose 
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slurry was added to the supernatant and rotated at 4 °C for 2 hours. The slurry was 
poured into a column, allowed to settle, and drained of flow through (Glass econo 
column, 2.5 cm ID x 5 cm, Bio-Rad, Hercules, CA). The beads were washed twice with 
250 CVs of Buffer A20 with protease and phosphatase inhibitors and once with 20 CVs 
of Buffer A60 (60 mM imidazole, 0.5 M NaCl, 20 mM tris-HCl pH 8) to elute weakly-
bound proteins. The remaining protein was eluted in four 3 CV fractions with Buffer 
A1000. Samples from each wash step and fraction were denatured, separated on a 
10% polyacrylamide-SDS gel, and visualized with colloidal Coomassie (LabSafe GEL 
Blue, G-Biosciences, St. Louis, MO). 
 
The eluates were then dialyzed to remove imidazole and concentrate the protein. The 
eluates were transferred into dialysis cassettes (Pierce Slide-A-Lyzer, 10,000 MWCO; 
0.5-3 mL capacity, Thermo Fisher Scientific, Waltham, MA) and stirred in 1.5 liters of 
Buffer D (300 mM potassium chloride, 20 mM HEPES, 3 mM magnesium chloride, 1 
mM dithiothreitol, 2% v/v glycerol, 0.1% v/v NP40, 0.5 mM phenylmethylsulfonyl 
fluoride) at 4 °C overnight, after which the cassettes were transferred to fresh Buffer D 
and allowed to dialyze for 6 hours. The dialysate of purified TRF1 was collected from 
the cassettes and stored at −80 °C. 
 
Recombinant human his-TRF2 was generously provided by Dr. Judith Campbell 
(California Institute of Technology, Pasadena, CA). 
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Mass spectrometry 
Purified human his-TRF1 and his-TRF2 were trypsinized and peptide mass 
fingerprinting was performed using tandem mass spectrometry. All MS/MS samples 
were analyzed using Mascot (Matrix Science, London, UK; version Mascot). Mascot 
was set up to search the uniprot_sprot_20100305 database (unknown version, 515203 
entries). Mascot was searched with a fragment ion mass tolerance of 0.80 Da and a 
parent ion tolerance of 50 PPM. Scaffold (version Scaffold_3_00_08, Proteome 
Software Inc, Portland, OR) was used to validate MS/MS based peptide and protein 
identifications. Peptide identifications with a probability of 95% or greater were accepted 
while protein identifications established at greater than 95% or greater and contained at 
least 1 identified peptide were accepted. 
 
Electrophoretic mobility shift assay 
The duplex telomeric substrate was hybridized by combining complementary ssDNA 
telomere oligonucleotides in a 95 °C, 1 L water bath and allowing to cool below 37 °C. 
20 pmoles of duplex substrate was radiolabeled at the 5′ termini with [γ-32P]ATP (3000 
Ci/mmol) using T4 polynucleotide kinase (New England Biolabs, Ipswich, MA), 
recovered using Illustra MicroSpin G25 columns (GE Healthcare, Waukesha, WI), and 
stored at −20 °C. 
 
25 nM, 50 nM, or 100 nM of recombinant TRF1 was added to labeled telomeric duplex 
(2.5 nM), in 1X TEL buffer (20 mM HEPES pH 7.9, 150 mM potassium chloride, 1 mM 
magnesium chloride, 0.1 mM EDTA, 0.5 mM dithiothreitol, 5% v/v glycerol, 0.1% v/v 
NP-40), and incubated for 20 minutes at 4 °C. For competitor reactions, 1:1, 10:1, or 
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100:1 cold telomeric duplex was added. The reactions were then run out on a native 5% 
polyacrylamide-TAE gel at 300 V at 4 °C for 2 hours. The gel was dried on a vacuum 
gel dryer at 80 °C for 1 hour, then imaged on film for four hours. 
 
Western blot analysis 
Proteins were quantified by running dilutions on a 10% polyacrylamide-SDS gel 
alongside bovine serum albumin (BSA) as standards. For western analysis, proteins 
were separated on a 10% polyacrylamide-SDS gel and transferred to a PVDF 
membrane and processed as previously reported (Saharia et al., 2010). Antibodies 
used were as follows: rabbit polyclonal anti-FEN1 (A300-255A, Bethyl Labs, 
Montgomery, TX), rabbit polyclonal anti-TRF2 (H-300, Santa Cruz Biotech, Santa Cruz, 
CA). 
 
Flap endonuclease activity assay 
Downstream/flap, upstream, and template oligonucleotides were ordered from and 
HPLC-purified by Integrated DNA Technologies (Coralville, IA). Downstream/flap 
oligonucleotide was radiolabeled at the 5′-terminus with [γ-32P]ATP (3000 Ci/mmol) 
using T4 polynucleotide kinase (New England Biolabs, Ipswich, MA) and recovered 
using Illustra MicroSpin G-25 columns (GE Healthcare, Waukesha, WI). Downstream 
oligonucleotide was annealed with the upstream and template oligonucleotides at a 
1:3:3 molar ratio by incubating in 1 L of 95 °C water allowed to cool to room 
temperature. 
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Ladder oligonucleotide was labeled as described above. To make a single base-pair 
ladder, 150 fmoles of labeled ladder were incubated in 1X nuclease assay reaction 
buffer (20 mM HEPES/potassium hydroxide pH 7.4, 1 mM dithiothreitol, 5 mM 
magnesium acetate/5 mM manganese acetate, 10 mM sodium chloride, 100 ug/mL 
BSA) with 0.14 units of snake venom phosphodiesterase, and samples at 5, 15, 30, 45 
seconds, and 3 minutes were collected in 95% formamide containing bromophenol blue 
and xylene cyanol to terminate the reaction.  
 
Labeled substrate and recombinant human FEN1 (MyBioSource, San Diego, CA) or 
Rad27p (Dr. Peter Burgers, Washington University School of Medicine) were incubated 
in reaction buffer (20 mM HEPES / potassium hydroxide pH 7.4, 1 mM dithiothreitol, 5 
mM magnesium acetate, 10 mM sodium chloride, 100 µg/mL BSA) for 5 minutes at 37 
°C. Reactions were terminated by addition of 95% formamide containing bromophenol 
blue and xylene cyanol. Reaction products were separated on a 20% polyacrylamide, 7 
M urea, tris-borate-EDTA gel and imaged using a storage phosphor screen. 
 
Enzyme-linked immunosorbent assay (ELISA) 
ELISA was conducted as reported with modifications (Muftuoglu et al., 2006). 10 nM 
his-TRF1 or his-TRF2 were prepared in 50 µL of ELISA carbonate buffer (16 mM 
sodium carbonate, 34 mM sodium bicarbonate, pH 9.6). The proteins were adsorbed to 
each well on a 96-well immunoassay microplate (BRANDplates, immunoGrade) by 
incubation at 37 °C for 2 hours. The plate was washed three times with 100 µL of ELISA 
wash buffer (PBS + 0.5% v/v Tween-20), and then blocked with 200 µL ELISA 
blocking/binding buffer (Pierce Blocker Casein (Thermo Fisher Scientific, Waltham, MA) 
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+ 0.1% v/v Tween-20) in each well, incubating at 37 °C for 2 hours. After blocking, the 
plate was washed three times with 200 µL ELISA blocking/binding buffer. A range of 
concentrations (0-40 nM) of his-FEN1 or his-FEN1ΔC were prepared in 50 µL of ELISA 
carbonate buffer, added in triplicate to the wells, and incubated at 37 °C for 2 hours. 
The plate was then washed three times with 200 µL ELISA conjugate buffer (50 mM tris-
HCl pH 8.0, 150 mM sodium chloride, 0.05% Tween-20, 1% BSA). 50 µL of primary 
antibody (1:5000 in ELISA blocking/binding buffer: polyclonal rabbit anti-FEN1, A300-
255A, Bethyl Labs, Montgomery, TX) was added to the wells, and incubated at 37 °C for 
one hour. The plate was then washed three times with 200 µL ELISA blocking/binding 
buffer and one time with 200 µL ELISA conjugate buffer. 50 µL of HRP-conjugated 
secondary antibody (1:10,000 in ELISA conjugate buffer: donkey anti-rabbit IgG, 
Jackson ImmunoResearch, West Grove, PA) was added to each well and incubated at 
37 °C for 1 hour. The plate was washed five times with 200 µL ELISA conjugate buffer. 
100 µL of OPD solution (0.1 M citric acid-phosphate buffer pH 5.0, 1 mg/mL o-
phenylenediamine dihydrochloride, 1 µL/mL 30% hydrogen peroxide) was added to 
each well and incubated at room temperature in the dark for 20 minutes. The reactions 
were terminated by adding 50 µL of 3 M sulfuric acid to each well and absorbances 
were read at 490 nm. Values for wells coated with TRF1 or TRF2 were corrected for the 
background signals obtained with addition of 0 nM FEN1. 
 
Oligonucleotides 
Oligonucleotides used were as follows. All oligonucleotides were ordered from 
Integrated DNA Technologies (Coralville, IA). Oligonucleotides used for PCR were 
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ordered with standard desalting; oligonucleotides for the flap endonuclease activity 
assay and EMSA were HPLC purified. 
KasI+FEN1-aa2: 5′-(ACT GGG CGC CGG AAT TCA AGG CCT GGC CAA)-3′ 
3' FEN1-HindIII: 5′-(GAC TAA GCT TTC ATT ATT TTC CCC TTT TAA ACT TCC C)-3′ 
Flap template oligonucleotide 5′-(GCC CAG TCA CGT TGT AAA ACG GGT CGT GAC 
TGG GAA AAC CCT GGC G)-3′ 
Downstream/flap oligonucleotide: 5′-(TCG CGC GTT TCA CGC CTG TTA CTT AAT 
TCA CTG GCC GTC GTT TTA CAA CGT GAC TGG G)-3′ 
Upstream flap oligonucleotide: 5′-(CGC CAG GGT TTT CCC AGT CAC GAC C)-3′ 
Ladder oligonucleotide: 5′-(GTG CCG TAG AAC GCT TTT TTT TTT TTC CGA TCG 
AGA CCT G)-3′ 
Telomere (G): 5′-(TTA GGG TTA GGG TTA GGG TTA GGG)-3′ 
Telomere (C): 5′-(CCC TAA CCC TAA CCC TAA CCC TAA)-3′ 
 
Results 
FEN1 interacts with TRF1 in vitro 
FEN1 is known to interact with TRF2 via the TRF2 myb domain (Muftuoglu et al., 2006), 
and TRF1 and TRF2 share substantial homology between their myb domains (Broccoli 
et al., 1997). Because human FEN1 depletion and murine TRF1 deletion both induce 
telomere fragility, and FEN1’s ability to prevent fragility does not depend on its 
interaction with TRF2, we hypothesized that FEN1 is recruited to the telomere by TRF1 
to prevent telomere fragility. While such an interaction could be indirect, as TRF1 and 
TRF2 are both part of the shelterin complex, our hypothesis was predicated on the 
possibility that FEN1’s interaction with TRF1 would occur independently of its interaction 
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with TRF2. We therefore used an in vitro approach with purified proteins to determine if 
a direct interaction exists between FEN1 and TRF1. We expressed and purified 
recombinant, hexahistidine-tagged (N-terminal) human FEN1 from Escherichia coli 
using immobilized metal ion affinity chromatography (IMAC), and verified its identity by 
western blot. An N-terminal tag was selected because the C-terminal domain of FEN1 is 
known to interact with at least 20 proteins (Guo et al., 2008). To determine if the 
recombinant protein was folded correctly, we carried out an in vitro flap endonuclease 
activity. However, because crystallography studies of human FEN1 have shown that the 
N-terminus localizes into the enzyme active site, we first cleaved the hexahistidine tag 
from the protein using AcTEV protease. Following cleavage and IMAC to remove the 
tag, the protein was incubated with a DNA flap structure in vitro (Figure S4.1A); as 
expected, FEN1 was able to cleave the 5' flap (Figure S4.1B). We also expressed and 
purified recombinant, hexahistidine-tagged human TRF1 from Sf9 cells using IMAC, 
verified the identify of the protein by peptide mass fingerprinting (Figure S4.2), and 
confirmed its conformational integrity using an electrophoretic mobility shift assay 
(EMSA) to determine if the protein bound telomeric dsDNA (Figure S4.3).  
 
To determine if FEN1 interacts directly with TRF1, we used the purified proteins to 
perform an enzyme-linked immunosorbent assay (ELISA). Recombinant TRF1 or TRF2 
(positive control) were adsorbed to an ELISA plate. Following a block for nonspecific 
interactions, recombinant FEN1 was incubated on the plate in a range of concentrations 
to allow binding interactions to occur. After extensive washing, FEN1 was detected with 
an anti-FEN1 antibody, conjugated secondary antibody, and colorimetric reaction. As 
previously reported (Muftuoglu et al., 2006), increasing concentrations of FEN1 
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produced increasing signal when incubated with TRF2 (Figure 4.1). Similarly, increasing 
concentrations of FEN1 produced increasing signal when incubated with TRF1, 
demonstrating that a direct interaction exists between FEN1 and TRF1 (Figure 4.1). 
 
FEN1 interacts with TRF1 via its C-terminal domain 
The observation that FEN1 and TRF1 interact directly supported our model that FEN1 
could be recruited by TRF1 to the telomere to prevent telomere fragility. To better 
characterize the interaction, we sought to determine if TRF1 interacted with FEN1 via 
the same domain that TRF2 interacts with: the C-terminus. Because the FEN1ΔC allele 
cannot rescue STL but does rescue telomere fragility, we anticipated that if the TRF1–
FEN1 interaction is important for preventing telomere fragility, TRF1 should bind to 
FEN1 at a domain other than its C-terminus. To address this possibility, we expressed 
and purified recombinant human FEN1ΔC in E. coli. We again carried out an ELISA, 
adsorbing TRF1 or TRF2 to the plate, and incubating either full-length FEN1 or 
FEN1ΔC on the plate. As before, full-length FEN1 exhibited concentration-dependent 
binding to both TRF1 and TRF2, and FEN1ΔC failed to interact with TRF2 as we 
previously showed using co-immunoprecipitation (Figure 4.2A) (Saharia et al., 2008). 
Strikingly, FEN1ΔC also failed to interact with TRF1, indicating that the FEN1–TRF1 
direct interaction occurs via the FEN1 C-terminal domain (Figure 4.2B). Combined with 
the data that the FEN1ΔC allele rescues telomere fragility, these data demonstrate that 
in contrast to our original hypothesis, the direct interaction between FEN1 and TRF1 
does not contribute to FEN1’s ability to prevent telomere fragility. 
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Discussion 
Our previous data demonstrate two distinct roles for FEN1 in maintaining telomere 
stability. First, FEN1 facilitates replication fork reinitiation in a mechanism dependent on 
its DNA repair activity and/or TRF2 interaction, and this activity prevents sister telomere 
loss on the lagging strand-replicated telomere (Saharia et al., 2008, 2010). Second, 
FEN1 resolves RNA:DNA hybrid/flap structures in a mechanism dependent on its 
nuclease activity, but independent of its replication and repair activities and interaction 
with TRF2. This activity of resolving RNA:DNA hybrid/flap structures is responsible for 
preventing telomere fragility on the leading strand-replicated telomere. Here, we 
investigate if a potential interaction between TRF1, which is known to prevent telomere 
fragility in a non-strand-specific manner (Sfeir et al., 2009), and FEN1 might contribute 
to the latter’s ability to prevent telomere fragility. We find that FEN1 does indeed directly 
interact with TRF1. However, because this interaction requires the C-terminus of FEN1, 
and that domain is dispensable for preventing telomere fragility on the leading strand, 
we conclude that the FEN1–TRF1 interaction is dispensable for FEN1’s ability to 
prevent telomere fragility. 
 
The fact that FEN1 does not require an interaction with either TRF1 or TRF2 to prevent 
telomere fragility merits investigation into whether FEN1’s ability to prevent telomere 
fragility is truly a telomere-specific role, or whether the proposed RNA:DNA hybrid/flap 
resolution activity contributes to genomic stability at non-telomeric loci as well. If FEN1’s 
biochemical activity in preventing telomere fragility occurs throughout the genome as 
part of a mechanism to respond to structures produced by replisome–RNAP collisions, 
then perhaps telomere fragility is simply a visible manifestation of the consequences of 
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a loss of this activity, rather than an indication of a telomere-specific role. Such a 
phenomenon would be consistent with the concept that chromosomal fragile sites are 
an inherent “reporter” of replication stress due to their enhanced sensitivity to conditions 
generating replication stress genome-wide (Ozeri-Galai et al., 2011); telomere fragility 
might simply result from an enhanced sensitivity to replisome–RNAP collisions that 
occur genome-wide and remain unrepaired in the absence of FEN1. On the other hand, 
should FEN1’s molecular activity responsible for preventing telomere fragility occur only 
at the telomere, the necessity of FEN1’s localization to the telomere for this role comes 
into question. If FEN1 does not require an interaction with TRF1 or TRF2 to prevent 
telomere fragility, how might it localize to the telomere for this role? Perhaps the 
presence of FEN1 at the replisome is sufficient for preventing telomere fragility. 
Alternatively, FEN1 might localize to the telomere for this role by an interaction 
independent of its C-terminus, whether an interaction with another shelterin protein or 
an indirect interaction. In addition to interacting with TRF1 and TRF2, FEN1 is known to 
interact with POT1, which stimulates FEN1’s flap endonuclease activity, though the 
domain of FEN1 that POT1 interacts with has not been reported (Miller et al., 2012). 
 
The observation here that TRF1 interacts with the same domain of FEN1 as TRF2 
raises additional questions. Previously, FEN1 has been presumed to localize to the 
telomere and prevent sister telomere loss on the lagging strand in a manner dependent 
on its interaction with TRF2, if not also its interactions with base excision repair proteins 
(Saharia et al., 2008, 2010). At the very least, these new data indicate that because the 
FEN1 C-terminal domain mediates interactions with TRF1 and TRF2, FEN1’s activity in 
preventing STL may be dependent on an interaction with either protein, rather than only 
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TRF2. Since TRF2 interacts with FEN1 via both the TRF2 basic domain (divergent from 
TRF1) and the TRF2 myb domain (conserved with TRF1) (Muftuoglu et al., 2006), it 
seems most likely that the myb domains of both TRF1 and TRF2 are capable of 
interacting with the FEN1 C-terminus, making separation-of-function experiments 
difficult to conduct due to the low probability of identifying a FEN1 mutant that interacts 
differentially with TRF1 and TRF2. However, given that FEN1’s role in preventing 
telomere fragility does not require an interaction with TRF1 or TRF2, it is possible that 
FEN1’s role in preventing STL is actually dependent on another FEN1 C-terminally-
mediated interaction, whether that interaction facilitates FEN1 recruitment to the 
telomere or simply enhances FEN1 activity, such as the FEN1–WRN interaction 
(Sharma et al., 2005). 
 
Though the data here were unable to identify different roles for TRF1 and TRF2 in 
FEN1’s activities at the telomere, they do not speak to the physiological roles that TRF1 
and TRF2 might play with FEN1 in vivo. Interestingly, in an unrepeated experiment, we 
found that TRF1 was able to immunoprecipitate FEN1 from cell lysates, suggesting that 
the interaction observed in vitro might indeed occur in physiological settings. Dissecting 
whether either interaction is more important for FEN1’s telomere roles in vivo would 
require the production of mutants of TRF1 and TRF2 that are competent and 
incompetent to interact with FEN1, either using a knock-in or dominant-negative 
approach. Despite the unanswered questions, this work provides new insight into the 
complexity of DNA replication and repair at the telomere, and proves that FEN1’s 
multiple activities at the telomere cannot be accounted for simply by interactions with 
two different telomere proteins. 
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Figure 4.1. FEN1 interacts with TRF1. 
ELISA showing the interaction between recombinant FEN1 and either TRF1 (green) or 
TRF2 (orange). TRF1 or TRF2 were adsorbed to an ELISA plate, after which varying 
concentrations of FEN1 were incubated on the adsorbed surface. Following extensive 
washing, bound FEN1 was detected with an antibody/horseradish peroxidase-based 
detection system. Error bars represent standard error of the mean; lines are linear 
regressions of each data set. 
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Figure 4.2. FEN1’s interactions with TRF1 and TRF2 are mediated by its C-
terminal domain. 
(A) ELISA showing the interaction between two FEN1 alleles and TRF2. TRF2 was 
adsorbed to an ELISA plate, after which varying concentrations of FEN1 (red) or 
FEN1ΔC (blue) were incubated on the adsorbed surface. Following extensive washing, 
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bound FEN1 was detected with an antibody/horseradish peroxidase-based detection 
system. 
(B) ELISA as in (A), with TRF1 rather than TRF2. In both graphs, error bars represent 
standard error of the mean; lines are exponential plateau regressions of each data set. 
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Figure S4.1. Flap endonuclease activity of recombinant FEN1 
(A) The substrate utilized to assess endonuclease activity. The red strand was 5' 
labeled and hybridized with the green and blue strands to produce the flap structure. 
(B) Untagged FEN1, his-FEN1, or Rad27p (positive control) were incubated with the 
labeled substrate and separated by denaturing polyacrylamide gel electrophoresis. The 
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presence of a 58-nt band indicates substrate that was not cut; cleaved products are 
observed as 38- and 39-nt bands. 
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Figure S4.2. Peptide mass fingerprinting of purified TRF1. 
Purified TRF1 (TERF1) was analyzed by peptide mass fingerprinting; the unique 
spectra corresponding to peptides within TRF1 and corresponding to 18% of the protein 
sequence are highlighted on the TRF1 protein sequence. 
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Figure S4.3. Electrophoretic mobility shift assay of purified TRF1. 
Purified TRF1 was incubated with a radioactive telomeric dsDNA substrate, with cold 
competitor sequence included as indicated. Binding of TRF1 to telomeric DNA is 
indicated by the upward shift of labeled substrate. 
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Conclusions 
Telomeres must be replicated with high fidelity to maintain their stability and ensure 
genome stability. When telomeres are not completely replicated, the consequential 
telomere dysfunction causes a host of cellular defects including activation of a DNA 
damage response, end-to-end chromosome fusions, breakage-fusion-bridge cycles, 
senescence, and cell death (Frias et al., 2012). The genome instability induced by 
telomere dysfunction can even promote carcinogenesis (Begus-Nahrmann et al., 2012). 
These potential problems necessitate mechanisms to ensure telomere replication 
completes in spite of the difficulties presented by the repetitive sequence and secondary 
structures found at telomeres. In this dissertation, I describe distinct roles for a DNA 
replication and repair protein, flap endonuclease 1 (FEN1). FEN1, a structure-specific 
endonuclease, has well-established roles in Okazaki fragment processing during 
lagging strand synthesis, long-patch base excision repair, and the prevention of 
trinucleotide repeat expansion (Balakrishnan and Bambara, 2013). More recently, FEN1 
has been identified as a contributor to telomere stability. Our lab recently demonstrated 
that FEN1 prevents sister telomere loss (STL) on the lagging strand-replicated telomere 
(Saharia et al., 2008). Additionally, FEN1 associates with TRF2 and localizes to the 
telomere during S and G2 phases of the cell cycle, maintains telomere length and 
stability in Saccharomyces cerevisiae and Schizosaccharomyces pombe, and can 
process flaps that form on substrates that fold into G-quadruplexes (Balakrishnan and 
Bambara, 2013). 
 
In light of these data, we chose to examine the roles that FEN1 plays in human 
telomere maintenance. In Chapter 2, we show that FEN1’s flap endonuclease activity, 
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gap endonuclease activity, and C-terminal interactions are required to facilitate 
replication fork restart, and in turn are also required to prevent STL on lagging strand-
replicated telomeres (Saharia et al., 2010). We propose a model in which the G-rich 
sequence encountered by the lagging strand machinery causes spontaneous replication 
fork stalling, which FEN1 is required to resolve. In the absence of FEN1, failure to 
restart the replication fork ultimately leads to STL (Saharia et al., 2010). In Chapter 3, 
we show that FEN1’s nuclease activity, but none of its previously identified activities or 
domains, is required to resolve RNA:DNA hybrid-dependent, leading strand-specific 
telomere fragility. We propose that FEN1 resolves RNA:DNA hybrid/flap structures that 
form following co-directional collisions between the replisome and transcribing RNA 
polymerases (RNAPs). Without FEN1, stochastic collision events cause an 
accumulation of RNA:DNA hybrid/flap structures that ultimately cause telomere fragility. 
Lastly, in Chapter 4, we show that FEN1 interacts directly with the shelterin protein 
TRF1 via the FEN1 C-terminus. We anticipated that the FEN1–TRF1 interaction might 
be required for preventing telomere fragility, as TRF1 knockout mice display increases 
in telomere fragility; however, because the FEN1–TRF1 interaction occurs via the FEN1 
C-terminus, and FEN1’s C-terminus is dispensable for its role in preventing telomere 
fragility, this hypothesis was incorrect. Nevertheless, the knowledge that FEN1 and 
TRF1 can directly interact provides a second means by which FEN1 can localize to 
telomeres, in addition to its established interaction with TRF2 (Muftuoglu et al., 2006). 
 
These data are most intriguing because FEN1’s roles in mammalian telomere 
maintenance appear independent of one another: the STL and telomere fragility 
phenotypes occurring in the absence of FEN1 are exclusively found on lagging and 
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leading strand-replicated telomeres, respectively. These two roles for FEN1 are also 
biochemically and genetically distinct from one another, as FEN1’s ability to reinitiate 
stalled forks and prevent STL is dependent on its C-terminal protein–protein 
interactions, gap endonuclease activity, and flap endonuclease activity. In contrast, 
FEN1’s putative ability to resolve RNA:DNA hybrid/flaps and prevent telomere fragility is 
only dependent on its flap endonuclease activity. Lastly, the work described here 
provides the first molecular mechanism for strand-specific telomere fragility, and the first 
known role for FEN1 in leading strand DNA replication. 
 
FEN1 facilitates replication fork restart and prevents STL on the lagging strand 
Our lab previously demonstrated that FEN1 is required for telomere stability on the 
lagging strand, where FEN1’s nuclease activity and C-terminally-mediated protein–
protein interactions are required to prevent lagging strand-specific STL (Saharia et al., 
2008). Additionally, our lab has shown that FEN1 is required for telomere stability in 
ALT-positive cells, but not telomerase-positive cells (Saharia and Stewart, 2009). While 
these data established a clear role for FEN1 in telomere maintenance, the molecular 
mechanism by which FEN1 prevented STL remained elusive. In Chapter 2, we identify 
the molecular role FEN1 plays at the lagging strand-replicated telomere: FEN1 
facilitates replication fork reinitiation following stalling in a manner dependent on its gap 
endonuclease activity. 
 
We show that while human FEN1 is not required for overt DNA replication in human 
cells, it is required for human cells to reinitiate replication forks stalled by treatment with 
hydroxyurea. A mutant analysis identified that this ability is dependent on FEN1’s 
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nuclease activity, C-terminally-mediated protein–protein interactions, and gap 
endonuclease activity, but is not dependent on FEN1’s interaction with PCNA. 
Strikingly, these requirements precisely mirror those for FEN1’s ability to prevent STL, 
strongly implicating FEN1’s activity at stalled replication forks as the means by which it 
prevents lagging strand-specific STL. Given the lagging strand specificity of the STL 
phenotype, and the fact that FEN1 interacts with the WRN and BLM helicases via its C-
terminus (Sharma et al., 2005), these data suggest an intriguing model for FEN1 
function in fork reinitiation. During DNA replication at the telomere, unwinding of the 
telomere duplex exposes ssDNA, which on the lagging strand template is composed of 
G-rich sequence. This sequence stochastically forms G-quadruplexes, which stall the 
replication fork and prevent further replication. Given that WRN and BLM are known to 
unwind G-quadruplexes and have established roles in telomere stability (Paeschke et 
al., 2010), we propose that FEN1, which is enriched at telomeres in the S and G2 
phases of the cell cycle (Saharia et al., 2008), recruits WRN or BLM to the stalled fork to 
resolve G-quadruplexes, thus facilitating fork reinitiation. 
 
FEN1 resolves replisome–RNAP collision intermediates and suppresses telomere 
fragility on the leading strand 
As we report in Chapter 2, in addition to suppressing lagging strand-specific STL, FEN1 
suppresses telomere fragility. Unlike the STL phenotype, FEN1 depletion-induced 
telomere fragility is not rescued by telomerase expression. Given this distinction, we 
sought in Chapter 3 to explore how FEN1 limits telomere fragility. We propose that 
collisions between the replication fork and transcription complexes at the telomere might 
drive the replication-dependent telomere fragility phenotype. We treated cells with α-
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amanitin to increase the number of stochastic collisions occurring between the 
replication fork and transcribing Pol II by slowing the rate of translocation of Pol II along 
its template. Strikingly, α-amanitin treatment increased the rate of telomere fragility in 
control cells and FEN1-depleted cells, suggesting that replisome–RNAP collisions are 
indeed responsible for telomere fragility. Because the telomere is only transcribed using 
the C-rich leading strand as a template, we surmised that if FEN1 helps resolve 
collision-induced replication stress to prevent telomere fragility, FEN1 depletion should 
induce telomere fragility only on the leading strand. CO-FISH analysis confirmed this 
hypothesis, showing that FEN1-depletion induced telomere fragility is restricted entirely 
to the leading strand-replicated telomere. Based upon work in prokaryotes 
characterizing co-directional replisome–RNAP collisions, we also predicted that 
collisions on the leading strand-replicated telomere should result in an RNA:DNA hybrid 
structure with a 5′ RNA flap. In support of this model, we found that ectopic expression 
of RNase H1, an RNA:DNA hybrid-specific endoribonuclease, rescued cells from the 
telomere fragility phenotype, whether induced by FEN1 depletion or α-amanitin 
treatment. We also showed by mutant knockdown/rescue experiments that FEN1’s flap 
endonuclease activity is required to limit telomere fragility, while its gap endonuclease 
activity, exonuclease activity, and ability to interact with PCNA or WRN are dispensable. 
Given the previous reports demonstrating that FEN1 is capable of cleaving RNA and 
DNA flaps (Bornarth et al., 1999; Liu et al., 2004; Stewart et al., 2006), the requirement 
for FEN1’s flap endonuclease activity is not surprising. Together these data support a 
model in which stochastic co-directional replisome–RNAP collisions occurring at the 
telomere produce an RNA:DNA hybrid/flap intermediate structure; FEN1 cleaves the 
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flaps from these structures and in doing so prevents their accumulation and suppresses 
subsequent telomere fragility. 
 
FEN1 and TRF1 interact via the FEN1 C-terminus 
In Chapter 3, we found that FEN1’s ability to prevent telomere fragility is independent of 
its C-terminally-mediated protein–protein interactions, unlike its ability to prevent STL. 
Notably, the FEN1 C-terminus is required for FEN1’s interaction with the shelterin 
protein TRF2 (Saharia et al., 2008). These data indicate that FEN1’s role in preventing 
telomere fragility does not require an interaction with TRF2, and raise the question of 
how FEN1 might localize to the telomere specifically to prevent telomere fragility. Given 
that the shelterin protein TRF1, which shares significant sequence and structural 
homology to TRF2 (Broccoli et al., 1997), is known to prevent telomere fragility by 
facilitating replication fork progression through the telomere (Sfeir et al., 2009), we 
wondered if a direct FEN1–TRF1 interaction existed, and if such an interaction could 
contribute to the ability of either protein to prevent telomere fragility. Because TRF1 and 
TRF2 are both part of the six-protein shelterin complex, we chose to assess whether 
FEN1 and TRF1 interact directly in vitro, rather than use immunoprecipitation, to avoid 
the possibility of detecting an indirect FEN1–TRF1 interaction that was mediated by 
TRF2. Using purified proteins, we found that FEN1 and TRF1 do interact. However, the 
FEN1–TRF1 interaction, like the FEN1–TRF2 interaction, depends on FEN1’s C-
terminus: a FEN1 mutant lacking its final 20 amino acids (FEN1ΔC) failed to interact 
with TRF1. Since the FEN1ΔC allele is competent to prevent leading strand-specific 
telomere fragility, but fails to interact with TRF1, we conclude that while FEN1 and 
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TRF1 do directly interact, this interaction is dispensable for FEN1’s ability to prevent 
telomere fragility. 
 
FEN1 in human cancers 
Several studies have reported mutations in FEN1 in human cancers. Two FEN1 
germline mutations have been identified that cause decreased FEN1 expression and 
correlate with significantly increased risk for the development of breast cancer (Lv et al., 
2014). A recent genome-wide association study of colorectal cancer in East Asians 
identified a polymorphism in the FEN1 3′-UTR associated with colorectal cancer risk 
(Zhang et al., 2014). Other work has focused on the expression of FEN1 in cancers as a 
potential biomarker. FEN1 is overexpressed in breast, uterine, colon, gastric, lung, and 
renal cancers, and in breast cancer has a hypomethylated promoter associated with this 
increased expression (Singh et al., 2008). In breast and ovarian cancers, higher FEN1 
mRNA and protein expression is associated with higher grade and poor survival, 
indicating its potential as a biomarker in multiple cancer types (Abdel-Fatah et al., 
2014). Perhaps the most persuasive work that suggests that FEN1 plays a role in 
cancer is a study that identified mutations in FEN1’s gap endonuclease and 
exonuclease activities. A mouse carrying the E160D mutation (gap endonuclease- and 
exonuclease-deficient) exhibited chronic inflammation and increased cancer 
susceptibility, especially in the lungs (Zheng et al., 2007). In another study, a FEN1 
germline mutation (E359K) was identified in a family with a history of breast cancer; 
following characterization showing that FEN1 E359K fails to interact with WRN, a 
mouse model carrying the E359K mutation was produced. Cells from E359K mice 
exhibit increased telomere fragility, spontaneous chromosomal anomalies, and 
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transformation. Most significantly, E359K mutants develop spontaneous cancers at a 
rate over four-fold greater than wild-type mice; more than half of E359K mice develop 
lung tumors (Chung et al., 2014). Given that a loss of FEN1 function leads to a DDR 
and replication stress at the telomere, the tumor models and human studies raise the 
possibility that telomere instability (STL and fragility) induced by FEN1 loss of function 
contributes to tumorigenesis.  
 
Future directions 
The molecular structure, formation, and consequences of telomere fragility 
The telomere fragility phenotype has been described in a wide variety of manipulations 
in both mouse and human cells (D’Alcontres et al., 2014; McNees et al., 2010; Saharia 
et al., 2010; Sfeir et al., 2009; Stewart et al., 2012; Vallabhaneni et al., 2013; Vannier et 
al., 2012). Despite these observations, a great deal remains unknown about the 
phenotype. The molecular structure(s) that leads to the observation of multiple or 
smeared telomere signals is unknown; given the three-dimensional structure of 
metaphase chromosomes, it is difficult to predict what primary structure would produce 
such signals, though telomere signal interrupted by non-telomere signal seems a likely 
candidate. Additionally, little is known about the mechanisms by which replication stress 
produces a fragile telomere, and especially whether a fragile telomere is a “lesser of 
evils” repair product that maintains genome stability (as compared to telomere loss), or 
a product of aberrant repair. Lastly, the consequences of fragile telomere formation are 
poorly understood – are these structures pathological or benign, and do they have long-
term consequences for the cell? 
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Several avenues may better elucidate the primary structure of a fragile telomere. One 
way to address this question would be to combine telomere PNA FISH and subtelomere 
DNA FISH on metaphase chromosomes. If the presumed primary structure of a fragile 
telomere is telomere sequence interrupted by non-telomere sequence, the most likely 
origin of the intervening sequence might be the subtelomere. The microhomology 
existing between subtelomere sequences, which is composed of degenerate telomere 
repeats, and telomere sequence, may be sufficient to allow insertion of subtelomere 
sequence into the telomere, or vice versa. Intriguingly, because TRF1 and TRF2 have a 
low tolerance for substitutions in the telomere repeat sequence for binding (Broccoli et 
al., 1997), FEN1 might be unable to localize to these insertions; the absence of TRF1, 
TRF2, or FEN1 in part of a telomere could theoretically destabilize the telomere. These 
types of insertion events could be detected as adjacent or interspersed FISH signals at 
chromosome termini using a combination of differentially labeled telomere PNA FISH 
and subtelomere DNA FISH. Because subtelomere probes are chromosome-specific, 
this approach holds the potential to reveal the source of intervening subtelomere 
sequence as an intra-chromosomal rearrangement or inter-chromosomal 
translocation/amplification. Additional information might also be gained by employing 
super-resolution microscopy to examine metaphase chromosomes. Recent work has 
employed stochastic optical reconstruction microscopy (STORM) to observe t-loops in 
interphase nuclei by PNA FISH (Doksani et al., 2013); while a chromosome is more 
compacted than an interphase nucleus, the application of similar techniques to 
metaphase chromosomes may yield additional clarity on the structure of a fragile 
telomere. Multiple telomere signals and telomere signal smears are both quantified as 
fragile telomeres, but it is unknown if they represent a similar structure due largely to the 
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diffraction limit in conventional fluorescence microscopy; the application of super-
resolution microscopy may allow for the classification of different “fragile” abnormalities 
to determine if they are of a common molecular origin. A complementary approach with 
the resolution to show the true linear structure of a fragile telomere would be to utilize 
FISH with DNA combing to examine individual, linearly stretched telomeres. However, 
the current microfluidic technology used in this technique is limiting for such an analysis, 
as the track lengths of DNA obtained are often shorter than the multiple kilobases that 
would be required to visualize a single telomere, much less a fragile telomere with 
additional sequence. Another route to identifying the sequence composition of a fragile 
telomere would be high-throughput sequencing; unfortunately, the read lengths of 
current sequencing technologies and short repeat composition of telomere sequence 
result in the inability to map non-telomere sequence that interrupts a telomere to a 
reference sequence. While the combing and sequencing approaches to examining 
fragile telomeres appear less practical due to technical limitations, the combination 
FISH approach on metaphase chromosomes is feasible, if labor intensive; super-
resolution imaging of metaphase chromosomes, on the other hand, could be as easily 
completed as a typical FISH experiment, with hardware availability being the only 
limitation. 
 
Addressing the mechanism of formation of a fragile telomere presents its own 
challenges. While assumptions have been made that fragile telomere formation likely 
requires the DNA repair machinery, elucidating which DNA repair pathways play a role 
remains an important goal in understanding telomere fragility. Normally, the best 
approach to such a question would be a genetic one, knocking down or knocking out 
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genes involved in various DNA replication and repair pathways to identify which are 
required for fragile telomere formation. However, because telomere fragility appears to 
be induced by replication stress, and knockdown of many DNA replication and repair 
proteins induces replication stress, this approach may be counter-productive. 
Nonetheless, even though knockdown of repair proteins such as Rad51 (required for 
homologous recombination) induces telomere fragility (Badie et al., 2010), the telomere 
fragility produced by the general replication stress induced upon Rad51 knockdown may 
be outweighed by a reduction in aphidicolin-induced telomere fragility upon Rad51 
knockdown if homologous recombination is required for fragile telomere formation – that 
is to say, a specific role of a particular DNA replication or repair protein in fragile 
telomere formation may have a greater influence on that protein’s impact on telomere 
fragility than the replication stress induced upon depletion of that protein. It is difficult to 
predict the outcomes of such experiments without conducting them. Another approach 
to this issue would be to use chemical inhibitors of replication and repair proteins, which 
would allow for titration of the inhibitor dose to achieve an impact on fragile telomere 
formation without necessarily inducing broad replication stress. Such experiments may 
need to be applied to different means of inducing telomere fragility, as the literature and 
our work suggest that multiple mechanisms for fragile telomere formation exist. Notably, 
telomere fragility induced by RTEL1 is antagonized by treatment with a G-quadruplex 
stabilizing compound; given that G-quadruplexes only form on the G-rich lagging strand 
telomere, RTEL1 loss may induce lagging strand-specific telomere fragility, though this 
question was not explored (Vannier et al., 2012). In contrast, we show that FEN1 
depletion induces leading strand-specific telomere fragility in an RNA:DNA hybrid-
dependent manner. Lastly, TRF1 deletion-induced fragility exhibits no strand specificity 
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(Sfeir et al., 2009). The different strand specificities of telomere fragility in different 
conditions, in addition to the broad range of manipulations that induce telomere fragility, 
suggest that multiple mechanisms exist for the formation of fragile telomeres, and any 
work attempting to identify replication or repair pathways involved in the phenotype 
should include multiple means of inducing telomere fragility. 
 
Lastly, the consequences of fragile telomere formation are poorly elucidated. While the 
manipulations that induce telomere fragility have known phenotypes, it is not clear if 
specific cellular functions are altered by higher rates of telomere fragility, and if there 
are any organismal consequences to the induction of telomere fragility. One of the key 
aspects of telomere fragility that has largely remained unexplored is the kinetics of the 
phenotype. Work in our lab has shown that telomere fragility induced by low doses of 
aphidicolin in BJT fibroblasts declines to control levels 48 hours following removal of the 
drug, and that this decline cannot be explained by the death of the cells in the 
population exhibiting fragility (Nguyen et al., unpublished). These data indicate that cells 
possess a mechanism to resolve telomere fragility, requiring at most two cell cycles to 
return fragility to background levels. These experiments did not address if different 
doses of aphidicolin or other means of inducing telomere fragility produce irreparable 
telomere fragility, or if the time required to repair telomere fragility is proportional to the 
initial increase in telomere fragility. However, the mere fact that fragile telomeres are 
resolved raises the possibility that persistent fragile telomeres are a pathological 
structure. Future experiments examining the physiological consequences of telomere 
fragility may need to first identify a method of inducing telomere fragility that does not 
cause a genome-wide, persistent DNA damage response, as higher doses and 
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extended treatment times with aphidicolin might. Given that in certain conditions, 
telomere DNA damage is irreparable yet damage in other parts of the genome is 
repaired, conditions likely exist in which telomere fragility might persist without genome-
wide replication stress (Fumagalli et al., 2012). If such conditions can be identified, then 
examining cells for phenotypes present during persistent telomere fragility may reveal 
the reasons why cells repair fragile telomeres when they are able. 
 
RNA:DNA hybrids and the telomere 
Our model for FEN1 activity at the leading strand-replicated telomere proposes that 
upon FEN1 depletion, RNA:DNA hybrid/flap structures accumulate, and that they are 
ultimately responsible for telomere fragility. This model is especially interesting in light of 
recent work in ALT cells demonstrating that RNase H1 regulates RNA:DNA hybrids. In 
the absence of RNase H1, RNA:DNA hybrids accumulate, RPA is recruited to 
telomeres, and telomeres are rapidly lost; in contrast, upon RNase H1 overexpression 
in ALT cells, telomeres shorten and become less recombinogenic (Arora et al., 2014). 
These data indicate that the presence of RNA:DNA hybrids at telomeres has dramatic 
effects on telomere stability, which would necessitate RNA:DNA hybrid regulation at the 
telomere. Our data suggest that FEN1 may also be an important regulator of RNA:DNA 
hybrids at the telomere. While the ability of ectopic RNase H1 expression to rescue 
telomere fragility induced upon FEN1 depletion and α-amanitin treatment supports our 
model that FEN1 processes post-collision RNA:DNA hybrid/flaps, it does not provide 
concrete evidence that hybrids actually accumulate in the absence of FEN1. 
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In Appendix 2, we sought to obtain physical evidence for RNA:DNA hybrid accumulation 
using DNA immunoprecipitation (DIP) with an antibody specific for RNA:DNA hybrids 
(monoclonal antibody S9.6). We ultimately found that in contrast to our expectation, 
RNA:DNA hybrids decreased at a portion of the β-actin locus known to form RNA:DNA 
hybrids and at the telomere upon shRNA-mediated FEN1 depletion. One explanation for 
this observation comes from the finding described in Appendix 1: because FEN1 
depletion induces rapid loss of RNase H1 at the protein level, it is possible that the long 
time-course of the shRNA-mediated FEN1 depletion in the DIP experiment leaves 
sufficient time and applies selective pressure for the cells to upregulate other proteins 
capable of processing RNA:DNA hybrids. Another potential explanation for the 
decrease in RNA:DNA hybrids observed upon FEN1 depletion may be rooted in the 
sequence length requirements of the S9.6 antibody, which likely requires at least 20–25 
nucleotides of hybrid sequence to efficiently bind an RNA:DNA hybrid (Hu et al., 2006). 
This latter issue in particular means that for detection of short RNA:DNA hybrids, which 
would be expected to be shorter than 20 nucleotides given the proposed model  of a co-
directional collision event, the S9.6 antibody may be inadequate. Recently, a single 
chain variable fragment (scFv) of the S9.6 antibody was produced that is capable of 
binding an RNA:DNA hybrid as short as 6 nucleotides (Phillips et al., 2013). It is 
possible that the S9.6 scFv could be used in a DIP experiment, either by capturing using 
protein L (which binds kappa light chains) or by producing a tagged S9.6 scFv for 
capture with FLAG or streptavidin beads. Another potential means to detect RNA:DNA 
hybrids would be use of a fusion protein of the DNA–RNA hybrid-binding domain of 
RNase H1 and GFP (HB-GFP), which has recently been used to identify RNA:DNA 
hybrids in vivo (Bhatia et al., 2014). Regardless of how they are identified 
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experimentally, RNA:DNA hybrids contribute substantially to telomere biology. In light of 
our work demonstrating that RNA:DNA hybrids contribute to telomere fragility (Chapter 
3), and work in both yeast and human ALT cells finding that telomeric RNA:DNA hybrids 
alter recombination at the telomere, RNA:DNA hybrids constitute an important new 
avenue of research in telomere biology. 
 
The telomere as a canary for genome stability 
One of the most intriguing questions surrounding DNA replication and repair proteins 
acting at the telomere is whether the proteins’ roles at the telomere are relevant at other 
non-telomeric loci in the genome. Our work suggests that FEN1’s role at the lagging 
strand telomere – preventing STL – is to recruit RecQ helicases that resolve G-
quadruplexes forming on the lagging strand during replication. There is little reason to 
believe that FEN1 could not perform this role elsewhere in the genome, though G-
quadruplexes are more likely to form at the telomere than most other portions of the 
genome. Along similar lines, we find that FEN1 prevents leading strand-specific 
telomere fragility, and that the fragility formed upon FEN1 depletion is transcription- and 
RNA:DNA hybrid-dependent, suggesting that co-directional replisome–RNAP collision 
events lead to telomere fragility in the absence of FEN1. We suspect that FEN1 
resolves the structures produced following these collisions regardless of the genomic 
locus at which they occur. If fragile telomeres form by a mechanism using 
recombination with subtelomeric DNA, it could simply be that telomeres serve as a 
“reporter” for collision events by producing a readily visible phenotype on metaphase 
chromosomes, while other loci do not produce substantial rearrangements. As such, the 
telomere may continue to prove an attractive target when exploring the role of various 
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proteins in maintaining genome stability, thanks to its increased sensitivity to replication 
stress and readily quantifiable phenotypes (notably, telomere fragility) under such 
conditions.  
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Introduction 
As described in Chapter 3, we demonstrated that ectopic expression of ribonuclease H1 
was sufficient to rescue telomere fragility induced by FEN1 depletion or α-amanitin 
treatment. In the course of these experiments, we first attempted to ectopically express 
human RNase H1 using a Moloney murine leukemia virus (MMLV) vector. Strikingly, 
while RNase H1 was successfully overexpressed approximately four-fold over 
endogenous levels and persisted in cells through one freeze-thaw cycle, expression of 
the ectopic and endogenous RNase H1 was abrogated by subsequent flap 
endonuclease 1 (FEN1) depletion. Given the necessity of successful RNase H1 
expression to demonstrate the involvement of RNA:DNA hybrids in the telomere fragility 
phenotype, we proceeded to clone human RNase H1 into an adenoviral vector and 
produced recombinant adenovirus. Even in the setting of the large overexpression 
produced by adenoviral transduction, we found again that RNase H1 expression 
appeared to be FEN1-dependent. We repeated these results and carried out additional 
experiments to identify if our observation of RNase H1 expression dependence on 
FEN1 was a technical issue or reproducible phenomenon, as described herein. 
 
Experimental Procedures 
Cell culture and virus production 
All cell culture was carried out as described in Chapter 3. Moloney murine leukemia 
virus (MMLV) was produced as described for lentivirus in Chapter 3 using the pUMVC3 
packaging vector and pCMV-VSV-G envelope vector (8:1). Lentivirus was produced as 
described in Chapter 3. Production of recombinant adenovirus type 5 was carried out 
using the AdEasy adenoviral vector system (Agilent Technologies, La Jolla, CA) 
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according to the manufacturer’s protocol, and virus was amplified as described in 
Chapter 3. 
 
Plasmids 
The human RNase H1 cDNA (cloned into pCMV6-AC) was purchased from Origene 
Technologies (Rockville, MD). For MMLV, the RNase H1 cDNA was cloned into pBABE-
hygro by excising the cDNA from pCMV6-AC using EcoRI and XhoI (New England 
Biolabs, Ipswich, MA) and ligating into the EcoRI and SalI sites in pBABE-hygro using 
the Rapid Ligation Kit according to the manufacturer’s instructions (Roche Applied 
Science, Penzberg, Germany). For adenoviral production, the RNase H1 cDNA was 
PCR amplified using Phusion polymerase according to the manufacturer’s instructions 
(New England Biolabs, Ipswich, MA) and gel purified using a QIAquick gel extraction kit 
(Qiagen, Venlo, Netherlands). 3′-A overhangs were added using Taq polymerase and 
the fragment was cloned into pCR2.1-TOPO (Life Technologies, Grand Island, NY). 
Finally, the RNase H1 cDNA was subcloned from pCR2.1-TOPO by digestion with 
HindIII and XhoI (New England Biolabs, Ipswich, MA) and ligation into the 
corresponding sites in pShuttle-CMV (Agilent Technologies, La Jolla, CA) using the 
Rapid Ligation Kit according to the manufacturer’s instructions (Roche Applied Science, 
Penzberg, Germany). 
 
Western blot analysis 
Western blot analysis was carried out as described (Honaker and Piwnica-Worms, 
2010). The following antibodies were used: rabbit polyclonal anti-FEN1 (A300-255A, 
Bethyl Laboratories, Montgomery, TX); mouse monoclonal anti-RNase H1 (H00246243-
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M01, Novus Biologicals, Littleton, CO); rat monoclonal anti-α-tubulin (ab6160, Abcam, 
Cambridge, UK). 
 
RNA preparation and quantitative reverse transcription PCR (qRT-PCR) 
RNA was prepared using TRI Reagent (Life Technologies, Grand Island, NY). cDNA 
was synthesized using Superscript III reverse transcriptase (Life Technologies, Grand 
Island, NY) according to the manufacturer’s instructions. qRT-PCR was conducted 
using TaqMan Gene Expression Assays (Life Technologies, Grand Island, NY) 
according to the manufacturer protocol. Assays used were RNASEH1 
(Hs00268000_m1) and GAPDH (Hs02758991_g1). Fold changes were computed using 
the ΔΔCt method. 
 
Results 
Endogenous and ectopic RNaseH1 expression is reduced upon FEN1 depletion 
We first expressed RNase H1 in BJT fibroblasts by transducing them with an MMLV 
carrying the RNase H1 cDNA. Following selection, we observed a modest but 
significant overexpression of RNase H1 compared to empty vector control cells by 
western blot using a monoclonal RNase H1 antibody that detects both endogenous and 
ectopic RNase H1 (Fig. A1.1A). Ectopic expression was maintained under drug 
selection through a single cell freeze-thaw cycle (data not shown). Next, we depleted 
cells of FEN1 using a lentivirus expressing an shRNA targeting the 3′-UTR of FEN1 
(shFEN1) or a control hairpin (shCtrl) (Saharia et al., 2008). Following selection, we 
observed a marked reduction in RNase H1 expression both in control (empty vector-
expressing) and RNase H1-overexpressing BJT fibroblasts (Fig. A1.1A), indicating that 
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both endogenous and ectopically expressed RNase H1 were reduced following FEN1 
depletion. 
 
Given our need to overexpress RNase H1 even in the absence of FEN1, we next 
produced a recombinant adenovirus encoding the human RNase H1 cDNA (Ad-RH1). 
We first depleted FEN1 from RPE1 cells using a lentivirus expressing shFEN1. During 
drug selection for shFEN1 expression, we infected the cells with Ad-RH1 to overexpress 
RNase H1 and collected the cells immediately following the completion of selection and 
transduction. As in BJT fibroblasts, FEN1-depleted RPE1 cells showed a marked 
decrease in endogenous RNase H1 levels compared to control cells (Fig. A1.1B). RPE1 
cells transduced with Ad-RH1 displayed strong overexpression of RNase H1, but 
strikingly, even this level of ectopic expression was reduced in FEN1-depleted cells 
(Fig. A1.1B). These data indicate that even when expressed at extremely high levels, 
RNase H1 protein levels are decreased by FEN1 depletion. 
 
FEN1-dependent RNase H1 expression is controlled post-transcriptionally 
Given the rapid reduction of both endogenous and ectopic RNase H1 expression 
following FEN1 depletion, we wondered if the loss of RNase H1 was controlled at the 
transcriptional or post-transcriptional level. First, we used the BLAST algorithm to 
identify if the shFEN1 targeting sequence was present in RNase H1 mRNA, and found 
that no sequence homology existed between the two (data not shown). Next, we 
isolated RNA from control and FEN1-depleted RPE1 cells and produced cDNA for qRT-
PCR analysis. Surprisingly, FEN1 depletion induced no change in the expression levels 
of the RNase H1 mRNA (Fig. A1.1C). The lack of a change in RNase H1 mRNA at a 
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time when the protein level observed by western blot analysis was so markedly reduced 
indicates that the RNase H1 reduction occurring following FEN1 depletion occurs post-
transcriptionally. 
 
Discussion 
Our studies of RNase H1 protein and mRNA expression following FEN1 depletion do 
not strongly support one mechanism explaining how RNase H1 is regulated upon a loss 
of FEN1. Nonetheless, the rapidity of the RNase H1 loss (we assayed as soon as 
selection for shFEN1-expressing cells was complete) better supports the possibility that 
the RNase H1 protein is destabilized in the absence of FEN1 than it supports the 
possibility that RNase H1 translation is downregulated. Future work to address the 
nature of this phenomenon might first include treatments with the translation inhibitor 
cycloheximide and proteasome inhibitor MG132 to identify if RNase H1 loss following 
FEN1 loss is mediated by either translation or proteasomal degradation. Additionally, 
protein levels could be assessed sooner after FEN1 depletion by the use of a 
transfected siRNA instead of a lentivirally-delivered shRNA. Lastly, it is unclear if the 
cell cycle plays a role in the regulation of RNase H1. Though FEN1 depletion only 
produces mild cell cycle aberrations and does not impact S-phase progression (Chapter 
2), we did not assess cell cycle distribution in these experiments, and such an analysis 
might yield additional information on RNase H1 regulation. 
 
It is also interesting to surmise the functional implications of the possibility that FEN1 
and RNase H1 are post-transcriptionally co-regulated. Do FEN1 and RNase H1 
physically interact, with such an interaction stabilizing RNase H1? Does the loss of 
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RNase H1 provide evidence that FEN1 loss results in the production of substrates upon 
which RNase H1 activity is ultimately toxic for the cell? Answers to these and other 
questions may lead to a better understanding of the relationship between FEN1 and 
RNase H1, which has long been restricted to Okazaki fragment processing. 
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Figure A1.1. RNase H1 protein expression decreases upon FEN1 depletion. (A) 
Western analysis of FEN1 and RNase H1 expression in BJT fibroblasts transduced with 
empty vector (EV) or RNase H1 (pB-RH1), and expressing a control shRNA (shCtrl) or 
FEN1-depleting shRNA (shFEN1). α-tubulin is shown as a loading control. (B) Western 
analysis of FEN1 and RNase H1 expression in control (shCtrl) or FEN1-depleted 
(shFEN1) RPE1 cells, with or without ectopically expressed RNase H1 (Ad-RH1). Two 
exposures of the same RNase H1 blot are shown. α-tubulin is shown as a loading 
control. (C) qPCR analysis of RNase H1 mRNA expression in cells expressing a control 
hairpin (shCtrl) or FEN1-depleted cells (shFEN1). mRNA levels in FEN1-depleted cells 
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are shown as a fold change relative to the control cells. Fold changes were calculated 
using the ΔΔCt method; fold changes from two biological replicates were averaged to 
produce the graph. The error bar represents standard error of the mean. 
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Introduction 
As discussed in Chapter 3, we propose that co-directional collisions between the 
replisome and transcribing RNA polymerases produce RNA:DNA hybrid/flap structures, 
which FEN1 processes to prevent telomere fragility. In our attempts to build support for 
this model, we wondered if we could show physical evidence that RNA:DNA hybrids 
accumulate upon FEN1 depletion, as would be predicted if FEN1 were required for their 
resolution. We sought to employ DNA immunoprecipitation (DIP), a technique similar to 
chromatin immunoprecipitation, differing in the absence of a crosslinking step and 
purification of protein-free genomic DNA rather than chromatin (Skourti-Stathaki et al., 
2011). Using an RNA:DNA hybrid-specific antibody (monoclonal antibody S9.6), this 
technique can be used to unambiguously identify the presence of RNA:DNA hybrids 
longer than approximately 25 nucleotides in length (Hu et al., 2006). Here, we sought to 
identify whether RNA:DNA hybrid levels change following FEN1 depletion at two loci: 
the telomere and the β-actin locus. 
 
Experimental Procedures 
Cell culture and virus production 
Cell culture of BJT fibroblasts was carried out as described in Chapter 3. Lentivirus 
expressing control (shCtrl) and FEN1-depleting shRNA (shFEN1) (Saharia et al., 2008) 
was produced as described in Chapter 3. 
 
Western blot analysis 
Western blot analysis was carried out as described (Honaker and Piwnica-Worms, 
2010). The following antibodies were used: rabbit polyclonal anti-FEN1 (A300-255A, 
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Bethyl Laboratories, Montgomery, TX); rat monoclonal anti-α-tubulin (ab6160, Abcam, 
Cambridge, UK). 
 
DNA immunoprecipitation (DIP) 
DIP was carried out as described with modifications (Skourti-Stathaki et al., 2011). 
Subconfluent BJT fibroblasts were collected from two 15 cm dishes by scraping. Cells 
were lysed in DIP lysis buffer (0.5% NP40, 85 mM potassium chloride, 5 mM PIPES), 
after which nuclei were pelleted. Nuclei were lysed in DIP nuclear lysis buffer (1% 
sodium dodecyl sulfate, 25 mM tris-HCl pH 8, 5 mM EDTA), sheared, and treated with 
two sequential, 1.5 hour, 55 °C, 100 µg proteinase K digests. Following 
phenol:chloroform extraction and ethanol precipitation (Sambrook et al., 1989), samples 
were split and digested overnight with recombinant ribonuclease H (Roche Applied 
Science, Penzberg, Germany) as a negative control or mock digested (no enzyme). 
Samples were diluted in DIP dilution buffer (0.01% sodium dodecyl sulfate, 1.1% Triton 
X-100, 1.2 mM EDTA, 16.7 mM tris-HCl pH 8, 166.5 mM sodium chloride) and 
sonicated to produce fragments approximately 200 bp in length. Nucleic acid content 
was quantified using the PicoGreen assay according to the manufacturer’s instructions 
(Life Technologies, Grand Island, NY).  
 
10 µg of lysate (measured by nucleic acid content) was immunoprecipitated overnight 
with 10 µg of S9.6 antibody or normal mouse IgG. Protein A magnetic beads (Life 
Technologies, Grand Island, NY) were equilibrated in DIP dilution buffer and used to 
capture antibody–DNA complexes. After extensive washing, antibody–DNA complexes 
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were eluted from the beads and treated with proteinase K; DNA was recovered using 
PCR cleanup columns (Qiagen, Venlo, Netherlands). 
 
Quantitative PCR (qPCR) 
Genomic qPCR was conducted using Power SYBR Green Master Mix (Life 
Technologies, Grand Island, NY) according to the manufacturer’s protocol. A fragment 
immediately 5′ to the β-actin pause element (known to form RNA:DNA hybrids; “5′-
pause”) was amplified to assess hybrid formation at the β-actin locus; a non-transcribed 
region (“C”) downstream of β-actin was used as a non-transcribed negative control 
locus. Thermocycling was performed per the master mix manufacturer’s instructions, 
using 58.7 °C as the annealing temperature. Primers used were: 5′-pause F: 5′-TTA 
CCC AGA GTG CAG GTG TG-3′ ; 5′-pause R: 5′-CCC CAA TAA GCA GGA ACA GA-3′; 
C F: 5′-TGG GCC ACT TAA TCA TTC AAC-3′; C R: 5′-CCT CAC TTC CAG ACT GAC 
AGC-3′. 
 
Southern hybridization 
Southern hybridization was carried out as previously described (Sambrook et al., 1989) 
with modifications. Briefly, DNA was serially diluted, denatured in 0.4 M sodium 
hydroxide at 95 °C, and spotted onto a Hybond-XL charged nylon membrane (GE 
Healthcare, Waukesha, WI) using a Bio-Dot Microfiltration apparatus (Bio-Rad, 
Hercules, CA) according to the manufacturer’s instructions.  Following UV crosslinking, 
the membrane was prehybridized in Southern hybridization buffer (6x SSC, 5x 
Denhardt’s solution, 0.2% sodium pyrophosphate, 0.2% SDS) containing 100 µg/mL 
denatured salmon sperm DNA for four hours at 65 °C.  A purified 1.6 kb fragment 
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consisting exclusively of vertebrate telomere repeats was random prime labeled with [α-
32P]dCTP (3000 Ci/mmol) using the High Prime DNA Labeling Kit (Roche Applied 
Science, Penzberg, Germany) according to the manufacturer’s instructions to produce a 
telomere-specific DNA probe; the probe was purified using an Illustra ProbeQuant G-50 
Micro Column (GE Healthcare, Waukesha, WI) and diluted to 1.2×106 dpm/mL in 10 mL 
of Southern hybridization buffer. Probe was hybridized to the membrane overnight at 65 
°C, after which the membrane was washed and imaged using a phosphor screen and 
imager or by autoradiography. 
 
Results 
In order to obtain direct evidence that FEN1 depletion could alter RNA:DNA hybrid 
levels in the genome, we carried out a DNA immunoprecipitation (DIP) on BJT cells 
transduced with a control shRNA (shCtrl) or depleted of FEN1 using a previously 
validated shRNA (shFEN1) (Saharia et al., 2008). Following confirmation of FEN1 
knockdown by western blot analysis, cells were isolated and processed for DIP. Given 
that ectopic RNase H1 expression rescues telomere fragility induced by FEN1 depletion 
(Chapter 3), we surmised that RNA:DNA hybrids might increase at the telomere in the 
absence of FEN1, and examined S9.6 immunoprecipitated DNA by Southern 
hybridization with a telomere-specific probe. We also assayed two specific portions of 
the β-actin locus: one known to form RNA:DNA hybrids in unperturbed conditions (5′-
pause region) and one downstream of the transcribed portion of the locus that should 
be unable to form transcription-associated RNA:DNA hybrids (C-region). As expected, 
we were unable to detect a significant presence of RNA:DNA hybrids at the C-region of 
the β-actin locus (data not shown). We observed RNA:DNA hybrids at both the 5′-pause 
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site of the β-actin locus (Fig. A2.1A) and at the telomere (A2.1B) in control cells; these 
were verified as specific by treatment of lysates with recombinant RNase H prior to 
immunoprecipitation, which abrogated precipitation of detectable β-actin 5′-pause site 
DNA (Fig. A2.1A). Surprisingly, following FEN1 depletion, RNA:DNA hybrids at the 5′-
pause site of the β-actin locus decreased dramatically following FEN1 depletion (Fig 
A2.1A). Similarly, RNA:DNA hybrids decreased substantially at the telomere (Fig. 
A2.1B). These data demonstrate that at multiple genomic loci, RNA:DNA hybrids are 
decreased or eliminated following lentiviral knockdown of FEN1. 
 
Discussion 
Our model proposed that replication stress and telomere fragility arise following co-
directional collisions that produce RNA:DNA hybrid/flap structures; FEN1 resolves these 
structures to prevent replication stress and telomere fragility (Chapter 3). Our model 
also suggested that in the absence of FEN1, RNase H1 is sufficient to process the 
RNA:DNA hybrid/flap structures and prevent telomere fragility. As such, we expected 
that upon FEN1 depletion, cells would exhibit an increase in RNA:DNA hybrids at the 
telomere and potentially at other transcribed loci, such as the β-actin locus. Our results 
found the opposite of this expectation. Nonetheless, the RNase H1 overexpression 
experiments described in Chapter 3 provide strong evidence that RNA:DNA hybrids are 
responsible for the telomere fragility induced upon FEN1 depletion and α-amanitin 
treatment: the only known function of RNase H1 is endoribonucleolytic cleavage of 
oligomeric RNA in RNA:DNA hybrids. 
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In attempting to reconcile these seemingly opposite findings, we found multiple possible 
explanations that could account for the discrepancy from expectations of the DIP data. 
First, we note that in all of the experiments reported herein, FEN1 depletion was 
achieved by lentiviral transduction, in which the cells undergo 48 hours of puromycin 
selection and at least 24 additional hours of culture before collection for DIP analysis; as 
such, the cells in question are collected between 72 and 96 hours following infection. As 
described in Appendix 1, FEN1 knockdown by this method substantially decreases 
RNase H1 levels as well. Given the amount of time the cells survive with diminished 
levels of FEN1 and RNase H1 in this experimental setting, we propose that over time 
the cells may achieve a compensatory upregulation of other proteins able to process the 
accumulating RNA:DNA hybrid/flap structures. Many proteins are known to cleave or 
unwind RNA:DNA hybrids – key suspects would be RNase H2, which possesses similar 
activity to RNase H1; senataxin, a helicase known to unwind RNA:DNA hybrids with 
known roles in telomere stability (De Amicis et al., 2011); and Dhx9, a helicase capable 
of unwinding RNA:DNA hybrids that has been identified as a telomere-associated 
protein (Nittis et al., 2010). Activation of these or other proteins to compensate for FEN1 
and/or RNase H1 loss might cause a subsequent dramatic loss of RNA:DNA hybrids. 
This idea is supported by preliminary data indicating that knockdown of FEN1 by siRNA 
(with collection occurring after only 36-48 hours) shows no change in RNA:DNA hybrids 
at the β-actin locus; the more rapid collection of cells following siRNA transfection may 
not leave enough time for the cell to upregulate compensatory proteins enough that 
RNA:DNA hybrids are eliminated. 
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Another complication of the DIP data comes from the length specificity of the S9.6 
antibody. Recent work has shown that the S9.6 antibody’s binding affinity to RNA:DNA 
hybrids is length dependent, with hybrids less than 20 nucleotides in length exhibiting 
no detectable binding, and the signal for a 25-nucleotide hybrid only 10% of that for a 
50-nucleotide hybrid (Hu et al., 2006). Crystallographic evidence indicates that if the 
RNA polymerases involved in co-directional collisions are normally progressing through 
their templates (i.e., not backtracking), no more than 9 nucleotides of hybrid should be 
present at the moment of the collision during active transcription (Gnatt et al., 2001); 
disengagement of the RNA polymerase and subsequent elongation by the replisome 
would not be expected to alter the length of hybrid at the site of the collision, meaning 
that the RNA:DNA hybrid/flap structures may possess as few as 9 nucleotides of 
RNA:DNA hybrid. In such an instance, the majority of the hybrids produced by co-
directional collisions would be undetectable by DIP with the S9.6 antibody. 
 
Especially in light of the data showing length dependence of the S9.6 antibody, we are 
forced to conclude that the DIP assay may be insensitive to the RNA:DNA hybrid/flap 
structures produced following a co-directional collision at the telomere. As such, the 
RNA:DNA hybrids observed in shCtrl cells (and eliminated in shFEN1 cells) likely 
correspond to long (>20 nucleotides) RNA:DNA hybrids, such as those that might be 
associated with an R-loop or backtracked Pol II elongation complex. It is unclear if long 
hybrids are more or less prevalent than collision-derived RNA:DNA hybrid/flaps, if they 
are impacted directly by FEN1, or if they play any role in telomere fragility. 
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Figure A2.1. RNA:DNA hybrids decrease at the β-actin 5′-pause site and telomere 
upon FEN1 depletion. (A) Representative qPCR of the β-actin 5′-pause site in DNA 
immunoprecipitated with the S9.6 antibody from control cells (shCtrl) or cells depleted of 
FEN1 (shFEN1). Lysates were untreated or treated with recombinant RNase H prior to 
immunoprecipitation (negative control). Pull down is shown as percent input. (B) 
Representative Southern analysis to detect telomere DNA in DNA immunoprecipitated 
with non-specific IgG or S9.6 antibody from control cells (shCtrl) or cells depleted of 
FEN1 (shFEN1). Serial dilutions of DNA were loaded onto a membrane, and a telomere 
repeat DNA probe was hybridized to the membrane. The membrane was visualized with 
autoradiography. 
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